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 Abstract 3
 
Huntington’s disease (HD) is a monogenic neurodegenerative disorder with no known cure.   
 
Selisistat is a novel, highly potent Sirt1 inhibitor with supportive pre-clinical data. Facilitation of 
autophagy and amelioration of transcriptional dysregulation are proposed as mechanisms of action. 
A first in disease Phase 1B study showed safety and tolerability. The peripheral immune dysfunction 
in HD could be modulated by Sirtuins which have both pro and anti-inflammatory activities. However 
selisistat did not alter the cytokine profile in this study. Phase 2 data over a longer duration was also 
well tolerated however potential hepatotoxicity is a concern. Sub-analysis of clinical assessments did 
not reveal any significant effect. Confirmation of proposed mechanisms of action is lacking and no 
Phase III studies are planned.  
 
Significant clinical heterogeneity exists in HD phenotypes which must reflect differing neuronal 
susceptibilities. A novel total motor score based sub-division of HD phenotypes failed to 
demonstrate any changes in a whole brain voxel-based morphometry (VBM) analysis. 
  
Clinical assessment alone lacks sensitivity over shorter time-spans in HD, and thus reliable, tolerable 
and sensitive biomarkers are required. Optical coherence tomography is a potential novel 
biomarker. The hypothesis that neuroretinal structures may be surrogate marker of intracranial 
disease was tested in a pilot biomarker study, the first of its kind in HD. Evidence of a statistically 
significant (p < 0.01) reduction in macular volume in HD subjects versus age and sex-matched 
controls is seen. No change in RFNL measures was seen. A correlation with increasing disease 
severity on ordinal regression was also noted. No correlation of macular volume and RNFL thickness 
with change in whole brain and caudate volumes. Furthermore, OCT was well tolerated by the 
majority of participants. Retinal abnormalities in HD have been confirmed in three subsequent 
independent OCT studies.  
 
(Word Count: 289) 
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 Impact Statement 4
 
Huntington’s disease is fatal neurodegenerative for which no disease modifying treatment exists. 
The body of work presented below has contributed to the field of Huntington’s disease research 
through demonstrating safety and tolerability of selisistat. It has raised concerns about the potential 
hepatotoxicity of the medication. It has further re-emphasised the importance of ensuring the 
presence of sound pre-clinical work demonstrating firstly, target engagement and the secondly that 
the target is a key modulator of the disease process. This underpins the successful transition of 
therapeutic candidates into clinical trials.  
 
Selisistat did not demonstrate modulation of the innate immune response, which is altered in 
Huntington’s disease. The role of optical coherence tomography as potential safe, quick and well 
tolerated biomarker has been suggested by work carried out here. The importance of demonstrating 
target engagement in therapeutic development prior to clinical trials is a well-established in principle 
in clinical trials here and its absence here, underscores its importance. 
 
There is no obvious impact of this work outside the wider scientific or non-scientific community. 
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 Introduction 5
5.1 Huntington’s Disease 
 
Huntington’s disease is a monogenic, autosomal dominant, neurodegenerative condition. The onset 
of disease is currently defined as the point at which characteristic motor signs develop, where a 
patient moves from being a premanifest gene carrier to having manifest disease. This distinction is 
somewhat arbitrary because most patients develop cognitive or psychiatric symptoms (or both) 
during the premanifest period, often many years before any motor signs are seen. 
 
Due to relatively early loss of function and productivity and the chronic, slowly progressive nature of 
the disease with its increasing requirements for medication, social and multidisciplinary care, HD 
carries a substantial resource burden (Aubeeluck & Wilson, 2008). Furthermore, as the disease is 
fully penetrant, a positive predictive HD gene test results in development of disease at some point. 
The premanifest phase therefore creates an invaluable window of opportunity, both to study the 
disease in its earliest stages, and a unique point at which to intervene therapeutically. 
 
Although no cure for the disease exists, in the last few years there has been an exponential rise in 
the number of publications, delineating its basic and clinical science, and therapeutic trials. 
Promising avenues exist, to broaden our understanding of disease processes from which suitable   
targets can be pinpointed, in the availability of suitably target-directed therapies, and finally in our 
ability to adequately and reliably establish disease modification. 
 
To date however no disease modifying therapy for a neurodegenerative disease exists.  
 
 
 
 
 Early Phase Disease Modification Trials with Selisistat and Optical Coherence Tomography as a Biomarker in Huntington’s Disease 
UCL PhD Submission 
17 
Dr Salman Haider (Student No.: 1054117) 
 
5.2  History 
 
Originally termed Huntington’s chorea, the nomenclature changed to its current form relatively 
recently in order to better represent the plethora of clinical features beyond the movement 
disorder. The first definite description of Huntington’s disease (HD) was given by Charles Oscar 
Waters in 1841, who gave a clear account of the natural history of the disease. On the 15th February 
1872, George Huntington, aged 21 and a recent graduate from Columbia University, presented the 
earliest most complete description of HD before the Meigs and Mason Academy of Medicine at 
Middleport, Ohio. It was published two months later in the Medical and Surgical Reporter of 
Philadelphia (Huntington, 1872).  
 
In an address to the New York Medical Society in 1909, Huntington summarised some important 
features we recognise today as being part of the disease, alongside the classical description of 
chorea, ‘‘. . . two women, mother and daughter, both tall, thin, almost cadaverous, both bowing, 
twisting, grimacing.’’  
 
By far the most important milestone of modern times was the herculean collaborative effort, driven 
notably by affected families, galvanising doctors and scientists and culminating in the identification 
of a mutation in the Huntingtin (HTT) gene in 1993 (The Huntington's Disease Collaborative Research 
Group, 1993) (Figure 1). The gene is located on the short arm of chromosome 4 (4p 16. 3) and in HD, 
it contains a CAG repeat expansion in exon 1, which results in an abnormal polyglutamine tract in 
the protein, huntingtin (HTT). The advent of gene silencing trials may herald another key milestone 
in the history of Huntington’s disease and full results are anxiously awaited. 
 
5.2.1 Epidemiology 
 
In the Western hemisphere prevalence reaches 7-10/100,000. In the United Kingdom (UK), incidence 
estimates range from 0.44 to 0.78 per 100,000 person-years, and prevalence ranges from 5.96 to 
6.54 per 100,000 of the population. From a primary care based study, a figure of at least 
12.4/100,000 was produced and even this may be an underestimate (Hoppitt et al., 2011;Rawlins, 
Figure 1- Milestones in Huntington's Disease 
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2010). HD is one of the most frequently occurring hereditary neurological disorders, after 
Neurofibromatosis Type 1, Charcot Marie Tooth disease and Duchenne muscular dystrophy (Harper, 
1992). 
 
5.2.2 Late Onset Huntington’s Disease 
 
This has been variously termed senile chorea or late onset HD, describing a subset of HD patients, 
who present above the age of 75. Of all known HD patients, approximately 25 per cent present 
above the age of 50. Although other causes of chorea should be looked for in this age group, the 
most likely cause remains HD. Chorea is almost universal but the course is milder and slower with 
mild cognitive and psychiatric disease. Gait disturbance and dysphagia are also seen but are not 
severe. It is usually associated with CAG repeat sizes of around 40, though lengths of up to 48 have 
been recorded. Often a family history can be lacking, which may reflect expansion of an 
intermediate range allele (James et al., 1994;Kremer et al., 1993).  
 
5.2.3 Juvenile Onset Huntington’s Disease 
 
Although Lyon is credited with the first description of Juvenile HD in 1863, closer examination 
reveals this cohort as more likely benign hereditary chorea, given the absence of significant disease 
progression (Bates et al., 2002;Lyon, 1863). Juvenile HD is defined as an age of onset prior to the age 
of 20. It accounts for 5-10% of all HD presentations and is paternally transmitted in 90% of cases. 
CAG repeat expansions are almost always greater than 55.  
  
In the largest case series of juvenile subjects, over half experienced symptom onset under the age of 
14, while 1 in 10 cases occurred under the age of 10. Under the age of 10, developmental delay 
specifically in speech and language may be prominent which may manifest as failure to progress at 
school. Behavioural changes, learning difficulties, rapid cognitive decline, psychiatric disease and 
parkinsonian motor features, with predominating rigidity and bradykinesia seen in 50% of cases, as 
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well as dystonia and ataxia. The range of psychiatric disease can include drug and alcohol abuse as 
well as eating disorders (Ribai et al., 2007). 
 
In a multi-sourced survey of prescribing practices in juvenile HD, the most commonly prescribed 
agents were anti-psychotics, anti-depressants, anti-parkinsonian medications and anti-epileptics, of 
which Valproic Acid was the most commonly used. Polypharmacy was an issue in minority of cases. 
The most common symptoms reported by the families were speech difficulties, dysphagia, stiffness, 
spasticity, sleeping difficulty, pain and behavioural problems (Robertson et al., 2012).  
 
In contrast to the adult form, chorea itself is rare and early oropharyngeal dysfunction appears more 
commonly in juvenile cases. Similarly, seizures occur in around 25-50% of juvenile HD cases. They are 
usually generalised or myoclonic in nature though absence seizures have also been noted and 
occasionally seizures prove intractable (Gonzalez-Alegre & Afifi, 2006).   
 
5.2.4 Akinetic-Rigid or Westphal Variant 
 
Westphal described an 18-year-old patient with prominent rigidity, which later became known as 
the akinetic-rigid Westphal variant (Westphal, 1883) and is most typically associated with juvenile 
HD. However, this variant has also been noted rarely in young adult populations, with much lower 
CAG repeat sizes. In one 3 patient case series no significant eye movement or cognitive 
abnormalities were seen though mild cardiovascular dysautonomia was present (Racette & 
Perlmutter, 1998) (Reuter et al., 2000). Pathologically, the Westphal variant may be different, with 
studies demonstrating loss of both direct and indirect striatopallidal pathways (Albin et al., 1990) 
(Bugiani et al., 1984). 
 
5.2.5 Adult Onset Disease 
 
In the classical adult onset disease, symptoms usually manifest between the ages of 30-50 and 
progress over 15-20 years. Here we find the classical triad of motor, cognitive, and psychiatric 
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features. However, even within the same family, there can be a striking difference in the relative 
manifestation and severity of these features.  
 
 
5.2.6 Clinical Symptoms 
 
5.2.6.1 Motor 
Although there are a legion of motor signs in HD, they can be reasonably divided into 
those representative of impairment of voluntary motor control e.g. limb inco-
ordination or loss of fine motor control of fingers, those in keeping with loss of 
involuntary motor control e.g. loss of balance and postural reflexes and finally, those 
that indicate the presence of involuntary movements e.g. chorea, tics and dystonia. 
There can evidently be overlap of features, for example where chorea or dystonia of 
the trunk are superimposed upon impairment of postural reflexes, impacting 
additively on balance and mobility. 
 
Intriguingly, even quite marked chorea often remains unnoticed by the patient. It 
can also be passed over initially by relatives as nervousness but it is usually their 
persistence that prompts the first medical consultation. Alternatively, in those with a 
clear family history, partners or relative can comment on similarities of behaviour or 
movement between generations. Descriptions such as ‘twitchy’, ‘fidgety’ or ‘restless’ 
can be applied, and subjects themselves can report symptoms of akathisia. Typically, 
there are minor movements of the hands or toes, though movements can be much 
larger amplitude of a whole body part where they are termed ballistic. Subtle 
deterioration in fine motor control can be suggested by a change in handwriting or 
loss of dexterity in the use of a computer, mobile phone or cutlery.  
 
This can be accompanied by walking difficulty, which is related to composite loss of 
voluntary motor control, excess voluntary movements, as well as impaired co-
ordination and balance. It can produce a gait that is often difficult to classify, with 
 Early Phase Disease Modification Trials with Selisistat and Optical Coherence Tomography as a Biomarker in Huntington’s Disease 
UCL PhD Submission 
21 
Dr Salman Haider (Student No.: 1054117) 
 
varying amounts of appendicular and limb ataxia, chorea and dystonia. Early mild 
swallowing impairment or dysarthria can also be seen. However, it is clear that the 
motor features can vary significantly in their relative predominance and location- 
chorea itself can be seen extra-axially in the face, mouth and tongue.  
 
Generally, mild amounts of dystonia, bradykinesia and rigidity of limbs co-exist with 
relatively more prominent chorea, which itself reaches a peak in mid-stage disease, 
after which this balance reverses as disease progresses. In moderate and advanced 
stages, loss of both involuntary and voluntary movement occurs with abnormal fixed 
postures especially of the trunk or neck, which are usually dystonic in origin. Flexion 
contractures can ensue reflecting overriding spasticity and rigidity and representing 
more florid degeneration of corticospinal tracts.  
 
The exception is the Westphal, akinetic-rigid variant, where rigidity and bradykinesia 
prevail and tremor and chorea are rarely seen. This is the characteristic presentation 
of juvenile HD though does occur in around 10% of adult cases. Axial rigidity appears 
to be more significantly associated with disability and loss of ambulation than chorea 
(Nance, 1998). 
 
Motor impersistence is also seen in HD, characterised by an inability to maintain 
muscle contraction at a fixed level which has given rise to the term ‘’milkmaid’s 
grip’’. The patient is unable to apply a constant force during the handshake (Gordon 
et al., 2000) and it can also be elicited by asking the patient to maintain a fully 
protruded tongue for ten seconds. 
 
5.2.6.2 Balance and Posture 
Balance impairment can occur early on in concert with the above motor features, 
but may only be noticed when the patient is in an environment that presents a 
greater motor challenge- at night or on getting onto or off an escalator or whilst 
walking on uneven ground. Formal quantitative analysis using an obstacle test, sit-
 Early Phase Disease Modification Trials with Selisistat and Optical Coherence Tomography as a Biomarker in Huntington’s Disease 
UCL PhD Submission 
22 
Dr Salman Haider (Student No.: 1054117) 
 
to-stand test and a step and turn test using kinematic and kinetic variables has 
shown that HD patients perform slower in all three tests, produce less rising force 
and have greater sway velocity of the centre of gravity. Patients display significant 
abnormalities in postural control deficits when replicating motor skills employed in 
activities of daily living, emphasising the functional impairment these symptoms 
confer (Panzera et al., 2011). 
5.2.6.3 Eye movements 
The broken pursuit movements and slowed saccades (vertical worse than horizontal) 
seen early on the disease worsen, requiring head movements or eye blinking to 
initiate and at the advanced stages, a complete supranuclear gaze palsy is possible 
(Quinn & Schrag, 1998). A characteristic sign is gaze impersistence with difficulty 
fixating on an object. These oculomotor abnormalities are likely to represent 
disruption to the fronto-striatal control of eye movements (Lasker & Zee, 1997).   
 
5.2.6.4 Dysphagia 
The swallowing difficulties seen in HD likely reflect several processes: lack of 
coordination between the oral and pharyngeal stage, tachyphagia, or rapid 
uncontrolled swallowing secondary to impaired sensory and corticobulbar function, 
buccolingual chorea resulting in food being transferred inadvertently, failure of the 
normal respiratory-deglutition cycle as well as oesophageal dysmotility (Manor et al., 
2018;Shoulson & Fahn, 1979). Patients report difficulty swallowing solid and liquids 
and can choke occasionally also, emphasising the importance of speech and 
language therapists, dieticians and judicious investigation in the form of video 
fluoroscopy. In the later stages, progressive swallowing and speaking impairment 
gives way to anarthria and mutism. 
 
5.2.6.5 Continence 
Urge incontinence with associated frequency and urgency is probably the most 
commonly reported complaint, usually occurring in mid stage disease. In advanced 
stages patients become doubly incontinent. There is minimal literature specifically 
on this subject though a study of 6 patients revealed four with detrusor instability 
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while two had a normal study suggesting a non-organic disturbance. A characteristic 
urodynamic pattern, consisting of choreiform movements of the pelvic floor 
musculature during filling with selective suppression of choreiform contractions in 
the perineum during detrusor contraction was observed though to best of my 
knowledge, this has never been followed up (Wheeler et al., 1985).  
 
In a large study of autonomic symptomatology in HD, using a clinical questionnaire 
rather than formal urological investigation, urgency, urinary incontinence, 
frequency, nocturia, incomplete emptying and straining on defecation were all found 
in both manifest and premanifest subjects (Aziz et al., 2010).  
 
5.2.6.6 Sleep disturbance 
The aetiology of sleeping difficulties in HD is likely to be multi-factorial as patients 
have a profound circadian rhythm disturbance, which mirrors that seen in transgenic 
mice, where diminished gene expression in the suprachiasmatic nucleus is noted 
(Maywood et al., 2010) (Morton et al., 2005). Hypothalamic-pituitary dysfunction 
does undoubtedly play a role leading to sleep fragmentation and sleep-wake cycle 
reversal. Depression and apathy may contribute also through a loss of daytime 
stimulation and activity. Involuntary movements can hinder getting off to sleep as 
well as contribute to middle insomnia. Clinical research has shown that sleep 
disturbance in HD includes insomnia, advanced sleep phase, periodic leg 
movements, REM sleep behaviour disorders and reduced REM sleep (Arnulf et al., 
2008) as well as reduced melatonin levels (Kalliolia et al., 2014). 
 
5.2.6.7 Dysautonomia 
This is a relatively new clinical entity in the HD phenotype though research has 
shown patients with HD commonly have impairment of the autonomic nervous 
system (Bar et al., 2008;Kobal et al., 2004). In a recent study, the most prevalent 
symptoms in 63 patients with HD and 21 pre-manifest mutation carriers, were 
dysphagia, erectile and ejaculatory dysfunction, sialorrhea though xerostomia can 
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also be seen, early abdominal fullness and light-headedness whilst standing (Aziz et 
al., 2010).   
 
5.2.6.8 Cognitive  
A global dementia is not seen in HD until the later stages, rather an affectation of 
specific domains and their connections- a focal frontal subcortical dementia, 
manifesting typically as a dysexecutive syndrome, where patients complain of 
mental slowing, difficulty multi-tasking, failure to initiate, plan and organise tasks, 
maintain concentration and rigid thinking. Occasionally this may manifest or indeed 
be supplemented with a prominent behavioural change such as aggression or 
alternatively withdrawal and change of personality. 
 
Symptoms may be present from the premanifest stage, with one study showing that 
38% of subjects in the premanifest stage had mild cognitive impairment (Duff et al., 
2010). Deficits in processing speed, visuospatial processing, time estimation and 
timekeeping, learning and working memory are also seen in this group. 
Correspondingly, they report difficulty in picking up new tasks though retrieval of 
task specific memories is affected also. There is also reliable evidence of olfactory 
impairment in both premanifest and manifest subjects (Paulsen, 2011;Stout et al., 
2011). It is clear also that cognitive and behavioural symptoms place the greatest 
burden on carers and correlate with functional decline and institutionalisation 
(Hamilton et al., 2003). 
 
Language is markedly spared until the advanced stages where there is undoubtedly a 
mixed component of both dysphasia and dysarthria. However, comprehension is 
believed to be well preserved even in late stages of the disease. Communication 
however can be impacted upon by diminished processing speed and loss of co-
ordinated oro-motor function with respiration (Paulsen, 2011). 
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Characterisation of the cognitive impairment seen in HD has been driven largely by 
clinical research. Although there is substantial evidence of cognitive impairment in 
HD, there is no accepted cognitive battery for testing in premanifest HD clinically. 
Current practice may include the Verbal Fluency, Symbol Digit, Stroop, Category 
fluency as well as Trails A and B and the Hopkins Verbal Learning Test, as derived 
from several years of observational data (Paulsen, 2011;Tabrizi et al., 2011;Tabrizi et 
al., 2012).  
 
In summary there are a large number of clinical symptoms that occur in the course 
of Huntington’s disease (Table 1).  
Table 1- Symptoms & Signs of Huntington's Disease (adapted from (Novak & Tabrizi, 2010)) 
Neurological  
Motor:  
Chorea, dystonia, bradykinesia, rigidity, spasticity, myoclonus, tics, motor impersistence. 
Loss of postural reflexes and balance, walking difficulty and impairment of voluntary motor control. 
Dysphagia and dysarthria. 
Non-motor: 
Urge incontinence 
Sleep disturbance including sleep wake cycle reversal, insomnia, periodic leg movements, REM sleep behaviour 
disorders. 
Cognitive  
Perseveration, impulsivity, perceptual distortions, lack of insight, distractibility and difficulty in learning new 
information. Difficulties with planning, initiating and organising thoughts, activities and communication. 
Psychiatric 
Depression, obsessive-compulsive disorders, anxiety, bipolar disorder, irritability, apathy, hypersexuality, 
psychosis. 
Verbal and/or physical aggression. 
Other 
Weight loss, muscle wasting. 
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5.2.7 Stages of Huntington’s Disease 
 
A working classification of HD denotes early, middle and late stages while the most commonly used 
clinical scale rates the person’s functional abilities over five domains- the Shoulson and Fahn Total 
Functional Capacity Rating Scale (Shoulson & Fahn, 1979) (Table 2). 
 
 
The early stage (I-II) represents the point at which patients have minimal limitation, are usually able 
to maintain employment without comprise and continue to live independently. Minor involuntary 
movements, psychiatric disease and some difficulty when multitasking may be reported. 
The major difference at the moderate stage (III) is the loss of employment while still maintaining 
activities of daily living. Chorea is usually at its peak at this stage, with loss of fine motor control, 
increasing falls and abnormal mobility and gait. Mental inflexibility will manifest more prominently. 
 
At advanced disease stage (IV-V), complete immobility is present as individuals are bed bound and 
require assistance in all activities of daily living. Profound dysarthria also occurs to point of severe 
communication difficulties. Chorea gives way to rigidity, dystonia, and bradykinesia. There is a high 
risk of medical complications. 
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Table 2- Clinical Staging of Huntington’s Disease (Huntington Study Group, 1996; Shoulson et al., 1989a) 
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5.3 Huntington’s Disease Pathophysiology 
5.3.1 Introduction 
 
In the two decades that have passed since the discovery of the gene, much progress has been made 
in elucidating the pathological processes of HD. Huntingtin (HTT) is ubiquitously expressed 
throughout the body but is found in particularly high concentration in the brain, in neurones more 
so than glia, and testes and to a moderate extent in the lungs, liver and heart. It is predominantly a 
cytoplasmic protein, which is amenable to cleavage by proteases.  
 
5.3.2 Neuropathology 
 
It is well established that in HD there is selective neurodegeneration of vulnerable neuronal 
populations. In specific terms, neuronal loss and atrophy occur particularly in the neostriatum- the 
caudate and putamen, though the former is affected to a greater extent.  
 
 
As the disease progresses, generalised brain atrophy ensues such that at post-mortem the brain is 
between 300-400 grams lighter than the average adult brain weight for that age (Mann et al., 1993) 
and the striatum only accounts for 20g of this. Interneurones are generally spared while in contrast, 
the striatal medium spiny neurons, which comprise 90% of the striatal neuronal population, are 
selectively lost. These are predominantly the enkephalin containing projections to the external 
globus pallidum rather than the substance P neurones that connect to the internal globus pallidum. 
From a functional neuroanatomical perspective, the occurrence of chorea early in disease, may 
reflect preferential damage to the indirect pathway of basal ganglia-thalamocortical circuitry 
(Paulsen et al., 2005). In later disease the direct pathway is affected, as well as cortical neurons, 
which may contribute to the loss of motor control, abnormalities of eye movements and 
neuropsychiatric symptomatology.  
 
 
The substantia nigra, distinct cortical layers, the hippocampus, angular gyrus in the parietal lobe, 
Purkinje cells of the cerebellum, hypothalamus and the thalamus are all also affected in HD (Heinsen 
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et al., 1999;Jeste et al., 1984;Kremer et al., 1991;Macdonald et al., 1997;Macdonald & Halliday, 
2002;Spargo et al., 1993). At a microscopic level, cortical neurons show decreased staining of nerve 
fibres, neurofilaments, tubulin, and microtubule-associated protein 2 and diminished complexin 2 
concentrations, suggesting impairment of synaptic function, cytoskeleton and axonal transport 
(DiProspero et al., 2004;Modregger et al., 2002). Nuclear, cytoplasmic and neuritic HTT inclusions 
are seen even in the premanifest stage of disease and are the pathological hallmark of HD. 
Ubiquinated HTT aggregates are found throughout vulnerable and seemingly more preserved 
regions (DiFiglia et al., 1997). Accordingly, a direct toxic effect is not supported by current research, 
instead it may represent the increasingly self-injurious attempt by the neurons to sequester toxic 
protein fragments and render them biologically inert that leads eventually to their downfall (Saudou 
et al., 1998).  
 
 
At 15 years prior to calculated disease onset, there is demonstrable striatal, thalamic and cortical 
white matter loss and whole brain atrophy on brain MRI (Paulsen et al., 2010;Rosas et al., 
2005;Tabrizi et al., 2011). In pathological studies, 80% of the human HD brains show atrophy of the 
frontal lobes, bilateral atrophy of the striatum in 95%, while non-striatal regions show atrophy of 
variable severity or have normal appearance (Halliday et al., 1998;Vonsattel & DiFiglia, 1998). 
 
 
The most well recognized neuropathological classification is the Vonsattel grade. There are five 
grades: grade 0, in which HD brains show no gross or generalised microscopic abnormalities 
consistent with HD, despite premortem symptomatology and positive family history, progressing to 
grade 4, which shows extreme atrophy (Vonsattel et al., 1985). 
 
 
Importantly, compensatory and pathological changes co-exist simultaneously in many different 
areas in the brain, indicating that there is process of dysfunction prior to degeneration, and raising 
the possibility that these tissues could be salvaged with an effective intervention.  
 
 
 
 
 
 
 
  
 Early Phase Disease Modification Trials with Selisistat and Optical Coherence Tomography as a Biomarker in Huntington’s Disease 
UCL PhD Submission 
31 
Dr Salman Haider (Student No.: 1054117) 
 
5.3.3 Role of Huntingtin Protein  
 
Huntingtin is a 348kDA protein, expressed at different levels depending on the tissue type and is 
present within the nucleus and cytoplasm. The normal functions of huntingtin are not yet fully 
known however, neural development, modification of neurotransmitter synthesis and transport as 
well as a role in the integrity and function of the cytoskeleton are proposed (Bates et al., 2015). This 
latter role in organelle trafficking as well as in ciliogenesis and endocytosis, suggest a key role for 
Huntingtin in multiple cellular processes (Saudou & Humbert, 2016).  However, while diminished 
huntingtin function may play a part in pathogenesis, Huntington’s disease is primarily mediated by a 
toxic gain-of-function, through alteration of the conformational state of huntingtin and thus its 
subsequent interactions.   
 
The human HD gene comprises 67 exons and encodes 3,144 amino acids, making up the wild type 
HTT protein and is expressed throughout the brain, in cytoplasm, nuclei, dendrites and axon 
terminals.  The expanded polyglutamine (>36 repeats) mutant HTT is similarly distributed (Vonsattel 
et al., 2008).  
 
Proteolysis of the N-terminal fragment of mutant huntingtin may be important as a pathogenic 
mechanism as they are a major component of the hallmark nucleolar and cytoplasmic HTT 
aggregates found in pathological studies from animal and cellular models. However aggregates in 
themselves are not thought to be toxic and may in fact reflect a compensatory cellular mechanism to 
cordon off toxic fragments. Mutant HTT itself and these N-terminal fragments however have an 
ability to sequester other proteins including transcription factors, which may be a more valid 
pathological pathway.   
 
Dysfunctional axonal trafficking is evidenced in transgenic mice and in mammalian neurones, where 
mutant HTT appears to restrict trafficking of vesicles and mitochondria (Ross & Tabrizi, 2011).  
 
Homozygous HD patients, who by definition only produce mutant HTT, have similar phenotypes to 
their heterozygous counterparts, suggesting that gain of toxic function may be the predominating 
effect (Durr et al., 1999). 
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5.3.4 Mitochondrial pathology in Huntington’s disease 
 
Mutant htt appears to be toxic to mitochondria in R6/2 mice (Beal & Ferrante, 2004). This is 
complemented by in vivo work using Magnetic Resonance spectroscopy in HD subjects, including 
pre-symptomatic, under maximal exercise, which reveals defective mitochondrial oxidative 
metabolism (Lodi et al., 2000). Multiple mitochondrial DNA deletions were found by polymerase 
chain reaction (PCR) analysis as well as variable deficits in complex I of the mitochondrial respiratory 
chain, in muscle of patients with HD (Arenas et al., 1998). Reflecting their early involvement in 
disease, myoblast cell cultures from presymptomatic and symptomatic HD subjects showed 
mitochondrial abnormalities, impaired cell differentiation and htt inclusions (Ciammola et al., 2006). 
 
The transcription co-activator PGC-1α plays a role in mitochondrial biogenesis and cellular 
metabolism. Mutant htt is proposed to inhibit expression of PGC-1α through a promoter interaction 
and disruption of its transcriptional pathway. PGC-1α is reduced exclusively in the medium spiny 
neurons which are preferentially affected in HD striatum (Cui et al., 2006), as well as muscle and 
adipose tissue of HD subjects (Chaturvedi et al., 2009;Phan et al., 2009). Its involvement across 
several tissues marks it out as a key target for further study. 
 
In post-mortem studies, severe deficiencies in mitochondrial complex II and III and sometimes 
complex IV have been reported in the striatum (Bowling & Beal, 1995;Gu et al., 1996). Mutant 
huntingtin may also impact on mitochondrial function through direct physical interaction.  
 
 
5.3.5 Transcriptional dysfunction 
 
The R6/2 mouse model has provided evidence of transcriptional dysregulation, early on in disease. 
Transcriptional down-regulation of mRNA levels of different genes of influential neuronal structures 
and proteins has been noted in humans and animal models. Indeed there exists a significant degree 
of consistency in profiles across these models, underscoring its importance pathologically.  
Mechanistically, nuclear translocation of toxic N-terminal fragments can affect various parts of the 
transcriptional process such as DNA, chromatin modification and interact negatively with 
 Early Phase Disease Modification Trials with Selisistat and Optical Coherence Tomography as a Biomarker in Huntington’s Disease 
UCL PhD Submission 
34 
Dr Salman Haider (Student No.: 1054117) 
 
transcription factors, to cause transcriptional dysregulation (Kumar et al., 2014;Luthi-Carter et al., 
2002;Luthi-Carter et al., 2000). 
 
 
A micro-array analysis of human HD brains versus unaffected controls reveal transcriptional changes 
in the caudate, motor cortex and cerebellum, including in genes governing cannabinoid CB1 
receptor, dopamine D1 receptor and encephalin (Hodges et al., 2006). 
  
5.3.6 Proteasomal and autophagic dysfunction 
 
HD mouse model studies have shown that truncated N-terminal htt fragments with an expanded 
polyQ tract are susceptible to misfolding and aggregation and are more harmful. The degradation of 
these proteins therefore has received some focus from the research perspective. Nuclear HTT 
inclusions are also ubiquitin positive across cellular, animal models and human HD brains, suggesting 
involvement of the ubiquitin proteasome system (UPS) (DiFiglia et al., 1997) 
 
 
In various cellular and animal models of HD, as well as in the post-mortem brains of HD patients, 
nuclear polyQ inclusions are positively labelled by antibodies against ubiquitin (DiFiglia et al., 
1997;Gutekunst et al., 1999). This colocalization led to subsequent studies of whether there is the 
sequestration of UPS components by polyQ inclusions. Indirect assays of UPS function through 
pharmacological inhibition or labelling, have found aggregate accumulation in cellular models, 
however using whole cell homogenates of HD mouse brains, reduced UPS activity was not detected 
(Bett et al., 2006;Diaz-Hernandez et al., 2003;Wang et al., 2008).  
 
 
Removal of misfolded proteins and cell organelles is a slower process, termed autophagy, and is 
solely cytoplasmic. Ubiquitin-proteasome system (UPS) and autophagic inhibitors directly injected 
into the striatum of Hdh (CAG)140 knockin mice demonstrated that UPS is more important to 
clearance of soluble mutant HTT than autophagy  (Li et al., 2010). 
 
 
Although there is not as compelling a role for UPS and autophagic dysfunction in HD pathogenesis as 
some of the other mechanisms described, it is known that both UPS & mitochondrial function 
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declines with age. Thus in combination with ageing, and other unrelated cellular stressors induced 
by the presence of mutant HTT, a gradual slowing and then failure of removal of misfolded HTT may 
occur in the latter stages of the HD pathogenic process.  Indeed work in neuronal and mouse models 
has suggested that there is a preliminary stage of UPS derangement in the presence of HTT 
inclusions, followed by adaptation and restoration of function (Ortega et al., 2010;Mitra et al., 2009). 
A separate disturbance in the autophagy-lysosome pathway has been inferred from experimental 
work showing deficiency in axonal transport as well of the autophagic apparatus in the sequestration 
of substrates (Wong & Holzbaur, 2014;Ochaba et al., 2014;Jimenez-Sanchez et al., 2017). 
 
 
5.3.7 Immunity and inflammation 
 
There is clear evidence from a number of sources for a role for the immune system and 
inflammatory pathways in the kindling, maintenance and progression of HD.  
 
 
Mitochondrial dysfunction which is supported itself by several lines of evidence in HD, may activate 
‘’inflammasomes” with lymphoblasts from homozygous HD patients show mitochondrial 
abnormalities at an ultrastructural level (Squitieri et al., 2006). Chemotaxis or migration of immune 
cells may be impaired in HD leading to unchecked, chronically heightened levels. In a BAC HD mouse 
model, deficient migration of macrophages to an inflammatory stimulus that was mutant HTT 
dependent was demonstrated. Cell migration of monocytes from HD patients was also shown to be 
impaired (Kwan et al., 2012b). 
 
 
Microglia are primary mediators of neuroinflammation in the CNS and in HD, microglia have been 
shown to be stimulated many years before onset of symptoms and has also been shown in an R6/2 
mouse model (Simmons et al., 2007;Tai et al., 2006). 
 
There is evidence of symmetry between the central and peripheral immune system in HD, with the 
finding of increased IL-6 and IL- 8 levels in plasma and striatum, mediated possibly by mutant HTT 
acting distinctly but similarly between compartments {Simmons, 2007 4837 /id;Bjorkqvist, 2008 102 
/id}. R6/2 mice given an IL- 6 neutralizing antibody showed diminution in weight loss and 
improvement on rotarod (Bouchard et al., 2012). 
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The role of the adaptive immune system, including dendritic cells, has only recently been explored. A 
study examining human HD T lymphocytes characteristics including subpopulations and cytokine 
output showed no functional differences in the presence of mutant HTT. This would suggest that 
alteration of innate immune system is the major contributor to the immune dysregulation seen in 
HD (Miller et al., 2015).   
 
5.4 Therapeutic Approaches in Huntington’s Disease 
5.4.1 Pathology to Therapy 
 
Based on the known pathogenesis of HD, several potential therapeutic approaches are possible 
(Figure 2).  
 
  
Figure 2- Outline of potential therapeutic approaches in Huntington’s disease 
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5.4.2 Enhancing Clearance of Mutant Huntingtin 
 
Conditional HD mouse models have supported the idea the continuous presence of mutant HTT is 
required to maintain toxicity and pathology. Consequently, HTT lowering strategies are an attractive 
therapeutic option (Regulier et al., 2003;Yamamoto et al., 2000). Huntingtin-lowering strategies 
include antisense oligonucleotides and RNA interference targeting mRNA, and zinc finger 
transcriptional repressors and CRISPR-Cas9 methods aiming to reduce transcription by targeting 
DNA.  
 
5.4.2.1 Gene Silencing 
Gene silencing or HTT lowering is arguably the most promising of all experimental 
therapies in Huntington’s disease, given its monogenic and dominant inheritance. It 
offers the tantalising possibility to target the pathogenic gene directly and reduce 
HTT levels. There are two main candidates- RNA interference (RNAi), in which the 
silencing molecules are small interfering RNA (siRNA), and antisense oligonucleotides 
(ASOs). 
 
In other genetic neurodegenerative disroders such as superoxide-dismutase 1 
(SOD1) mutation-associated amyotrophic lateral sclerosis, ASOs therapy has been 
employed with no safety or tolerability issues reported (Miller et al., 2013).  In spinal 
muscular atrophy, nusinersen another ASO, is demonstrating slowing of disease 
progression in a previously untreatable neurodegenerative condition (Finkel et al., 
2016).  
 
In rodent models, both approaches have demonstrated efficacy in lowering HTT 
protein, reducing pathology and improving phenotype via intracranial delivery 
(Carroll et al., 2011;Franich et al., 2008;Harper et al., 2005). In primates, proof of 
concept studies have taken place with an RNAi based approach. ASO therapy infused 
via CSF into primate brain regions resulted in reasonable distribution including into 
the cortex without complications. HTT suppression continued for 3 months after the 
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therapy finished, which together suggests that intermittent HTT lowering may be an 
effective strategy (Kordasiewicz et al., 2012).  
 
Exosomes have emerged as another potentially exciting delivery method. They are 
endogenously occurring vesicles that transport RNAs and proteins and deliver to 
their intracellular targets. They have also been used to reduce expression of BACE1 
gene in an Alzheimer’s mouse model (Alvarez-Erviti et al., 2011).  
 
Other approaches to gene silencing include using mismatch-containing duplex RNA 
that targets mutant HTT. In vitro, this has been shown to alter mutant HTT 
production, and reduce generation of toxic HTT fragments (Neuroperspective, 2012). 
 
Genomic editing via zinc-finger nuclease is a novel, potentially promising approach 
for Huntington’s disease that has been successfully applied to treat liver cells from 
mice with haemophilia B (Li et al., 2011). 
 
Finally and most promisingly, in 2015-17 the IONIS-HTTRx trial was conducted with 
early HD patients receiving four lumbar intrathecal bolus doses of ASO or placebo, in 
a multiple escalating dose design with mutant CSF HTT levels as a potential 
therapeutic readout. An open-label extension study is planned and preliminary 
analysis of data would suggest that the drug is safe and well tolerated and does lead 
to reduction of mutant HTT levels in CSF (Ionis Pharmaceutical Press Release 
December 2017). 
 
Trials for other ASOs are foreseen in the near future while viral vector based RNA 
interference therapies and zinc-finger transcriptional repressors are currently being 
investigated in animal experiments. 
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5.4.2.2 Other Approaches to Enhancing Clearance of Mutant Huntingtin 
Studies have shown that acetylation of HTT has been shown to target the mutant 
protein for degradation. Acetylation at a single lysine (K444) facilitates trafficking of 
mutant HTT into autophagosomes and improves clearance of the mutant protein by 
macroautophagy (Jeong et al., 2009).  
 
Pharmacological activation of mTOR (mammalian target of rapamycin)-dependent 
autophagy with rapamycin, attenuated the toxic effects of mutant HTT in fly and 
mouse models of HD. Small-molecule enhancers of autophagy including mTOR-
independent pathways such as autophagy inducers, are in preliminary development 
and being tested in cell models (Pan et al. 2009a). Inhibition of farnesyl transferase, 
a protein responsible for the farnesylation, or lipid modification, of a number of 
proteins has been touted as a possible means of influencing autophagy (Pan et al. 
2009b). This is complicated by the fact that a knock-in mouse HD model suggests 
that HD-specific alterations in autophagy block the trafficking or degradation of HTT, 
necessitating a precise understanding and targeting of the autophagic process 
(Martinez-Vicente et al. 2010).  
 
HD-derived lymphoblasts may provide a good cell model in which to study potential 
therapeutic compounds as autophagic deficits are established in this cell type. The 
important issues to address remain whether peripheral change can have central 
effect. Secondly, current approaches utilising peripheral inhibition of mTOR 
signalling have significant side-effects including ulcerative mucositis, anaemia, and 
neutropenia, which will need to be avoided, as new compounds develop (Mesa, 
2006). 
 
A screen of 253 approved drugs identified several candidates that appear to down-
regulate huntingtin through autophagy, though this has not been definitely 
confirmed. They included L-type calcium channel blockers like nimodipine, the alpha-
2 agonist clonidine, and the antihypertensive minoxidil (Williams et al., 2008).  
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5.4.2.3 Genetic Modifiers and New therapeutic targets  
About 50-70% of the variance in age of onset of HD symptoms is determined by HTT 
CAG repeat length with the remainder potentially also genetically based. A member 
of the DNA mismatch repair pathway, MSH3 has recently been identified via a 
genome wide association study as a novel genetic modifier of disease progression 
(Hensman Moss et al., 2017a). Targeting this modifier directly or its downstream 
pathways therefore has the potential to significantly affect disease trajectory. 
 
5.4.3 Restoring Connectivity 
 
In HD mouse models, researchers have found that the levels of 3’-5’-cyclic adenosine mono 
phosphate (cAMP) in the striatum are lower than in normal mice. Mutant huntingtin disables cAMP 
signalling and transcription mediated by the cAMP response element–binding protein (CREB) (Gines 
et al., 2003;Sugars et al., 2004;Sugars & Rubinsztein, 2003). Enhancing synaptic function through 
preventing breakdown of cAMP and cyclic guanosine monophosphate (cGMP) is a potential 
mechanism being explored currently. However, Amaryllis, a phosphodiesterase (PDE) 10a inhibitor 
which improves striatal and cortical pathology in R6/2 HD mouse, did not meet its targets in the 
human trial (Pfizer, 2017).  
 
A mGluR5 antagonist, had initially positive results in Fragile X but the final outcome was negative in 
HD (Neuroperspective, 2012). Targeting glutamate mediated excitotoxicity was the basis for a month 
long Novartis funded trial of a mGluR5 antagonist called AFQ056. The outcome measure was 
improvement of the chorea seen in HD, but it was negative and no further studies have been 
conducted (Reilmann et al., 2015). 
 
5.4.4 Restoring Healthy Gene Regulation 
 
Mutant HTT mediated transcriptional dysregulation and reduced chromatin deacetylation has been 
well established as a as a pathogenic mechanism in HD (Cha, 2000;Benn et al., 2008). Rolipram, a 
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PDE4 inhibitor, may be able to exert influence on transcriptional processes via modulation of cAMP 
response element binding protein (CREB) signalling with efficacy demonstrated in the R6/2 mouse 
model (DeMarch et al., 2008;Giampa et al., 2009).  
 
Genetic and pharmacological reduction of Sir2, the orthologue of human SirT1, in drosophila, 
rescued neurodegeneration and promoted survival (Pallos et al., 2008). The success of non-selective 
HDAC inhibitors such as suberoylanilide hydroxyamic acid (SAHA) in ameliorating HD phenotypes in 
the R6/2 mouse (Hockly et al., 2003) prompted investigation of other individual HDACs, with class II 
HDAC-selective inhibitors in preclinical development. Trials of HDAC 4 inhibitors are also planned in 
future, after promising knockdown results in HD mice although the mechanism of action is not yet 
clear (Cronk et al., 2012). Preclinical development and early phase results of a class III HDAC SirT1 
inhibitor, Selisistat, are described in Chapter 7. 
 
Other approaches include upregulation of SirT1. Genetic overexpression confers survival and 
neuropathological benefits as well as increased expression of brain-derived neurotrophic factor 
(BDNF) (Jeong et al., 2012). In another separate study, genetic SirT1 overexpression improves motor 
function, reduces brain atrophy and attenuates metabolic abnormalities through maintaining BDNF 
concentrations and the signalling of its receptor, TrkB (Jiang et al., 2012). However no highly 
selective, small molecule activators of SirT1 currently exist. 
 
Transglutaminase inhibitors were suggested to have a role in preventing HTT aggregation. A 
transglutaminase inhibitor cystamine prolonged survival and improved motor features in an animal 
model of HD, though aggregation load was not altered (Bailey & Johnson, 2006;Dedeoglu et al., 
2002). Its effect may be explained by upregulation of neuroprotective genes, including perhaps 
BDNF, which has been seen in drosophila models (Borrell-Pages et al., 2006). An aspartyl protease 
has a key role in the cleavage of HTT, raising the potential for the development of specifically 
targeted inhibitors (Neuroperspective, 2012). 
 
  
 Early Phase Disease Modification Trials with Selisistat and Optical Coherence Tomography as a Biomarker in Huntington’s Disease 
UCL PhD Submission 
43 
Dr Salman Haider (Student No.: 1054117) 
 
5.4.5 Reducing Peripheral & Central Inflammation 
 
Intrastriatal injection of quinolinic acid (QUIN), an NMDA receptor agonist, in rats was shown to 
recapitulate many features of HD (Schwarcz et al., 1983). Glutamate receptor-mediated 
excitotoxicity and free radical formation have been correlated with decreased levels of the 
neuroprotective metabolite kynurenic acid in HD mouse models. Genetic deletion of kynurenine 3-
monooxygenase (KMO) was found to suppress toxicity in a HD model (Giorgini et al., 2005). KMO is 
largely expressed in microglial cells and not found in neurones (Giorgini et al., 2008;Guillemin et al., 
2003), suggesting a pathological mechanism beyond that occurring within the neurone itself.  
 
In the transgenic HD mouse model, a peripherally administered KMO3 inhibitor, prevents formation 
of the neurotoxic QUIN and ameliorates neurodegeneration (Zwilling et al., 2011). The implied 
promise of this approach, which is yet to be validated in HD, is that by applying a compound 
peripherally, a meaningful central effect can be achieved.   
 
Mutant HTT mediated innate immune dysregulation has been suggested as a modifier of disease 
(5.3.7). Transplantation of healthy wild-type bone marrow into HD mice restored cytokine reactivity 
to normal levels and led to synaptic plasticity and amelioration of phenotypic and neuropathological 
measures (Kwan et al., 2012a). 
 
Cannabinoid system is known to regulate inflammatory cascades. Cannabinoid (CB)2 receptor 
knockout HD mice have accelerated clinical pathology; treatment with peripherally administered  
CB2 agonists, dampens microglial activation and levels of circulating pro-inflammatory cytokines 
(Bouchard et al., 2012;Palazuelos et al., 2009;Sagredo et al., 2009;Bouchard et al., 2012).  
 
Laquinimod reduces proinflammatory cytokine release in monocytes and acts to modulate astrocytic 
and microglial activity via NFκB signalling. Recent work in monocytes from premanifest and manifest 
HD patients and controls showed abrogation of the hyper-reactive cytokine release from all three 
groups with the manifest population impacted most strongly, and that this effect was NFκB 
independent (Dobson et al., 2016).   
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5.4.6 Neurotrophic Support 
 
The neurotrophic factor BDNF mediates neural development and neuroprotection, and is 
upregulated by normal huntingtin. A few studies have used adeno associated virus (AAV) to 
introduce BDNF expression into the subventricular zone, increasing striatal neuron survival in mouse 
models (Bemelmans et al., 1999;Kells et al., 2004).  
 
Ampakines have been shown to upregulate the production of BDNF, which in turn leads to a 
proliferation of neural stem cells in the striatum. Reduced degeneration and improvements in 
cognitive function were seen in a HD transgenic mouse model (Simmons et al., 2009). Research is 
being directed toward identifying TrKB receptor agonists to increase BDNF levels. 
 
5.4.7 Cell Transplantation  
 
Most cell-implant concepts for HD have focused on the striatum, and while this could be relevant to 
motor symptoms, the cognitive deterioration is unlikely to be affected. Surgically delivered striatal 
cell replacement therapy for HD has been attempted in small studies for over two decades, with the 
majority using human foetal tissue for cell harvesting. Although modest motor improvements have 
been seen, no sustained improvement has been achieved thus far. Importantly, deterioration of 
grafted cells was seen at autopsy in 3 subjects (Bachoud-Levi et al., 2000;Bachoud-Levi et al., 
2006;Cicchetti et al., 2009). Lack of integration with host neural architecture and early degeneration 
due to microglial activation are arguably the most significant difficulties to overcome. This approach 
appears to offer a temporary symptomatic benefit only. Autologous cell sourcing may be a viable 
alternative but needs to be developed.  
 
5.4.8 Post-translational Modification 
 
Post-translational modifications, such as phosphorylation, contribute significantly to the toxicity of 
mutant HTT. This is largely thought to be protective from the results of cell culture experiments (at 
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serine 13, 16 and 421) and thus therapeutic development would require targeting of the specific 
kinase to augment its function and repress the corresponding phosphatase activity (Zala et al., 
2008;Gu et al., 2009;Warby et al., 2005). By way of example, phosphorylation of serine 116 
heightens mutant HTT toxicity (Watkin et al., 2014), and thus targeting the responsible kinase would 
be a potentially promising strategy. HTT can undergo palmitoylation, specifically at cysteine 214, 
which enhances membrane association. Acetylation at lysine 444, augments its clearance (Jeong et 
al., 2009).  The N-terminus located 17 amino acids are highly disposed to modification, including 
phosphorylation, ubiquitination, and sumoylation (Ross et al., 2017).  
 
In murine models, intraventricular infusions of ganglioside GM-1, a natural component of ‘lipid rafts’ 
which serve a myriad of cell-signalling support roles in the brain, results in phosphorylation of 
mutant HTT, neutralising its toxic effects and improving motor function (Di et al., 2012). 
 
5.5 Clinical Trials Landscape in HD 
5.5.1 Introduction 
 
As an orphan disease, HD may not initially be perceived as financially attractive when it comes to 
outlay for drug development and clinical trials. However as a prototypical, neurodegenerative 
disease with a predictive, fully penetrant genetic test it does carry certain key advantages. Currently 
however, other than symptomatic treatment of chorea, there has been no disease modifying 
therapy established in human studies. While a lack of therapeutic compounds could be in part one 
explanation, the complexity and long-time course of the disease, necessitates development of valid 
biomarkers tested in well-designed and suitably powered clinical trials.  
 
The traditional determinant of disease onset has been the development of motor features. 
Paradoxically the absence of a clearly successful intervention that leads to a change in the TMS and 
confers a functional benefit to the patient has also hamstrung research. The UHDRS assessments 
were designed to quantify functional deficits in multiple domains such as motor, cognitive, 
behavioural and psychiatric. They were not however designed with clinical trials in mind. Indeed 
early motor features can be underrepresented by the TMS and legitimate concerns over inter and 
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intra-rater reliability exist. Imaging, novel quantitative motor and neuropsychiatric and cognitive 
assessments at the perimanifest/prodromal phase, have the potential to supplant clinical 
assessments. Similarly however, these biomarkers must be held to same standard namely that 
improvement in their metrics mirrors a functional improvement or as a minimum, functional 
stability. 
 
Broadly, clinical therapeutic approaches can be divided into ‘Advanced therapies’, with a regulatory 
definition of “new medical products based on genes (gene therapy), cells (cell therapy), and tissues 
(tissue engineering)—RNA-based therapies- interference RNA (RNAi), or antisense oligonucleotides 
(ASOs)”; new compounds; surgical strategies e.g. deep brain stimulation and finally ‘Reinforcement 
or stimulation’ therapies- repetition of a procedure e.g. aerobic exercise or cognitive training 
(Sampaio et al., 2014). 
 
5.5.2 Current Trials in HD 
 
At the present moment, no drug has been shown to delay disease progression in HD. The vast 
majority of clinical trials to date in HD use drugs that were not developed specifically for the 
treatment of HD (Table 3).  
 Early Phase Disease Modification Trials with Selisistat and Optical Coherence Tomography as a Biomarker in Huntington’s Disease 
UCL PhD Submission 
47 
Dr Salman Haider (Student No.: 1054117) 
 
Table 3- Currently active trials in Huntington’s Disease (McColgan & Tabrizi, 2018) 
 
5.5.2.1 Cysteamine 
Cysteamine increases brain-derived neurotrophic factor, a growth factor depleted in 
the brains of HD patients. The effect of cysteamine on motor progression in HD has 
been evaluated in a 3-year phase 2/3 trial. This revealed that it was safe and well 
tolerated but no statically significant change in motor progression was evidenced 
(Ross & Tabrizi, 2011). 
 
5.5.2.2 PDE10A Inhibitors 
Phosphodiesterase 10A (PDE10A) is found in the striatum and is reduced in HD 
patients many years before the onset of manifest disease (Niccolini et al., 2015). In 
the Pfizer Amaryllis phase 2 trial, no change was seen in motor, cognitive or 
behavioural measures (Pfizer, 2017). 
 
5.5.2.3 Pridopidine 
Pridopidine, a dopamine modulator, has been studied in three separate large phase 
3 trials, MermaiHD, HART and Pride-HD failed to meet their primary end-points 
(McColgan & Tabrizi, 2018). Pridopidine associates particularly with active D2 
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receptors and is thus viewed as a dopamine modulator, rather than a pure 
antagonist of the D2 dopamine receptor. In two large, phase III trials, although 
Pridopidine was safe and well tolerated it failed to meet the primary end-point. 
However, an improvement in the UHDRS total motor score (TMS) in two randomised 
controlled clinical trials at 90mg dosing led to a new phase II/III trial (PRIDEHD) to 
explore a new dose range but unfortunately this did not prove effective (de Yebenes 
et al., 2011;The Huntington Study Group).  
 
5.5.2.4 Deep Brain Stimulation 
DBS implantation has been employed in Parkinson’s disease, essential tremor, and 
dystonia. However, information regarding the potential use of DBS in HD is limited 
and its utility in managing chorea questionable, given that chorea usually declines 
with disease progression. Moreover, concerns over the potential negative cognitive 
impact of DBS must also be addressed. A small 12 week phase II trial is planned 
(Wojtecki et al., 2016). 
 
5.5.2.5 PBT2 
PBT2 is a second-generation metal protein attenuating compound (MPAC) designed 
to restore copper and zinc ion homeostasis that can be disrupted in 
neurodegenerative diseases. The Reach2HD phase II trial was carried out in 2012/13, 
comparing a 6-month course of 100mg or 250 mg of PBT2 once-daily to placebo in 
109 patients with mild to mid-stage HD. Compared with placebo, neither PBT2 100 
mg nor PBT2 250 mg significantly improved cognitive scores, aside from the Trail 
Making Test Part B score in the PBT2 250 mg group. The authors concluded that 
PBT2 was generally safe and well tolerated but that a larger study is required to 
determine whether the cognitive improvement is a robust finding (Huntington Study 
Group, 2015).   
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5.6 Biomarkers in Huntington’s Disease  
 
Although primary clinical endpoints are readily apparent in some diseases, e.g. mortality and tumour 
size in cancer, for neurodegenerative diseases, especially Huntington’s disease, such measures are 
not yet defined.  
 
Indeed noting the chronic and degenerative nature of HD and related conditions, it is unrealistic for 
a given therapeutic intervention, to completely reverse the phenotype in manifest subjects; rather a 
slowing of disease progression may be a more reasonable outcome. Intervention in premanifest 
subjects may reasonably aspire to delay motor onset of the disease, the traditional determinant of 
the diagnosis of clinical HD.  
 
Moreover given a mean life expectancy of 20 years from disease onset in HD, it is unlikely that 
outcomes used to determine the diagnosis of HD e.g. UHDRS motor or those that look at physical 
performance qualitatively, are sensitive enough to determine progression over the sort of time 
frames required for clinical trials. 
 
Therefore in order to establish disease modification a biomarker or set of biomarkers is required 
that reliably marks disease progression over 6 months to 2 years. At present there are no biomarkers 
sensitive enough to detect disease progression over the sort of time frames that would be required 
for cost-effective clinical trials in premanifest HD. In early HD there are emerging measures over a 24 
month period. It is likely that no single modality will be sufficient to assess the effect of a treatment 
and that a range of functional measures will be needed.  
 
5.6.1 Observational Studies 
 
Several large, multi-national, longitudinal, observational studies such as PREDICT-HD, TRACK-HD, 
COHORT, REGISTRY and ENROL-HD are examining clinical markers (Euro-HD Network REGISTRY 
Steering Committee, 2003;Paulsen et al., 2008;Tabrizi et al., 2009;, 2012).  
 Early Phase Disease Modification Trials with Selisistat and Optical Coherence Tomography as a Biomarker in Huntington’s Disease 
UCL PhD Submission 
51 
Dr Salman Haider (Student No.: 1054117) 
 
5.6.1.1 REGISTRY & ENROLL-HD 
The European HD Network’s (EHDN) REGISTRY study is the largest study of HD to 
date and is an observational, prospective, multi-centre cohort study of HD which 
aims to establish a well-characterised European-based HD population to facilitate 
high-quality research. It collects phenotypical data and biospecimens from 
individuals who are at risk of, premanifest or manifest for HD, and includes age- and 
gender-matched control participants (Orth et al., 2010). The Enroll-HD study will 
combine patients from COHORT and REGISTRY studies and include additional 
patients from Central and South America in the largest natural history study of HD 
(Enroll-HD, 2012). 
 
5.6.1.2 PREDICT-HD 
This study aims to identify biological predictors of disease onset and progression, in 
premanifest subjects. Psychomotor processing, emotion recognition, and working 
memory are found to be the most sensitive in distinguishing individuals according to 
time to predicted disease onset (Stout et al., 2011).  
 
5.6.1.3 TRACK-HD 
TRACK-HD is a multi-site international study aimed at determining what assessments 
are suitable as outcome measures in clinical trials. Using a unique, novel objective 
quantitative motor assessment battery for finger tapping, tongue protrusion and 
postural control, one is able to differentiate patients according to disease stage 
(Tabrizi et al., 2009). However, only the indirect circle tracing task changed 
significantly over 1 year in premanifest individuals. In the early HD group, the largest 
effect size was seen in the symbol digit modality test, a test of cognitive and motor 
processing (Tabrizi et al., 2011). 
 
Longitudinal imaging data has also been acquired and analysed as part of TRACK-HD 
where significantly greater progressive grey-matter, white-matter, whole-brain, and 
regional atrophy was seen in the premanifest and early HD groups, with the caudate 
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and white matter most affected. However, no significant functional changes over 24 
months were seen in the premanifest group (Tabrizi et al., 2012). Thus a series of 
validated assessments can be recommended as sensitive outcome measures, for use 
in disease modifying trials in early HD subjects. 
 
5.6.1.4 PADDINGTON Imaging Biomarker Study 
For the purposes of clinical trials, a crucial question is whether MRI brain and other 
assessments are sensitive enough to detect change over a 6 month interval. The 
PADDINGTON Imaging Biomarker Study seeks to answer this question. All subjects 
had a baseline visit and then at 6 months and 15 months. Subjects underwent 
clinical, neuropsychiatric, cognitive, quantitative motor and MRI assessments as well 
as donating fasting and non-fasting blood samples at each visit, for cholesterol 
metabolites, amino acid and immunity marker measurements. Longitudinal changes 
in macrostructural neuroimaging measures such as caudate atrophy and ventricular 
expansion were significantly larger in HD than controls, over the 6-month, 9-month 
and 15-month intervals, suggesting a potentially viable time-frame for clinical trials 
(Hobbs et al., 2015). 
 
5.6.2 Unified Huntington’s Disease Rating Scale 
 
The UHDRS is a comprehensive tool for the clinical assessment of HD patients developed first in 
1996 and refined in 1999, comprising motor, behavioural, cognitive, functional and historical 
domains (Huntington Study Group, 1996;Huntington Study Group, 1999). It remains the most 
utilised assessment in observational and clinical trials. The Total Functional Capacity (TFC) subscale 
of the UHDRS represents the rate of functional decline in Huntington’s disease patients but limited 
reliability and sensitivity of this informal 13-point scale may diminish its usefulness in clinical trials.  
 
Progression of UHDRS item scores was assessed in a longitudinal study of 379 patients suffering from 
early HD, with linear progression found for all three functional measures and specific motor features 
including chorea, finger tapping and pronation/supination, gait, tongue protrusion and tandem 
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walking, suggesting a potential role for an abbreviated version (Meyer et al., 2012). However, the 
time frames necessary in which to see a reliable change are not feasible for clinical trials which are 
usually designed with six month to one year efficacy intervals. Item scores may also be subject to 
bias and intra-rater and inter-rater variability (Henley et al., 2005).   
 
Moreover, no matter how rigorously clinical assessment is carried out, it represents the end-point of 
a series of pathological events. It can be influenced by other factors, some unrelated to the 
underlying pathology of the disease, such as medication, training and practice effects, as well as the 
general physical and psychological state of the patient.  
 
5.6.3 Other Imaging Biomarkers 
 
5.6.3.1 Functional MRI and Diffusion Tensor Imaging 
In premanifest subjects with normal cognitive scores, fMRI revealed enhanced 
activation in selective cortical regions, which may be explained by a compensatory 
response to on-going primary striatal or localised cortical dysfunction (Paulsen, 
2009). Alternatively, these unexpected activation patterns might be markers of 
neuronal dysfunction (Georgiou-Karistianis, 2009). However results have been 
inconsistent using this modality and though its potential to interrogate specific 
neural networks is clear, further technical advancements need to be made. 
 
A longitudinal study of white matter microstructural change using Diffusion Tensor 
Imaging (DTI) demonstrated advancing but diffuse leukoencephalopathy, with some 
regions unchanged in the early HD stage (Gregory et al., 2015a). 
 
In another DTI study of premanifest and early HD subjects, significant correlations 
between depression scores and reduced fractional anisotropy (FA) in the splenium of 
the corpus callosum were noted. Those with prominent irritability showed more 
widespread loss of FA and were further from disease onset. This adds to the natural 
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history of the evolution of symptoms in HD, suggesting that white matter changes 
relating to both depression and irritability in HD occur at different times (Gregory et 
al., 2015b). 
 
5.6.3.2 Magnetic Resonance Spectroscopy (MRS) 
Lower concentrations of putaminal N-acetyl aspartate were seen in HD subjects 
following an MRS study, suggestive of striatal pathology and confirming earlier 
studies (Sturrock et al., 2010). MRS can also provide a means of assessing striatal 
glutamate and glutamine and therefore a way of modelling excitotoxicity in HD.  
 
5.6.3.3 White Matter in Huntington’s Disease 
The white matter loss seen in HD occurs first within the corpus callosum, and in the 
posterior white matter tracts. The order in which these changes occur and why these 
white matter connections are specifically vulnerable is unclear. A diffusion 
tractography study in premanifest HD subjects, suggests that the length of white 
matter connections between a brain area and its neighbours predicts the rate of 
atrophy over 24 months (McColgan et al., 2017).  
 
Corticostriatal, interhemispheric, and intrahemispheric white matter connections at 
baseline and over 24 months in premanifest Huntington's disease are associated 
with gene expression profiles enriched for synaptic genes and metabolic genes, with 
the former carrying more genes associated with abnormal transcription in HD. This 
suggests that transcription dysregulation in synaptic genes rather than metabolic 
may be responsible for white matter loss seen in HD (McColgan et al., 2018). 
 
5.6.3.4 Positron Emission Tomography  
PET has been employed to assess regional patterns of glucose uptake and 
dopaminergic signalling as potential disease markers in HD. Accordingly, striatal and 
cortical glucose reductions have been recorded. In patients with HD and in 
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premanifest gene carriers, longitudinal PET imaging revealed a rate of deteriorating 
striatal metabolism that seemed more aggressive in manifest than in premanifest 
individuals. Reduced D1 and D2 receptors, which are highly expressed in vulnerable 
medium spiny neurons, have been observed correlating with disease duration, 
cognitive impairment and motor deficits (Berent et al., 1988;Ciarmiello et al., 
2006;Kuwert et al., 1990;Young et al., 1986).  
 
The toxic effect of mutant huntingtin primarily in striatal medium spiny neurons, 
which highly express phosphodiesterase 10A (PDE10A) is well established. PDE10A 
could be a key therapeutic target in Huntington's disease. Combined positron 
emission tomography (PET) and multimodal magnetic resonance imaging was 
employed to determine PDE10A expression in vivo in a unique cohort of 12 early 
premanifest Huntington's disease gene carriers with a mean estimated 90% 
probability of 25 years before disease onset. PDE10A expression in early premanifest 
Huntington's disease was decreased in striatum and pallidum and increased in motor 
thalamic nuclei, compared to a group of matched healthy controls (Niccolini et al., 
2015).  
 
5.6.4 24S-hydroxycholesterol 
 
24S-hydoxy cholesterol (24OHC) is a product of brain oxidative cholesterol metabolism and is 
thought to be important for CNS development and function. Lowered concentrations of plasma 
24OHC have been reported in patients and premanifest individuals, and they correlated with 
caudate atrophy and probability of onset of motor symptoms (Leoni et al., 2008). 
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5.6.5 Novel Biomarkers 
5.6.5.1 Genomic profiling  
This approach has significant potential but a limited number of studies have been 
carried out, one of which found transcriptional alterations in HD participants, 
sensitive enough to distinguish between controls and premanifest individuals 
(Borovecki et al., 2005). 
 
5.6.5.2 Huntingtin Quantification 
A novel soluble mutant huntingtin assay, using a technique known as Förster 
resonance energy transfer (FRET) has shown that mean mutant HTT levels in 
monocytes, T cells, and B cells differ significantly between patients, controls, pre-
manifest mutation carriers and those at clinical onset. An association with disease 
burden scores and caudate atrophy rates in patients with HD was also seen (Weiss et 
al., 2009). Development of HTT assays will allow quantification from a variety of 
sources (cerebrospinal fluid, blood and peripheral tissues) and will be important for 
mutant HTT reduction based therapies.  
 
An ultrasensitive single-molecule counting (SMC) mutant Huntingtin (mHTT) 
immunoassay was used to quantify mHTT levels in CSF samples from individuals 
bearing the HD mutation and from control individuals. mHTT was undetectable in 
CSF from all controls but quantifiable in nearly all mutation carriers, which was 3-
fold higher in manifest patients than premanifest subjects. mHTT levels also 
correlated with disease progression and were associated with 5-year onset 
probability (Wild et al., 2015). 
 
Quantification of huntingtin levels from peripherally, is evidently a much preferred 
option. Previously mutant HTT (mHTT) was significantly elevated in purified HD 
patient leukocytes compared with controls. Peripheral blood mononuclear cells 
(PBMCs) levels of mHTT were measured using a more efficient ELISA-based Meson 
Scale Discovery (MSD) electrochemiluminescence immunoassay platforms, 
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confirming previous findings that mHTT increases with advancing disease stage in 
patient PBMCs (Hensman Moss et al., 2017b). 
 
5.6.5.3 Neurofilament light chain  
Neurofilament light (NfL) protein in blood plasma has been proposed as a biomarker 
of neurodegeneration in general and work recently in HD has found associations 
between increased NfL levels and reduced brain volume in cortical and subcortical 
grey matter and within white matter. Longitudinally, NfL predicted subsequent 
occipital grey matter atrophy and widespread white matter reduction (Johnson et 
al., 2018) (Byrne et al., 2017). 
 
5.6.5.4 Immune Biology  
The pivotal role of the immune system acting as a modifier of disease, has been 
demonstrated both centrally, mediated through activated microglia in early disease 
(Tai et al., 2006), and by their monocyte counterparts peripherally, through the 
innate immune response. In premanifest and early Huntington’s disease there is 
widespread evidence of innate immune activation detectable in plasma throughout 
the course of HD, starting before the onset of clinical symptoms (Dalrymple et al., 
2007). Elevated cytokine levels have been found in post-mortem brain and plasma 
samples of patients with HD. Concentrations of interleukin 6 were increased in 
premanifest subjects 16 years from predicted phenoconversion, the earliest 
biochemical abnormality recognised in gene carriers (Bjorkqvist et al., 2008). 
 
5.6.5.5 Optical Coherence Tomography 
Optical coherence tomography (OCT) is a non-ionising imaging modality of the 
retinal nerve fibre layer (RFNL) at micrometre resolution, with rapid, consistent data 
acquisition. The speed of sampling, in the order of a few minutes, confers a 
considerable advantage over MR scanning. It has been employed in clinical use in 
monitoring of glaucoma, retinal diseases as well as in research studies looking at 
optic neuritis. This is explored in Chapter 11. 
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 Aims of Thesis 6
 
1. To determine safety and tolerability of selisistat in early Phase trials in Huntington’s 
disease. 
 
2. To determine if the disordered innate immune system in Huntington’s disease is a 
target for selisistat. 
 
3. To determine if a useful motor phenotype segregation method can be developed in 
Huntington’s disease.   
 
4. To utilise the segregation method to see if regional atrophy may underlie the 
differences in clinical phenotype. 
 
5. To determine the viability of optical coherence tomography as a biomarker in 
Huntington’s disease. 
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 Phase 1B Study 7
7.1 Sirtuins 
7.1.1 Selisistat- Biology  
 
SEN0014196 (6-chloro-2, 3, 4, 9-tetrahydro-1H-carbazole-1-carboxamide), or selisistat, functions as a 
sirtuin inhibitor, deacetylating lysine residues. It is a highly selective inhibitor of the silencing 
information regulator T1 (SirT1), 200 fold greater than SirT2 or SirT3 and likely functions as a 
nicotinamide mimetic. It is classed as a histone deacetylator (HDAC). 
  
7.1.2 Histone Deacetylators 
 
Regulation of transcription is controlled by a 
number of factors, one of which is alteration of 
the accessibility to DNA. Mechanistically this is 
achieved through post-translational 
modification to proteins, including histones, 
which, through their intimate association with 
chromatin, control access to DNA. Acetylated 
histones correspond with gene activity, while 
deacetylated histones reduce transcription 
(Kouzarides, 2007). HDACs are highly 
conserved across species and can be 
subdivided in to the zinc-dependent or classic 
HDACs and the NAD+-dependent Sir2-like 
group of Sirtuins (class III HDACs) (Table 4).  
 
However, it is clear also that HDACs have targets beyond the histones themselves, including 
transcription factors and have been implicated in potential roles in ageing, metabolism and lifespan 
(Finkel et al., 2009). 
Table 4- HDAC Orthologs in Yeast, Worm, Fly. Adapted from 
(Pallos et al., 2008) 
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7.1.3 Sirtuins 
 
Sirtuins are class III, nicotinamide adenine dinucleotide (NAD) dependent HDACs, possessing a 
conserved catalytic core domain comprised of approximately 275 amino acids. They regulate 
transcription, cell survival and metabolism.  
 
There are seven human Sirtuins (SirT1–7) and they are differentiated in part by their cellular 
localisation. SirT1 is located in the nucleus and cytoplasm, SirT6 and SirT7 are found in the nucleus 
and SirT3-5 within mitochondria (Frye, 2000). With the exception of SirT4 they all possess a 
deacetylase activity. The coupling of their deacetylase activity to availability of NAD+ has led to the 
suggestion that they may act as metabolically gated sensors of the cell.  
 
7.1.3.1 SirT1 
Amongst the seven identified mammalian homologues, SirT1 is believed to most 
closely resemble yeast Sir2 (silent information regulatory 2). Indeed Sirtuins were 
first characterised as orthologues of the yeast Sir2 protein, where increased activity 
of the protein lead to an extended replicative life span in yeast, C.elegans and 
D.melanogaster (Kaeberlein et al., 1999;Rogina & Helfand, 2004;Tissenbaum & 
Guarente, 2001). Conversely, experimental lowering of Sir2 activity in the context of 
malnutrition increased chronological life-span (Fabrizio et al., 2005). 
 
There is evidence that SirT1 modulates transcription factors such as PGC-1α, p53 and 
FOXO 3a (Morris, 2005;Luo et al., 2001;Rodgers et al., 2005). Differences in tissue 
specific expression are also noted, with SirT1 found in neurones, heart, liver, kidney, 
blood and spleen (Gao et al., 2012). SirT1 itself has a molecular mass of 81.7kDA and 
is predominantly found in the nucleus in association with euchromatin but has also 
been identified in the cytoplasm (Tanno et al., 2007). 
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7.1.3.2 SirT1 in Health and Disease 
SirT1 appears to have important roles in development, DNA repair, cell fate, 
metabolism and ageing. SirT1 complete knockout mice around birth and suffer with 
retinal, bone and cardiac defects (Finkel et al., 2009).  There is evidence that SirT1 
has a role in both pro- and anti-apoptotic processes from a variety of cellular 
experiments (Cheng et al., 2003;Brunet et al., 2004). SirT1 may have role in 
mediating vascular tone and vascular disease via augmentation of endothelial nitric 
oxide through deacetylation of its calmodulin-binding domain (Mattagajasingh et al., 
2007). SirT1 may regulate PGC1a, which is involved in glucose metabolism, lipolysis 
and mitochondrial biogenesis (Escande et al., 2010;Milne et al., 2007). Expression of 
SirT1 is reduced with correspondingly increased levels of NFkB activity, in lungs of 
smokers and sufferers of chronic obstructive pulmonary disease (COPD) 
(Rajendrasozhan et al., 2008). 
 
7.1.4 SirT1 and Neurodegenerative Disease 
 
In neuronal tissues a role for SirT1 is implicated in differentiation, abrogating neurodegeneration, 
with pharmacological and genetic reduction of SirT1 protective in Alzheimer’s disease (AD) and 
amyotrophic lateral sclerosis models (Kim et al., 2007). 
 
Activation of SirT1 via calorie restriction has been shown to decrease the number of amyloid plaques 
in a mouse model of AD (Qin et al., 2006) while in vitro NFκβ inhibition via SirT1 abrogates amyloid-
beta Aβ toxicity (Chen et al., 2005).  
 
In a mouse AD model, pharmacological enhancement of SirT1 by resveratrol improved functional 
outcomes and deacetylated p53 and PGC1α (Kim et al., 2007). SirT1 has also been shown to 
deacetylate tau and thus aid in it removal, which can improve cognitive function and neuronal loss in 
mice (Min et al., 2010). However SirT1 inhibition has also been shown to neuroprotective in AD (Li et 
al., 2008). In Parkinson’s disease, SirT1 overexpression in cellular and animal models reduced 
formation of α-synuclein aggregates (Donmez et al., 2012). 
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7.1.5 SirT1 and Huntington’s Disease 
 
In a Caenorhabditis elegans neuronal model, SirT1 upregulation and augmentation by resveratrol 
treatment was neuroprotective in the presence of mutant HTT (Parker et al., 2005). Utilising the 
same compound in the N171-82Q transgenic HD mouse model, no effect was seen on weight loss, 
motor function or striatal atrophy, though interestingly peripheral markers in adipose tissue and 
blood glucose levels did show improvement (Ho et al., 2010). 
 
In the HD R6/2 mouse model crossed with a brain-specific SirT1 knockout (BSKO) or knockin (SirT1-
KI), the former was associated with a more severe neurodegenerative phenotype, the latter, with an 
improvement in pathology, lifespan and BDNF levels. Mechanistically, the presence of CREB-
regulated transcription co-activator 1 (TORC1) was shown to be required for BDNF expression (Jeong 
et al., 2012).  
 
Using different mouse models, bacterial artificial chromosome (BAC-HD), a full length HTT model, 
and a N171-82Q model, overexpression of SirT1 was found to be beneficial in terms of 
neuropathology and physical attributes, with its deacetylase function key to its function. Interaction 
with Foxo3a, with improvement in BDNF levels, was suggested as potential mechanism for this 
effect. Importantly, inhibition of SirT1 deacetylase activity by mutant HTT was also evidenced, 
suggesting this as a potential pathological step that could be targeted therapeutically (Jiang et al., 
2012). 
 
7.1.6 Other HDACs & Huntington’s Disease 
 
Expression of mutant HTT exon 1 in PC12 cells results in a global hypoacetylation of histones, which 
is abrogated by the HDAC inhibitors sodium butyrate, trichostatin A (TSA) and suberoylanilide 
hydroxamic acid (SAHA). In Drosophila bearing Httex1p 93Q that are fed SAHA or sodium butyrate, 
or subject to genetic reduction of HDAC activity, increased survival and reduced rhabdomere 
degeneration is seen (Steffan et al., 2001).  
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In R6/2 mice, sodium butyrate improved longevity while both sodium butyrate and SAHA improved 
rotarod performance, neuropathology and reversed global hypoacetylation of histones (Ferrante et 
al., 2003;Hockly et al., 2003).  
 
In HD-N171-82Q mice given phenylbutyrate at 75 days of age, lifespan extension and decreased 
striatal atrophy and ventricular enlargement was noted, however no effect on motor performance, 
weight loss or HTT aggregate formation was seen (Gardian et al., 2005).  
 
Treatment with class I histone deacetylase inhibitor prevented initiation of the kynurenine pathway 
in microglia expressing a mutant huntingtin fragment in a yeast HD model. Application of SAHA 
blocks production of neurotoxic kynurenine pathway metabolites in microglia of HD mice (Giorgini et 
al., 2008). Other work has intriguingly suggested that certain HDACs are novel promoting factors for 
tri-nucleotide repeat expansion in budding yeast and human cells (Debacker et al., 2012).  
 
7.1.7 Histone Deacetylators as Therapeutic Targets 
 
Although several HDAC inhibitors (HDACi) are in trials, largely as anti-cancer therapies, vorinostat 
(SAHA) is one of only a few used in current clinical practice, in the treatment refractory cutaneous T 
cell lymphoma. Sodium valproate which has been used for many users as an anti-epileptic drug and 
mood stabiliser has weak, broad spectrum HDACi activity. 
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7.2 Selisistat Pre-clinical Data 
(Unless stated, all data presented here is confidential data reproduced with kind permission of Siena 
Biotech SpA.) 
 
7.2.1 Cellular Models- PC12 & Primary Rat Striatal Neurones 
 
Selisistat is neuroprotective in a transfected inducible mutant HTT PC-12 and primary rat striatal 
neurone cell line (Figure 3) (Smith et al., 2014).  
 
 
 
 
 
7.2.1.1.1 Drosophila 
 
 
 
 
 
 
 
7.2.2 Drosophila 
 
In a drosophila model expressing mutant HTT exon 1, Sir2 (SirT1 mammalian orthologue) levels were 
manipulated, genetically by knockdown and pharmacologically, using inhibitors, with growth, 
survival and neurodegeneration as outcomes measures (Figure 4). 
p<0.006 
  
 
p>0.05 
Figure 3- Neuroprotective effects of selisistat in rat striatal neurons challenged with mutant Htt 
(N171-Q82) or wtHtt (N171-Q19), through lentiviral delivery. Neuronal numbers (NeuN count) are 
significantly decreased in cultures challenged with mutant Htt (Smith et al., 2014) 
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7.2.2.1  
 
 
 
 
 
 
 
 
A neurodegeneration and survival benefit is shown with reduced dose genetically and 
pharmacologically in a HD drosophila. In the presence of the compound (Figure 4 Panel C) the 
neurodegeneration is abrogated in a similar manner to the above. Overexpression however does not 
offer any benefit, while complete Sir2 knockouts show more neuronal loss and loss of climbing 
ability, suggesting a haploinsufficiency or reduced dose effect of Sir2 is beneficial.  
Survival Neurodegeneration 
Neurodegeneration 
A 
C 
B 
Figure 4- (Pallos et al. 2008 (A & B) & (Smith et al. 2014) (C)) Reduced sirtuin levels are neuroprotective in 
a drosophila HD model: A- 50% reduction of Sir2 (i.e. heterozygous null) leads to greater survival to 
adulthood, B- an increased number of photoreceptor neurons of Httex1p Q93-expressing flies and C- 
selisistat (Compound E) phenocopies Sir2 haploinsufficiency and pharmacological inhibitors used in A. 
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7.2.3 R6/2 Mouse Data  
  
At differing doses (5, 20 and 40mg/kg), selisistat reduces neuropathology, improves survival, body 
weight and motor characteristics in R6/2 mice (Figure 5 & Table 5). 
Figure 5- (Smith el al. 2014) A therapeutic study in the R6/2 HD mouse model demonstrated amelioration of 
pathology- number and size of intranuclear inclusion bodies and ventricular volume. 
Table 5- Heat map showing effects of chronic administration of compounds A and B (Selisistat) on basic 
physiology tests and tests of motor function performed at PsychoGenics. Probability values above 0.3 are 
not shown. Trends (p<0.3) are indicated by light pink and blue, significant effects (p<0.05) by darker pink 
and blue – indicates no effect. Compound A: unrelated compound tested in the same model at the same 
facility. 
 Early Phase Disease Modification Trials with Selisistat and Optical Coherence Tomography as a Biomarker in Huntington’s Disease 
UCL PhD Submission 
70 
Dr Salman Haider (Student No.: 1054117) 
 
7.2.4 Proposed Mechanism of Action 
 
Dysfunctional protein acetylation is known to be an important factor in HD and the restoration of 
normal protein acetylation levels is thought to be a potentially efficacious therapeutic approach, as 
demonstrated by the significant interest in histone deacetylase (HDAC) inhibitors in the HD field 
(Butler & Bates, 2006). 
 
There is evidence of substantial transcriptional dysregulation and widespread histone de-acetylation 
in HD (Benn et al., 2008;Cha, 2000). Other work has shown transcriptional dysregulation in caudate 
samples and whole blood from Huntington’s disease patients, occurring in a similar pattern centrally 
as peripherally (Anderson et al., 2008). 
 
Modulation of acetylation levels through the use of broad-spectrum HDAC inhibitors has been 
shown to confer benefit in both cellular and animal models of HD, demonstrating at least partial 
reversal of toxicity, motor and body weight phenotypes, as well as reversal of transcriptional 
dysregulation (Thomas et al., 2008). 
 
Post-translation modifications of HTT can influence its behaviour, with acetylation at lysine 444 
known to activate autophagic removal of the protein (Jeong et al., 2009). In a cellular model, 
application of selisistat impaired deacetylation at K444 and facilitated macroautophagic clearance of 
mutant HTT. However, many toxic HTT species do not contain lysine residues and therefore selisistat 
may be acting therapeutically through alternate pathways (confidential unpublished data from Siena 
Biotech SpA and Krainc laboratories, MassGeneral Institute for Neurodegenerative Disease, Boston). 
 
Therefore two mechanisms of action are proposed for selisistat: 
 
1. Restoration of transcriptional dysregulation seen in HD. 
 
2. Selective reduction in levels of mutant HTT without disturbing levels of wild-type HTT. 
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7.3 Selisistat- First in Human Data  
 
A randomised, double-blind, placebo-controlled study involving healthy volunteers was carried out 
with the aim of establishing the safety, tolerability and pharmacokinetics of selisistat. At single doses 
of up to 600mg, selisistat was safe and well tolerated in healthy male subjects and by healthy female 
subjects at a dose of 300 mg.  Multiple doses of up to 300 mg for 7 days in male subjects, and 100 
mg for 7 days in female subjects, were safe and well tolerated. 
 
Most adverse events (AEs) were mild in severity and resolved without need for therapy. There was 
one severe AE with a male subject experiencing postural syncope. No serious adverse events (SAE) 
occurred during the study and no withdrawals as a result of AEs. 
 
No abnormalities in haematological, liver function and other clinical laboratory evaluations, as well 
as vital signs, or electrocardiogram (ECG) were seen. There was no evidence that selisistat affects 
cardiac repolarisation and no evidence of prolongation of the QTc interval was observed at any dose 
level.  There were no clinically significant findings in physical examinations, postural control, or 
neurological examinations (Westerberg et al., 2015). 
 
7.4 Introduction- A Phase 1B Study (Sussmuth et al., 2014) 
 
A multi-centre, randomised, double-blind, placebo-controlled, parallel group study at 3 dose levels 
(10 mg, 100 mg and placebo) was conducted. It included 6 visits over a 4-5 week period including a 
two week treatment period and two week washout (Figure 6).  
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Figure 6- Schematic diagram of design of Phase 1B Study  
 
Patients were required to reside in an in-patient facility from Day –1 (baseline) (the day prior to start 
of dosing) to the morning of Day 2 (24 hours post-dose) and for 24 hours starting in the morning of 
Day 14. Patients returned for a visit to the clinic on Day 7 (+/- 1 day). All participants returned for a 
post-study visit 14 days after their final dose (± 3 days). 
 
The objectives of the study: 
 
1. Obtain biosamples to determine effect of selisistat on pharmacodynamic parameters: 
 
• Acetylation status of mutant HTT 
• Levels of soluble HTT 
• Transcriptional signatures 
• Modulation of innate immune markers 
• Modulation of BDNF mRNA levels 
 
2. Pharmacokinetic data in HD subjects. 
 
3. Assessment of acute phenotypical effects of selisistat in HD patients. 
 
4. Safety and tolerability of selisistat in HD patients. 
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7.5 Methods (Sussmuth et al., 2014) 
Reproduced from methods as in clinical study protocol and (Sussmuth et al., 2014). 
The Study were carried out following the Helsinki protocol (Ethical Principles for Medical Research 
Involving Human Subjects), with local research ethics committee approval and clinical research 
organisation supervision including site initiation, monitoring and final visits. All study members were 
trained in good clinical practice.  
 
7.5.1 Study Population 
 
The study comprised genetically confirmed early stage (I and II Shoulson and Fahn (Shoulson & Fahn, 
1979)) HD subjects, aged 18 to 70 years. 
 
7.5.2 Inclusion Criteria  
• Patients with early Huntington’s disease (age: 18 to 70 years), i.e. genetically confirmed (CAG 
repeat length ≥ 36) HD, motor signs of HD (motor score of the UHDRS > 5) and a TFC of ≥ 7. 
• All patients will have a body weight greater than 50 kg. 
• Female subjects must be surgically sterile or post-menopausal (defined as at least two years post 
cessation of menses and/or follicular stimulating hormone >18 mIU/mL and serum oestradiol 
<110 pmol/L), no spontaneous menstruation for at least one year before the first dose, non-
lactating and have a negative serum pregnancy test. (Note: For post-menopausal females 
treated with oestrogen replacement therapy, FSH levels are artificially lowered <40 IU/L. 
Oestradiol and LH measurements need to be performed to confirm reason for low FSH value. 
HRT is acceptable, provided the above criteria are respected.) 
• Male subjects participating in the trial and their female partners must agree to use a highly 
effective method of contraception from the time of taking the first dose of the study drug until 
three months after taking the last dose. This must include a condom or other barrier method 
(i.e. a diaphragm or cervical/vault cap), with spermicidal cream/gel plus one extra method (i.e. 
established use of oral, injected or implanted hormonal contraception or IUD or Coil). 
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• If the female partner is already pregnant, use of condoms is mandatory during sexual 
intercourse from the time of taking the first dose of Study drug until three months after taking 
the last dose of study drug. 
• All subjects must be capable of providing written informed consent. 
• Subjects must have no clinically significant and relevant history that could affect the conduct of 
the study and evaluation of the data, as ascertained by the Investigator through detailed medical 
history and screening assessments. 
 
7.5.3 Exclusion Criteria  
• Participation in a study of an investigational drug within 30 days of the baseline visit. 
• Subjects with presence of psychosis and/or confusional states. 
• Subjects with clinically significant laboratory or ECG abnormalities at Screening. 
• Subjects with clinically relevant haematological, hepatic, cardiac or renal disease. 
• A medical history of infection with human immunodeficiency virus, hepatitis C and/or hepatitis 
B. 
• Any relevant condition, behaviour, laboratory value or concomitant medication which, in the 
opinion of the Investigator, makes the subject unsuitable for entry into the study. 
• Subjects who have previously received histone deacetylase inhibitors e.g. vorinostat or have 
participated in a clinical trial using a histone deacetylase inhibitor. 
• A history of malignancy of any type within 2 years prior to screening. 
• A history of surgically excised non-melanoma skin cancers is permitted. 
• Subjects with a significant history of drug allergy as determined by the Investigator. 
• Subjects who consume more than 28 units (males) or more than 21 units (females) of alcohol 
per week or who have a significant history of alcoholism or drug/chemical abuse as determined 
by the Investigator (one unit of alcohol equals 285 mL of beer or lager, one glass [125 mL] of 
wine, or 25 mL of spirits). 
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7.5.4 Assessments  
 
1. Motor Assessment using Unified Huntington's Disease Rating Scale (UHDRS) 
2. Functional and Quality of Life (QoL) Assessments 
• UHDRS Total Functional Capacity (TFC) 
• UHDRS Functional assessment (FA) (including Independence Scale) 
• Pittsburgh Sleep Quality Index (PSQI) 
 
3. Behavioural Assessments 
• European Huntington´s Disease Network (EHDN) Problem Behavioural Assessment 
– Short Version (PBA-S) 
• Hospital Anxiety and Depression Scale (HADS) with Snaith Irritability Scale (SIS) 
• Frontal Systems Behaviour Inventory-Self Rating Test Booklet (FrSBe-self) 
 
Optional 
• Frontal Systems Behaviour Inventory-Family Rating Test Booklet (FrSBe-other) 
 
4. Cognitive Assessments 
• Trails A 
• Trails B 
• Symbol Digit Modalities Test (SDMT) 
• Stroop Word Test 
• Verbal fluency 
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• Mini Mental State Examination (MMSE) 
 
5. Quantitative Motor Assessment (optional according to availability at the study centre) 
 Brainstem motor coordination test 
 Upper extremity motor coordination test 
 Upper extremity grip force test 
 Bradykinesia test 
 Neurophysiological chorea analysis 
 
6. Safety Assessments 
 Adverse Events (AEs) 
 Clinical laboratory tests (haematology, serum chemistry, and urinalysis) 
 Electrocardiogram (ECG) 
 Vital signs 
 Physical examination 
 
7. Pharmacokinetic (PK) Assessments 
 
8. Pharmacodynamic (PD) and Pharmacogenomic Assessments 
 Samples for Genotyping 
  Samples for Assessing Levels of Soluble Huntingtin 
 Samples for Assessing Huntingtin Acetylation Status by enzyme-linked immunosorbent assay 
(ELISA) 
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 Samples for Assessing Huntingtin Acetylation Status by liquid chromatography–mass 
 spectrometry (LC-MS/MS) 
 Samples for Transcriptional Profiling 
 Samples for Markers of Innate Immunity 
 
7.6 Phase 1B- Results 
Data presented here is with the kind permission of the study sponsor Siena Biotech SpA. It is the 
complete data set for all subjects, including 7 London subjects. For the London subjects, I was the site 
clinical lead at UCLH, carried out all clinical histories, physical examinations, UHDRS, ECG 
interpretation, TFC & Independence scale Scores, HADS-SIS assessments, cannulation and blood tests. 
Clinical observations (blood pressure, pulse, temperature, respiratory rate and oxygen saturation 
levels and blood tests) were carried out by clinical trials nurses at Clinical Research Facility (CRF), 
University College London Hospital (UCLH) and cognitive assessments by Dr Elin Rees and Dr Gail 
Owen. Processing of London biosamples was carried out by Dr Ralph Andre and trials nurses at the 
CRF, UCLH.  
 
7.6.1 Statistical Analysis 
Descriptive data analysis was performed by myself from raw data kindly provided by the study 
sponsor, unless otherwise stated. For the study, Quartesian Clinical Research, US, using SAS Version 
9.1.3 (or higher) were employed by the sponsor Siena Biotech SpA in a pre-existing arrangement 
using descriptive statistics for continuous variables.  
 
7.6.2 Demographics 
Table 6- Demographics of Phase 1B Study population (Sussmuth et al., 2014) 
Parameter Selisistat 10 
mg 
(N=17) 
Selisistat 100 
mg 
(N=19) 
Placebo 
(N=19) 
All Patients  
(N=55) 
Age 46.5  10.2 
[33-67] 
54.1  10.1 
[28-68] 
51.9  8.2  
[38-64] 
51.6  9.8 
[28-68] 
Gender M=14, F=3 M=13, F=6 M=12, F=7 M=29, F=16 
Age of onset 44.5  10.11 47.6  8.58 46.1  8.83  46.1  9.08 
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[28-62] [28-63] [28-61] [28-63] 
CAG Repeats 44.1  3.58 
[40-53] 
42.8  2.48 
[40-49] 
43.4  2.14 
[41-50] 
43.4  2.76 
[40-53] 
 
Age, age of onset and CAG repeat ranges between the dosing arms were relatively well matched 
following randomisation. A greater proportion of male subjects were noted most likely due to 
recruitment bias as a consequence of ineligibility of females of child-bearing age. Enrolled subjects 
were in good health without significant medical history, examination or laboratory findings. Mean 
values for vital sign measurements at screening and the day before dosing (baseline) were similar for 
all treatment groups (Table 6). 
 
7.6.3 Study Withdrawals and Completion 
 
There were four screen failures and four consent withdrawals before randomisation. All fifty-five 
participants completed the study and were included in the safety as well as pharmacokinetic 
analyses. One patient was excluded from the UHDRS outcome measures due to highly variable 
clinical presentation before, during and after the study independently from the study drug intake.  
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7.6.4 Total Motor Score (TMS) 
The UHDRS ’99 Motor score is a clinical assessment widely employed by HD clinicians to quantify to 
motor burden of disease (Appendix 13.1). 
 
Table 7- Mean change in Total Motor Score between screening and Day 28 for each of the three 
randomisation groups 
  Mean  SD Min Max 
Placebo n=19 -1.16 5.55 -8 14 
10mg n=17 -2.76 4.24 -11 7 
100mg n=19 -1.89 8.04 -29 7 
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Figure 7- Mean TMS Score by timepoint & treatment arm with no clinically significant difference seen in TMS 
between timepoints and treatment arms  
(Bars represent Standard Deviation). 
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Overall, there was good consistency between TMS at Baseline (day before therapy) and Day 1 (first 
day of therapy) across all treatment groups (Figure 7 and Table 7). However, although there were 
slight differences between groups at various time-points, none were sufficient to merit clinical 
significance.   
 
7.6.5 Chorea Sub-score 
 
One of the commonest symptoms reported in HD is chorea. A potential symptomatic improvement 
therefore would be therapeutically and evidently commercially important. However, there was no 
obvious change in this score over time and between groups (Figure 8). 
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Figure 8- Mean chorea Sub-Score by timepoint & treatment arm with no clinically significant difference seen 
in mean chorea subscore between timepoints and treatment arms (Bars represent Standard Deviation). 
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7.6.6 Total Functional Capacity 
This is a clinical staging tool based on functional ability and scored out of a maximum of 13 (Table 2 
Page 24). 
 
Overall, there were no differences between the three groups (Figure 9). 
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Figure 9- Mean TFC Score by timepoint & treatment arm with no clinically significant difference seen in TFC 
between timepoints and treatment arms (Bars represent Standard Deviation). 
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7.6.7 UHDRS Functional Assessment (FA) and Independence Scale (IS) 
Table 8- Functional Assessment Score (Appendix 13.5) with no clinically significant difference seen in FA 
between timepoints and treatment arms (represent range) (Sussmuth et al., 2014) 
 Group A 
(N= 17) 
Group B 
(N= 19) 
Group C 
(N= 19) 
All Patients 
(N= 55) 
FA Score 
(25 max) 
Observed Change 
from 
Baseline 
Observed Change 
from 
Baseline 
Observed Change 
from 
Baseline 
Observed Change 
from 
Baseline 
Baseline 
Mean (SD) 
 
21.5 (3.45) 
 
n/a 
 
20.3 (3.78) 
  
20.4 (3.65) 
  
20.7 (3.62) 
 
n/a 
Baseline 
Median 
(min, max) 
 
 
23.0 (14, 
25) 
 
 
n/a 
 
 
20 (12, 25) 
  
 
21 (13, 25) 
  
 
21 (12, 25) 
 
 
n/a 
Day 14 
Mean (SD) 
 
21.4 (3.78) 
 
-0.1 (0.6) 
 
20.5 (3.47) 
 
 0.2 (0.92) 
 
20.3 (3.68) 
 
-0.1 (0.52) 
 
20.7 (3.60) 
 
0.0 (0.71) 
Day 14 
Median 
(min, max) 
 
 
23 (13, 25) 
 
 
0 (-2,1) 
 
 
21 (13,25) 
 
 
0.0 (-2, 3) 
 
 
21 (13,25) 
 
 
0.0 (-2, 1) 
 
 
21 (13, 25) 
 
 
0.0 (-2, 3) 
Day 28 
Mean (SD) 
 
21.5 (3.64) 
 
-0.1 (0.56) 
 
20.6 (3.17) 
 
0.3 (1.25) 
 
20.4 (3.59) 
 
0.1 (0.4) 
 
20.8 (3.43) 
 
0.1 (0.83) 
Day 29 
Median 
(min, max) 
 
 
23.0 (14,25) 
 
 
0.0 (-2, 1) 
 
 
20.0 (16, 
25) 
 
 
0.0 (-2, 4) 
 
 
21.0 (13, 
25) 
 
 
0.0 (-1, 1) 
 
 
21.0 (13, 25) 
 
 
0.0 (-2, 4) 
 
There were no differences between groups and no significant change over time in FA, a 
questionnaire based assessment tool, looking specifically at performance in 25 areas of daily life 
(Appendix 13.5) (Table 8).  
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Table 9- Independence Scale (IS) (Appendix 13.5) with no clinically significant difference seen in IS between 
timepoints and treatment arms (Sussmuth et al., 2014). 
 Group A 
(N= 17) 
Group B 
(N= 19) 
Group C 
(N= 19) 
All Patients 
(N= 55) 
IS Score 
(100% max) 
Observed Change 
from 
Baseline 
Observed Change 
from 
Baseline 
Observed Change 
from 
Baseline 
Observed Change 
from 
Baseline 
 
Baseline 
Mean (SD) 
 
86.5 
(11.56) 
 
n/a 
 
82.4  
(12.18) 
 
n/a 
 
83.7 
(10.12) 
 
n/a 
 
84.1 
(11.23) 
 
n/a 
 
Day 14 
Mean (SD) 
 
85.9  
(11, 89) 
 
-0.6 
(1.66) 
-  
 
83,2  
(11.57) 
 
0.8 
(1.87) 
 
83.9  
(9.8) 
 
0.3  
(1.15) 
 
84.3 
(10.95) 
 
0.2 
(1.66) 
 
Day 28 
Mean (SD) 
 
85.9 
(11.49) 
 
-0.6 
(1.66) 
 
83.2  
(11.57) 
 
0.8 
(1.87) 
 
83.9 
 (9.8) 
 
0.3 
 (1.15) 
 
84.3 
(10.82) 
 
0.2 
(1.66) 
 
The independence scale is a percentage based assessment of independence- 100% representing 
complete independence (Appendix 13.5). The lack of significant change from baseline in Groups A & 
B from placebo group C, suggests that there were no treatment related effects in this measure 
(Table 9). 
 
7.6.8 MMSE  
 
Overall, no significant changes were noted in this 30 point scale of cognitive function (Appendix 
13.6) (Figure 10). 
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Figure 10- Mean MMSE Score by timepoint & treatment arm with no clinically significant difference seen in 
MMSE between timepoints and treatment arms (Bars represent Standard Deviation). 
 
 
7.6.9 Symbol Digit Modalities Test  
 
This timed cognitive test assesses visuomotor integration as it requires use visual scanning, tracking, 
and motor speed to complete the task (Appendix 13.8).   
 
At baseline and on Day 1, the SDMT data were missing for 1 patient, each, in Groups B. Overall 
however, no clinically significant changes were noted between groups and time-points. There was 
however a trend to improvement in clinical scores, which likely reflects practice effects (Figure 11). 
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Figure 11- Mean SDMT Score by timepoint & treatment arm with no clinically significant difference seen in 
SDMT between timepoints and treatment arms (Bars represent Standard Deviation). 
 
 
7.6.10 Sleep and Psychiatric Assessments 
There were no significant changes between groups during the course of the study on the Pittsburgh 
Sleep Quality Index, a self-assessment questionnaire, the problem behaviour assessment and the 
hospital anxiety and depression scale and the Snaith irritability score. 
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7.6.11 Clinical Efficacy 
7.6.11.1 Baseline Phenotypical Characteristics 
Table 10- Baseline phenotypical characteristics of Phase 1B study population (Sussmuth et al., 2014)  
(Values shown are mean +/- Standard Deviation, with range [ ] given) 
 
It is clear that at outset, a wide spread of baseline values were seen, reflecting the 
phenotypic heterogeneity known in HD. However between the groups a clear 
difference is not apparent, apart from in the cognitive domain, SDMT, where the 
10mg group have a higher SDMT score 28.8 versus the other treatment arms (Table 
10). 
 
During the comparatively short time period of study drug administration over two 
weeks, no clinically relevant and obvious changes in the parameters were apparent 
(Figure 12). 
 
Parameter Selisistat 10 
mg 
(N=17) 
Selisistat 100 
mg 
(N=19) 
Placebo 
(N=19) 
All Patients  
(N=55) 
UHDRS – TMS 29.5  14.5 
[8-64] 
35.2  15.37 
[17-81] 
32.1  11.55 
[14-53] 
32.4  13.81 
[8-81] 
UHDRS – TFC  10.6  2.06 
[7-13] 
9.9  2.23 
[7-13] 
10.0  2.13 
[7-13] 
10.2  2.13 
[7-13] 
UHDRS – FA 21.5  3.45 
[14-25] 
20.3  3.78 
[12-25] 
20.4  3.65 
[13-25] 
20.7  3.62 
[12-25] 
UHDRS – IS 86.5  11.56 
[65-100] 
82.4  12.18 
[60-100] 
83.7  10.12 
[65-100] 
84.1  11.23 
[60-100] 
PBA-s 9.6  10.87 
[0-42] 
10.1  11.95 
[0-45] 
8.1  7.36 
[0-27] 
9.3  10.07 
[0-45] 
MMSE 26.9  2.45 
[21-30] 
26.9  3.70 
[18-30] 
26.0  3.53 
[17-30] 
26.6  3.27 
[17-30] 
SDMT 28.8  15.6 
[12-70] 
21.3  9.2 
[2-36] 
19.6  7.8* 
[5-32] 
23.1  11.7 
[2-70] 
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7.6.11.2 Total Motor Score 
Formal statistical analysis to look for significant difference between treatment 
groups in the total motor score results, involved linear modelling of the three 
treatment groups. The resulting F value 3.49 (Degrees of Freedom (DF) 52) and P 
value 0.038 did suggest a difference between the groups. However, head to head 
dose-group post-hoc (Tukey's Studentised Range (HSD) Test for change) comparative 
analysis failed to demonstrate statistical significance, though the 10mg group did 
trend in the direction of treatment effect (Table 11). Analysis of the chorea sub-
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Figure 12- Percentage change in clinical parameters on Day 14 compared to baseline of patients receiving 
placebo, 10mg or 100mg. In a variety of clinical parameters no clear difference is seen between treatment 
groups. (Bars represent Standard Deviation). 
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score failed to evidence a treatment effect. (Analysis carried out at University of 
Ulm). 
Table 11- Dose-group comparisons of change of motor score between day -1 and day 14 with 
no evidence of effect noted on Tukey’s Studentised range test 
 
 
 
 
 
 
 
 
 
 
 
7.6.11.3 Other Clinical Assessments 
Applying this approach to other assessments, TFC, FA, PBA, Verbal fluency, Symbol 
digit modality, Stroop and Trails A & B showed no statistically significant treatment 
effect. 
 
The HADS-SIS irritability subscore analysis did suggest some significance, F value 4.30 
(DF- 46) P 0.0195. Post-hoc analysis showed a significant effect of 100mg group 
versus 10mg though not placebo. Intuitively this may suggest that the 100mg dosing 
was associated with increased levels of irritability amongst subjects. Further analysis 
suggested this effect was concentrated largely on inward irritability subscore. This 
however was not sufficient to cause a documented withdrawal from the study or 
produce a psychiatric adverse event and is unexplained. 
 
 
Comparisons significant at the 0.05 level are 
indicated by ***. 
dosegroup 
Comparison 
Difference 
Between 
Means 
Simultaneous 
95% 
Confidence 
Limits  
100mg   - Placebo 0.006 -11.207 11.218  
100mg   - 10mg 11.039 -0.499 22.577  
Placebo - 100mg -0.006 -11.218 11.207  
Placebo - 10mg 11.033 -0.505 22.571  
10mg    - 100mg -11.039 -22.577 0.499  
10mg    - Placebo -11.033 -22.571 0.505  
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7.6.12 Pharmacokinetic  
 
Selisistat was rapidly absorbed with a median tmax (time of maximum plasma concentration) of 3 
hours. High inter-patient variability was noted in the systemic exposure to selisistat. A 
pharmacokinetic steady state was reached before Day 14.  
 
7.6.13 Safety & Tolerability  
 
There were no deaths, SAEs, or AEs leading to withdrawal during the study. Overall, 25 patients 
experienced 44 AEs. 13 patients experienced 15 AEs which, in the opinion of the investigators, were 
thought to be related to the taking of selisistat. In terms of severity of AEs, 22 patients experienced 
40 mild AEs whereas 3 patients experienced 4 moderate AEs during the study. No patient 
experienced severe AEs. 
 
There was apparent dose-responsiveness to the side-effect frequency between 10mg and 100mg 
with the number of patients experiencing treatment-related AEs higher in 100mg group B (6) 
compared to 10mg Group A (4) and placebo Group C (3). 
 
The most commonly seen AE was hypertension (7 patients), followed by Headache (4 patients), 
anaemia (3 patients) and vomiting, nasopharyngitis, joint injury, neck pain, and tension headache (2 
patients). The moderate AEs included anaemia, nasopharyngitis, headache, and circulatory collapse 
and were reported in 1 patient (1.8%), each. No consistent trends were noted in laboratory values 
across groups. In 2 patients from Group B high alanine transaminase values were observed on Days 
28 and 14, respectively (Table 12). Mean changes from baseline of ECG intervals based on safety 
recordings interpreted at the clinical sites (PR interval, QT interval, heart rate, QTcB interval, and 
QTcF interval) on Days 1, 7, and 14, were not significantly different. 
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Table 12- Adverse Events Phase 1B study 
SOC/Preferred 
Term 
Selisistat, 10 mg 
 (N=17) 
Selisistat, 100 mg 
 (N=19) 
Placebo 
 (N=19) 
Suspected 
n (%) 
Not 
Suspected 
n (%) 
Suspected 
n (%) 
Not 
Suspected 
n (%) 
Suspected 
n (%) 
Not 
Suspected 
n (%) 
Total number of 
patients with AEs 
4 (23.5%) 5 (29.4%) 6 (31.6%) 3 (15.8%) 3 (15.8%) 4 (21.1%) 
Blood and 
lymphatic system 
disorders 
0 0 0 1 (5.3%) 1 (5.3%) 1 (5.3%) 
Anaemia 0 0 0 1 (5.3%) 1 (5.3%) 1 (5.3%) 
Leukopenia 0 0 0 0 1 (5.3%) 0 
Gastrointestinal 
disorders 
1 (5.9%) 0 1 (5.3%) 1 (5.3%) 0 1 (5.3%) 
Abdominal pain 1 (5.9%) 0 0 0 0 0 
Dyspepsia 0 0 1 (5.3%) 0 0 0 
Investigations 0 0 1 (5.3%) 0 1 (5.3%) 0 
Alanine 
aminotransferase 
increased 
0 0 1 (5.3%) 0 0 0 
Protein total 
decreased 
0 0 0 0 1 (5.3%) 0 
Nervous system 
disorders 
2 (11.8%) 2 (11.8%) 0 2 (10.5%) 1 (5.3%) 1 (5.3%) 
Headache 1 (5.9%) 0 0 1 (5.3%) 1 (5.3%) 1 (5.3%) 
Paraesthesia 1 (5.9%) 0 0 0 0 0 
Renal and urinary 
disorders 
0 0 1 (5.3%) 0 0 0 
Leukocyturia 0 0 1 (5.3%) 0 0 0 
Vascular disorders 1 (5.9%) 1 (5.9%) 3 (15.8%) 1 (5.3%) 1 (5.3%) 1 (5.3%) 
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Hypertension 1 (5.9%) 1 (5.9%) 3 (15.8%) 1 (5.3%) 1 (5.3%) 0 
 
 
7.6.14 Validation of Mechanism of Action 
 
Preliminary data indicates that selisistat lowers total soluble HTT levels in peripheral blood 
mononuclear cells (PBMCs) (Westerberg et al., 2012) but has not been fully and definitively 
established.   
 
7.7 Discussion on Phase 1B Study Results 
 
Data from the Phase 1B study of a novel SirT1 inhibitor, selisistat, administered for the first time in 
HD patients, at 2 dose levels (10 mg and 100 mg) over 14 days suggests that selisistat is safe and well 
tolerated in HD patients. No serious side-effects were observed and no dose- or treatment-related 
trends in terms of clinical laboratory evaluations, vital signs, or ECG parameters were detected. 
 
7.7.1 Sirtuin Inhibition or Activation? 
 
It is clear that aspects of sirtuin biology require further resolution. Inhibition of SirT1 specifically and 
of other HDACs has been shown to be neuroprotective in drosophila while overexpression and SirT1-
KI in mouse models is beneficial (Jeong et al., 2012;Jiang et al., 2012;Pallos et al., 2008;Steffan et al., 
2001). Increased gene dosage of Sir2 prevented early neuronal dysfunction, in a polyglutamine 
c.elegans model (Parker et al., 2005). In Type 2 diabetes, cancer and cardiovascular disease a role for 
SirT1 activators has been advocated from experimental work (Milne et al., 2007).  
 
These findings could be explained in part by experimental differences, namely the lack of 
equivalence of Drosophila models and murine models, and by differences between human HDACs 
and their cross species orthologs i.e. divergence of genetic function. Even within the same species, 
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differing effects are seen, with BAC-HD mice showing improvement of inclusion pathology with SirT1 
overexpression, decreased aggregation of mutant HTT in R6/2 mice but no effect seen in N171-82Q 
mice (Jeong et al., 2012;Jiang et al., 2012;La Spada, 2012). 
The influence of experimentation has been noted previously in the Sirtuin field. The life-span 
extending properties of Sir2 is another similarly controversial area where previously found positive 
results have been called into question and attributed to differences in genetic background arising 
from the methodology (Burnett et al., 2011;Kaeberlein et al., 1999). 
 
However, selisistat, a SirT1 inhibitor, has been shown to phenocopy genetic and pharmacological 
inhibition in the same drosophila model as well improving pathology and performance of the R6/2 
mouse model (Chapter 7.2.3). Therefore although sirtuin biology in general remains unclear, the 
effect of selisistat is in keeping with the original Drosophila work and in contradiction to more recent 
mouse model work. 
 
It is suggested from work carried out by Steffan et al. 2001 that different HDACs within the same 
class, and different classes of HDAC, can mediate the same effect. They employed a HDAC inhibitor 
4b, which had activity on both HDAC 1 and HDAC 3, within the same class (I). SAHA and butyrate 
have been utilised as pharmacological HDAC inhibitors but also have effects on multiple classes of 
HDACs, with the former acting on I, IIa, IIb and IV (Hockly et al., 2003;Rasheed et al., 2007;Steffan et 
al., 2001). 
 
Sirtinol, nicotinamide and niacin were used similarly to reduce Sir2 levels. Indeed combinatorial 
reduction of class I and class III HDAC activity, via Rpd3 and Sir2 respectively, was shown to be 
independent and additive in its neuroprotective effect (Pallos et al., 2008). Finally, HDAC7 has 
recently been shown to mediate its neuroprotective effective via a mechanism that is independent 
of its deacetylase activity, involving the inhibition of c-jun expression (Ma & D'Mello, 2011).  
 
Therefore the possibility that selisistat could be acting on multiple other targets and exclusive of its 
HDAC activity seems a reasonable one. However, unpublished data shows no effect of selisistat in 
mutant HTT challenged flies that have homozygous null alleles for Sir2, with replicated findings in 
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murine HD models (unpublished data from Siena Biotech SpA and Marsh laboratories, University of 
California Irvine), suggesting that the major effect is Sirtuin dependent.  Although the potential for 
cross-over effects on zinc dependent HDAC classes (I, II & IV) is low as selisistat exhibits over a 1000 
fold selectivity for SirT1, the effect on other Sirtuins e.g. SirT4-7 is not known. 
 
A dosing effect may instead be in operation as Sir2 haploinsufficiency in drosophila has been shown 
to abrogate neurodegeneration while SirT1 knockouts are harmful (Jeong et al., 2012;Pallos et al., 
2008). Experiments using heterozygous Sir2/SirT1 models with the compound have not been carried 
out thus far. Selisistat may thus achieve pharmacologically, what haploinsufficiency does genetically. 
The ability of SirT1 to mediate multiple different effects in both the central nervous system and 
periphery may thus be tissue specific and dose dependent. Therefore, at either reduced or 
overexpressed doses, SirT1 may access undisclosed, complimentary and possibly distinct pathways.  
 
This could be assessed pharmacologically with SirT1 activators and although resveratrol has shown 
some promise in improving peripheral but not central deficits in a HD mouse model, questions 
remain as to whether its mode of action is SirT1 dependent  (Pasinetti et al., 2011;Ho et al., 2010;Ho 
et al., 2010). No other highly selective SirT1 activators are available at present. 
 
Evidently direct assessment of SirT1 deacetylase activity may be helpful in calibration of activity, but 
has only been carried indirectly in vitro through assessment of acetylation of p65 subunit of NFkβ 
(Yeung et al., 2004). Measurement of SirT1 RNA levels is another possibility but has not been 
explored. 
 
Finally, activity beyond histone deacetylation is also suggested from pre-clinical and cellular data 
where selisistat can render mutant HTT to an acetylated status, which could potentially facilitate its 
clearance. Restoration of transcriptional dysregulation, which may in part be achieved via direct 
activity on transcription factors, as well as altering the conformational status and accessibility of 
DNA i.e. a histone deacetylating effect, has also been proposed. In vivo data from healthy volunteers 
receiving Selisistat does corroborate this potential latter mode of action (Westerberg et al., 2015) 
but has not been formally evaluated in HD patients. 
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7.7.2 Mechanism of Action of Selisistat 
 
Although increase in soluble HTT levels was seen during the study, there is no published data at 
present on amelioration of transcription dysregulation or acetylation related facilitation of HTT 
clearance. At the time of study, means of measuring the HTT protein were not established but have 
been subsequently in blood, PBMCs and CSF. Identifying the effects of Selisistat on HTT levels in each 
of these compartments would have been an essential step in developing a sound justification for its 
continued study. 
 
7.7.3 Efficacy Measures  
 
Although this study was not designed to determine efficacy, a symptomatic change in chorea for 
example, might have been a reasonable expectation, though no evidence for this was found. 
However, clinical experience with anti-chorea medication such as Tetrabenazine would indicate that 
such an effect may take up to a month to manifest. 
 
For a chronic neurodegenerative condition like Huntington’s disease, it is reasonable to postulate a 6 
month window in which a treatment may bring about a clinical improvement. This draws parallels 
from the time taken to recover after stroke or head injury, where a recovery window of up to 2 years 
is often quoted but is evidently influenced by site of lesion- cortical versus subcortical and 
premorbid status, environmental and as yet unknown biological and genetic factors. 
 
Similarly, although imaging changes do not always equate to functional changes, deterioration in 
volumetric measures have been seen in imaging studies over 6 months (Hobbs et al., 2015). By 
extension therefore, a clinical improvement may be expected over a similar sort of time frame, 
though mechanistically this may be achieved through a combination of diminution of pathology and 
activation of compensatory mechanisms.  
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Evidently, data from later phase trials (II and III) are required together with validation of mechanism 
of action from pharmacodynamic analyses, before a disease modifying label can be justifiably 
applied. Additionally, data on ability of HD patients to access compensatory networks and relearn 
tasks would be important to quantify recovery and thus set reasonable expectations for disease 
modifying therapies. 
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 Selisistat & Innate Immune System 8
8.1 Introduction 
SirT1 and the Immune System 
 
Due to their effects on various transcription factors, SirT1 plays a role in thymocyte and lymphocyte 
activation. In addition, SirT1 may have effects in both the innate and adaptive immune response via 
their regulation of NFkB and AP-1 pathways respectively. SirT1 knockout mice are more susceptible 
to inflammatory disorders including a lupus-like phenotype (Sequeira et al., 2008). 
 
SirT1, NFkB & AP-1 
 
NFkB is a key component in the pathway that leads to cytokine production and lymphocyte 
activation.  SirT1 is proposed to reduce NFkB activity through acetylation of p65 at multiple lysine 
residues (Chen et al., 2002). AP-1 activity is associated with production of an immune response, 
particularly in T cells comprising proliferation, interleukin (IL) -2 release and differentiation. 
 
SirT1 & Macrophage Function 
 
Macrophages are the main source of pro-inflammatory cytokines TNF-a, IL-6 and IL-1 secreted in 
response to infection and inflammation. SirT1 restricts the pro-inflammatory phenotype of 
macrophages via inhibition of the NFkB pathway (Gao et al., 2012). Intraperitoneal macrophages in a 
mouse SirT1 knockdown model, showed increased tumour necrosis factor (TNF) alpha levels on 
lipopolysaccharide (LPS) stimulation (Yoshizaki, 2011). 
 
However, in a LPS stimulated J774 macrophage model, use of sirtinol and cambinol as Sirtuin 
inhibitors attenuated the release of pro-inflammatory cytokines, TNFα and IL-6, via a decrease in 
NFkB activity (Fernandes et al., 2012).  
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Sirtuins- Pro or Anti-inflammatory? 
 
As discussed earlier (7.7.1), these conflicting results may reflect in part experimental differences, 
knockouts versus pharmacological inhibition, but also the fact that sirtinol and cambinol have effects 
on SirT2 levels. Inhibition of SirT2 via genetic manipulation or pharmacological inhibition has been 
shown to be neuroprotective in striatal neurone and drosophila HD models, with reduction in sterol 
biosynthesis proposed as a mechanism (Luthi-Carter et al., 2010). Finally their effect on SirT4, SirT6 
& SirT7, which have competing effects, is not known (Fernandes et al., 2012). By way of example, 
SirT6 has been shown to positively influence TNF-a levels via a post translational mechanism (Van & 
Veenstra, 2009). In the absence of a full understanding of the wider effect of Sirtuin inhibition, 
caution must be taken in interpreting results. 
 
8.1.1 The Immune System and Huntington’s Disease 
 
There is substantial evidence of the deleterious effects of the HD gene mutation on the immune 
system of both the periphery and that of the brain. HD lymphoblasts show a variety of deficits in 
mitochondrial morphology and calcium handling capacity, autophagy and transcriptional dysfunction 
(Borovecki et al., 2005;Mormone et al., 2006;Panov et al., 2002).  
 
LPS stimulation of HD monocytes reveals an inherent hyper-reactivity that is similar to that seen in 
microglia, suggesting a cell-autonomous effect of mutant huntingtin in peripheral myeloid cells as 
well as in the CNS. A pattern of pro-inflammatory cytokine elevation has been observed in plasma in 
HD, with IL-6 significantly elevated in a group of subjects predicted to be, on average, 16 years from 
disease (Figure 13). A parallel post-mortem cytokine expression profile is seen in HD striatum (Tai et 
al., 2006;Bjorkqvist et al., 2008) . 
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Figure 13- (Bjorkqvist et al., 2008) Altered immune profile peripherally in HD. (A) Multiplex ELISA 
quantification of cytokine levels in plasma from HD patients (premanifest, early and moderate HD stages) 
compared with control subjects. Graphs show mean concentrations with standard error bars. Significant 
differences between individual groups are shown (ANOVA with post-hoc Tukey HSD test). (B) The overall 
trend for increasing levels of cytokines across all groups, analysed using linear regression, was highly 
significant for IL-6 and IL-8 and significant for IL-4, IL-10, TNF- , and IL-5. R-values (partial correlation 
coefficients) are corrected for age and sex. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.  
 
Correlations between regional sites of neuronal loss and levels of microglial as well as astrocytic 
activity have been noted. It is unclear whether microglia are functioning as primary modulators of 
disease or simply appearing in reaction to neuronal loss, or both. Indeed microglia can mediate free 
radical production, excitotoxicity and initiation of caspase pathways (Kim et al., 2005;Tikka & 
Koistinaho, 2001;Wang et al., 2005). 
 
PET studies demonstrating activation of microglia in early HD patients may support their 
involvement in the preliminary pathological stages of disease (Tai et al., 2006;Politis et al., 2011). HD 
striatum also demonstrates significant complement deposition versus normal controls and gene 
expression studies revealed significantly higher levels of complement pathway components in HD 
brains (Singhrao et al., 1999).  
 Early Phase Disease Modification Trials with Selisistat and Optical Coherence Tomography as a Biomarker in Huntington’s Disease 
UCL PhD Submission 
101 
Dr Salman Haider (Student No.: 1054117) 
 
 
Evidence therefore suggests simultaneous dysfunction of CNS and peripheral inflammatory 
pathways in HD. Sirtuins have a potential regulatory role in the innate immune system through 
modification of both pro and anti-inflammatory transcription factors. The relative impermeability of 
the blood brain barrier and the potential morbidity as well as practical difficulties associated with 
administration of therapies directly into the cerebrospinal fluid or brain parenchyma, makes the 
peripheral immune system an attractive therapeutic target.  
 
Notwithstanding, the PET studies detailed above, the role of the immune system as a modifier of 
disease is buoyed further by the finding that bone marrow transplantation partially ameliorated 
motor abnormalities in HD mouse models (Kwan et al., 2012a). Additionally, administration 
peripherally of JM6, an inhibitor of the kynurenine 3-monooxygenase (KMO) tryptophan degradation 
pathway found on microglia, enhances levels of the neuroprotective, kynurenic acid, augments 
longevity, reduces synaptic loss and microglial reactivity in a HD mouse model (Zwilling et al., 2011). 
Genetic deletion of CB2 receptors, which are involved in down-regulation of the immune system, in a 
R6/2 mouse model foreshortens the motor onset and worsens the phenotype. Application of a CB2 
receptor agonist peripherally, with no central microglial action, abrogates these effects (Bouchard et 
al., 2012).  
 
Experimental evidence using HD primary myeloid cells also suggests that their hyper-reactivity is 
directly caused by the expression of mHTT via the NFkβ pathway (Trager et al., 2014), which is itself 
modulated by SirT1. This provides a potential mechanistic link between immune dysregulation and 
Sirtuins. 
 
Given the known immune abnormalities in HD and the role that Sirtuins play in regulating the 
immune system, comparative analysis of the plasma cytokine profile of Huntington’s disease 
patients at four time points- screening, baseline, day 14 and day 28, in each of the three treatment 
arms of the study was carried out, testing the hypothesis that SirT1 inhibition via Selisistat restores 
the altered cytokine profile seen in HD subjects. 
8.2 Methods 
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The experimental laboratory work was carried out solely by myself with initial supervision by Dr 
Ralph Andre. The reading of the multiplex plates was carried out under the initial supervision of Dr 
Ulrike Traeger and Dr Ralph Andre and using equipment at the UCL Institute of Child Health, 
Department of Haematology, London. Analysis plans were formulated by myself while statistical 
work carried out by Ruth Farmer & Professor Chris Frost, School of Hygiene and Tropical Medicine. 
The Study were carried out following the Helsinki protocol (Ethical Principles for Medical Research 
Involving Human Subjects), with local research ethics committee approval and clinical research 
organisation supervision including site initiation, monitoring and final visits. All study members were 
trained in good clinical practice.  
 
8.2.1 Cytokine Assays  
 
Assays were carried out using the Mesoscale Discovery (MSD) multiplex platform (Human 
ProInflammatory II 4-plex ultra-sensitive kit) as per the manufacturer’s instructions. Blood samples 
for cytokine assays were taken pre-dose at screening, Day 1 & 14 of dosing, and finally at Day 28, 
two weeks after the last dose from all 55 Phase 1B study participants. The operator was blinded to 
the disease state of each sample during processing and statistical analysis was performed 
independently. 
 
Cytokines of interest included IL-1, IL-6, IL-8 and TNF-α, anti-bodies for which are pre-coated into 4 
spots per well. To this labelled detection anti-bodies are added. This label is an electroluminescent 
compound. The sample of interest is thus bound by the pre-coated antibodies at one end, and by the 
detection antibodies at the other. Application of a current causes light emission- the signal.  
 
Each sample representing one visit point of one patient was repeated in triplicate. Where samples 
failed to produce a result, they were repeated. A mean of the three values produced was used for 
data analysis. Where one value appeared aberrant versus the other two it was excluded. A calibrator 
solution with a graduated series of known concentrations generates a standard signal-concentration 
curve, against which the analysed samples are compared. Typically 8 dilutions are employed in 
producing a calibrator solution. However, previous work in our laboratory had suggested that a 9th 
dilution may be necessary to pick up signal for cytokines at low levels. 
8.2.2 Statistical Analysis 
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The model used for statistical analysis of these data is an extension of the usual ANCOVA model for 
randomised controlled trials with a single follow-up and baseline measures, allowing simultaneous 
estimation of treatment differences at all follow-up visits adjusted for baseline. This is achieved 
using a linear mixed model that allows for correlated responses at all timepoints, including the 
screening visit. The model enforces a zero treatment effect at screening, but imposes no restrictions 
from day 1 onwards. The model was fitted to log transformed data for each cytokine type due to 
improve normality assumptions.  
 
8.3 Selisistat & Innate Immune System Results 
 
There is no clear evidence of cytokine alteration across time-points and in different treatment arms 
for IL-1, IL-6, IL-8 and TNFα (Figure 14). A few outlying values are seen for each of the cytokines 
tested and are explored further in Chapter 8.4.  
Figure 14- Box-plot Distribution of Cytokine Levels (pg/ml) by Treatment Arm & Time Point with no apparent difference 
seen in cytokine levels- Il-1, Il-6, Il-8 and TNFα between timepoints and treatment arms. 
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Using the data obtained to generate a statistical model, no apparent change in cytokine levels over 
time is noted in each of the three treatment arms. The influence of the outliers in this model is also 
noted (Figure 15).  
 
Finally, analysis of the data looking for any evidence of statistically significant effect of treatment 
with 10mg or 100mg of selisistat on cytokine levels, fails to support this hypothesis (Table 13). 
 
 
 
 
Figure 15- Model Predicted Mean Cytokine Levels (pg/ml) for each Treatment Arm. Despite some mild evidence of outlier effects, no 
clear evidence of treatment group on cytokine levels of Il-1, Il-6, Il-8 &TNFα is seen. ANCOVA modelled log transformed data. 
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8.4 Outlier Analysis 
 
A handful of subjects with outlying values were noted during these analyses (Figure 14). A 
retrospective, observational analysis of these subjects, looking for alternative explanations such as 
illness e.g. flu or infection, new medications or presence of any other change to pre-treatment state, 
was undertaken.  
 
8.4.1 IL-1 Outlier 
 
One subject was noted to have values greater than 500 pg/ml at Day 1, 14 and 28, the latter time 
point being 14 days after dosing. This subject was on 10mg of selisistat. No obvious changes were 
noted on review of the clinical database aside from transitory hypertension on day 1. 
 
 
 
Table 13- P-values indicating evidence of treatment effect (10 mg & 100 mg) at each time-point with no 
evidence of statistically significant difference (joint Wald test) of treatment on cytokine levels. 
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8.4.2 IL-6 Outlier 
 
In one subject, in the 10mg treatment group, a screening measurement of 1940 pg/ml was noted 
followed by subsequent readings of about 600 pg/ml. Non-specific headache was noted at screening 
which resolved by the next visit. No other explicatory factors were identified. 
 
8.4.3 IL-8 Outliers 
 
One subject in the 10mg treatment group had a value above 3000 pg/ml at baseline. At screening he 
had a non-serious fall on his way back home and reported some migraine, which was pre-existing at 
baseline. Another subject in 10mg treatment arm showed a high reading throughout the study 
period but with no obvious explanation. Finally a subject in 100mg treatment group had a peak at 
Day 14. However detailed investigation of the clinical record revealed no helpful findings. 
 
8.5 Discussion- Selisistat & Innate Immune System 
 
Analysis of data indicates that selisistat is unlikely to have biologically significant effects on 
modulation of IL-1, IL-6, IL-8 and TNFα levels. Furthermore, results here suggest that SirT1 inhibition 
is not acutely pro-inflammatory, in contrast to work previously carried out in macrophages, adipose 
and myocardial tissues, as well as in autoimmune disease (Kong et al., 2012).  
 
Experimental work in a macrophage-based cellular model, using Glucan encapsulated siRNA particles 
(GeRPs), has shown a significant decrease in IL-6 and TNFα production in both HD patient and 
control cells. This suggests that HTT is necessary for the hyper-reactive phenotype in HD myeloid 
cells (Trager et al., 2014) and therefore that selisistat may not be having a HTT lowering effect in 
myeloid cells. This hypothesis is eminently testable through application of the compound to a human 
macrophage cell model using the above paradigm and by measurement of HTT levels in PBMCs from 
treatment groups. Although SirT1 expression is thought to be widespread and sirtuins are heavily 
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implicated in an immune modifying role, it is also possible that SirT1 is not expressed at significant 
levels in myeloid cells to abrogate the hyper-reactive phenotype. 
 
Secondly, the duration and/or strength of dosing may not have been sufficient to provoke an effect. 
One notes the PK absorption data, which showed that a steady state was not achieved until day 4, 
and further pharmacokinetic analysis suggested the induction of other absorption mechanisms by 
day 14. The phase 2 study where treatment occurred over 3 months may be able to shed some light 
on this issue. Correlation of drug concentration levels with cytokine levels could also be looked at 
directly. 
 
The original work carried out by Bjorkqvist & Wild et al. 2008 comprised 194 subjects including 60 
controls and demonstrated a convincing, statistically significant elevated cytokine profile in HD 
patients. Sirtuins mediate the balance of pro- and anti-inflammatory action and therefore the 
absence of effect in either direction could reflect an equilibrated state. Although Selisistat appears 
to be highly selective for SirT1 above SirT2-3, counter-balancing effects on other Sirtuins, or indeed 
other pathways, are not excluded by current work. However the absence of a difference between 
the placebo group and treatment arms would suggest selisistat has no effect on the cytokine profile 
of HD patients. 
 
In Huntington’s disease it is proposed that the immune system may be functioning as a peripheral 
modifier of disease, acting peripherally on muscle and adipose tissue and potentially centrally, 
though this is not yet evidenced in humans. Moreover, it is not clear that the innate immune system 
of all HD patients is hyper-reactive or indeed remains consistently so. By extension, the Phase 1B HD 
population may not exhibit this phenotype.  Similarly, phenotypic diversity within HD is not unusual 
at all. Indeed it is clear that different motor sub-types of HD exist, akinetic rigid and classical 
hyperkinetic and that cognitive or psychiatric disease may be manifest strongly in some and be 
absent or mild in others. A control, HD gene negative population, would have been required for this 
set of experiments, to test this hypothesis adequately. Comparison to historical controls used in the 
work by Bjorkqvist & Wild et al. 2008 was considered, but was felt to be unviable given differences in 
methodology between studies. 
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The work that first demonstrated innate immune hyperactivity in HD monocytes employed 
lipopolysaccharide (LPS) stimulation as part of the experimental paradigm (Bjorkqvist et al., 2008).  
LPS is derived from the outer membrane of gram negative bacteria and interacts with the innate 
immune system via the Toll-like receptors (TLR) which in turn leads to transcriptional changes. It is 
believed to play a role in mediation of septic shock and the inflammatory response to infection. 
Indeed recent work in HD myeloid cells has shown a pathologically altered pro-inflammatory 
transcriptome even in the absence of LPS stimulation, suggesting that myeloid cells may be primed 
to overreact on receipt of the correct stimulus (Miller et al., 2016). However a clinical manifestation 
of this phenomenon is not apparent, although has never been carefully looked for. One would 
speculate that immune hyper-reactivity would lead to lower rates of infection, which would 
evidently not be reported. Conversely, one may expect a higher prevalence of auto-immune 
conditions.  
 
It may however explain the often noted clinical scenario of decompensation of a chronic 
neurodegenerative condition in the context of infection, where the disease progression of the 
patient appears to accelerate seemingly over days and then returns over subsequent months. 
Additionally some patients report a preceding medical illness prior to onset of a neurodegenerative 
disorder, as well as other chronic disorders in general (De et al., 2012;Deleidi & Isacson, 2012).  
 
Thus in the phase 1B study, no such stimulation was given, and therefore it may be that in some HD 
patients the baseline state is altered, while in others it remains at normal levels, but upon 
stimulation, this hyper-reactivity emerges, and there may be a final group which are no different 
from controls. 
 
The outlier analysis implies that cytokine levels may also be subject to inherent variability. Although 
substantial data is lacking, one study examined cytokine profiles of health controls and fibromyalgia 
patients over a 24hr period. They noted some clustering of peak values around the time of first 
sampling, despite having had time to acclimatise to the research facility and sampling itself (Togo et 
al. 2009). Further work has shown evidence of the pulsatile secretion of IL-1 suggesting variability 
may be inherent (Licinio et al. 1994). In addition, the influence of other factors such as physical 
activity as well as time of sampling is not accounted for in this study. 
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 Phase 2 Study of Selisistat 9
With kind permission of the study sponsor Siena Biotech SpA, data presented here is the complete 
data set for all subjects, including 6 London subjects, where I was the site clinical lead. In this role, I 
undertook all clinical histories, physical examinations, UHDRS, ECG interpretation, TFC & 
Independence scale Scores, HADS-SIS assessments, cannulation and blood tests.  Routine clinical 
observations were performed by clinical trial nurses at Clinical Research Facility (CRF), University 
College London Hospital (UCLH) and cognitive assessments by Miss Monica Lewis. Processing of 
London biosamples was carried out by Miss Nicola Robertson at the CRF, UCLH.  
 
9.1 Introduction  
 
Selisistat, a SirT1 inhibitor, has been specifically developed for Huntington’s disease, with a 
mechanism of action based on acetylation of mutant Htt, activating cell based autophagy. As 
presented earlier, the first-in-human study showed Selisistat to be safe and well tolerated in healthy 
volunteers, with the majority of adverse events determined as mild in severity and not requiring 
treatment and no SAE. The phase 1B study revealed no SAEs and no subjects were withdrawn from 
the study as a result of adverse events.  
 
Herein is described a phase 2,  double-blind, placebo-controlled parallel group design study with 
three treatment groups to assess the safety and tolerability of selisistat in male and female patients 
between 30 and 70 years of age with Stages I to III HD. 
 
 
9.2 Methods (Reilmann et al., 2013) 
The Study were carried out following the Helsinki protocol (Ethical Principles for Medical Research 
Involving Human Subjects), with local research ethics committee approval and clinical research 
organisation supervision including site initiation, monitoring and final visits. All study members were 
trained in good clinical practice.  Below are the methods reproduced from the clinical study report 
(Reilmann et al., 2013) unless otherwise indicated. 
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9.2.1 Summary of Design 
 
The study was also designed to evaluate short-term clinical outcomes and the pharmacokinetics of 
Selisistat over a 12 week dosing period, involving 18 centres and approximately 144 patients 
randomised in order to achieve 120 completed patients (40 patients per treatment group) in three 
countries: Italy (four sites), Germany (seven sites), and the United Kingdom (UK) (seven sites). 
 
Screening took place within 5 to 21 days prior to the Baseline Visit (Day 1) when the randomisation 
and first dose administration took place. All Baseline assessments (including verification of patient 
eligibility) had to be completed before randomisation and dosing with study drug. Determination of 
standardised CAG repeat length at Baseline was required for participation in the study. CAG repeat 
number assessment for eligibility had to be done prior to screening and was not a study procedure. 
Dose changes were not permitted.  
 
Patients, who in the opinion of the Investigator had intolerable AEs on their assigned dose, could 
have a 3- to 5-day drug ‘holiday’. However, after the drug holiday, the study drug had to be restarted 
at the same dose level as previously administered (same supply). If intolerable AEs reappeared after 
reintroducing the study drug, the patient was to be withdrawn, rather than undergoing further drug-
free periods. 
 
9.2.2 Primary Objectives  
 
To assess safety and tolerability of 12 weeks of treatment with selisistat at doses of 50 mg and 
200mg in HD patients. 
 
Primary outcome measures were: 
 
• Type and frequency of AEs. 
• Clinical laboratory tests (haematology, serum biochemistry, and urinalysis) 
• 12-lead electrocardiogram (ECG). 
• Physical and neurological examination findings. 
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• Vital signs. 
• Suicide risk and suicide-related events (behaviour and/or ideation) as assessed by the    
Columbia-Suicide Severity Rating Scale (C-SSRS). 
 
9.2.3 Secondary Objectives 
 
To assess short-term clinical effects, modulation of candidate pharmacodynamic (PD) markers and 
the pharmacokinetic (PK) profile of Selisistat at 50 mg and 200 mg in patients with HD treated for 12 
weeks, through the following outcomes: 
 
• Clinical Impression. 
• Global Clinical Impression (GCI) (patient and Investigator-based). 
• Unified Huntington’s Disease Rating Scale (UHDRS) Total Motor Scale (TMS). 
• Functional Assessment. 
• Independence Scale Assessment. 
• Problem Behaviours Assessment. 
• Cognitive Battery (Symbol Digit Modalities Test, Stroop Word Test, Verbal fluency, Mini-
Mental State Examination [MMSE]). 
• Change from Baseline levels of soluble Huntingtin protein (HTT) 
• Change from Baseline in acetylation status of mutant HTT 
• Pharmacokinetics of selisistat at steady state with the maximum observed plasma 
concentration (Cmax), time of maximum observed plasma concentration (tmax), AUC from 
time zero to the length of the dosing interval (τ) (AUC0-τ), AUC from time zero to the last 
quantifiable concentration (AUC0-last), and inter-patient variability. 
 
9.2.4 Inclusion Criteria 
 
Male and female HD patients as defined by the following inclusion criteria were eligible to enrol in 
the study: 
 
1. Genetically confirmed, manifest HD (CAG repeat length 36) and motor signs of HD 
(motor score of the UHDRS≥ 5). 
2. Clinical Stages I to III (TFC of ≥ 4). 
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3. Anticipated to be ambulatory and able to attend outpatient visits for the duration of the 
study. 
4. Aged ≥ 30 years and ≤ 70 years. 
5. Body mass index between 18 and 31 kg/m2 inclusive and a body weight > 50 kg. 
6. Able to give informed consent or have a legal representative who could consent on their 
behalf. Patients had to be able to comply with trial procedures. 
7. No clinically significant and relevant medical or psychiatric history that could affect the 
conduct of the study and evaluation of the data, as ascertained by the Investigator 
through detailed medical history and screening assessments. 
8. Male patients had to agree to use condoms during the entire duration of the study and 
for 3 months following the last dose of study drug. 
9. Females of childbearing potential (last menses less than 1 year prior to enrolment): 
- Negative pregnancy test at Screening and at Baseline (Day 1). 
- Could not be breastfeeding. 
- Had to be either be surgically sterile (hysterectomy, bilateral oophorectomy, or 
tubal ligation), postmenopausal (cessation of menses for at least 1 year), or agree to 
use a medically accepted, highly effective method of contraception during the entire 
duration of the study and for 3 months after the last dose of the study drug. An 
effective method of birth control was defined as those methods, either alone or in 
combination, which has a low failure rate when used consistently and correctly, such 
as implants, injectables, combined oral contraceptives, non-hormonal intrauterine 
devices, sexual abstinence, a vasectomised partner or use of a double-barrier 
contraception method (e.g., condom with diaphragm/occlusive cap and spermicide 
cream). 
 
9.2.5 Exclusion Criteria 
 
A patient was not eligible for inclusion in the study if any of the following criteria were met: 
 
1. Participation in a study with an investigational drug within 30 days of the Baseline Visit. 
2. Any prior or concomitant use of Class I or Class II HDAC inhibitors such as Zolinza®/vorinostat 
or belinostat. 
3. Clinical evidence of significant or unstable medical illness in the Investigator's judgement, 
including screening transaminases (aspartate aminotransaminase [AST] or alanine 
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aminotransaminase [ALT]) ≥ 1.5 times the upper limit of normal (ULN), or an estimated 
glomerular filtration rate (GFR) (modification of diet in renal disease [MDRD] equation) of < 
60 mL/min, or unexplained proteinuria or microscopic haematuria in an uncontaminated 
sample obtained at Screening and confirmed on repeat testing. 
4. Corrected QT interval using Fridericia’s formula (QTcF) interval> 450 ms in men and 470 ms 
in women or PR> 220 ms, or other clinically relevant abnormal ECG findings that, in the 
Investigator’s judgement, would present an unacceptable risk to patient safety. 
5. Women who were pregnant or breastfeeding. 
6. Clinically significant abnormalities in the screening laboratory studies which, in the opinion 
of the Investigator, would have interfered with participation in the study. 
7. Current evidence or history (within 1 year of baseline) of psychosis, hallucinations or 
delusions, including major depression with psychotic features, as defined in the Diagnostic 
and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR). Patients experiencing mild 
depression, or moderate depression, which is adequately and appropriately treated, in the 
judgement of the Investigator, could participate if depression was not expected to interfere 
with study participation. 
8. Suicide risk, as determined by meeting any of the following criteria: 
- A suicide attempt within the past year or suicidal ideation within 60 days of the 
Baseline Visit (Day 1). 
- Significant risk of suicide, as judged by the Principal Investigator, based on the   
psychiatric interview or information collected in the C-SSRS. 
9. Current diagnosis or history (within 1 year of baseline) of any alcohol or substance abuse 
(except nicotine and caffeine-related disorders) as defined in the DSM-IV-TR. 
10. Known allergy to any ingredient in the study drug (active and/or placebo). 
11. A history of malignancy of any type within 2 years prior to screening. A history of surgically 
excised non-melanoma skin cancers was permitted. 
12. Any relevant condition, behaviour, laboratory value, or concomitant medication which, in 
the opinion of the Investigator, made the patient unsuitable for entry into the study. 
13. Following pre-dose assessments, patients could be excluded from the study also for the 
following reasons: 
– Intercurrent illness or medically significant AEs. 
– Positive urine drug screen or alcohol breath test result, which suggested 
substance abuse and was not explained on the basis of prescription or over-
the-counter medication that was used according to instruction. 
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9.2.6 Patient Withdrawal  
 
Patients could be withdrawn after discussion with the Sponsor’s Medical Monitor, if any of the 
following criteria were met: 
 
• Any clinically relevant signs or symptoms which, in the opinion of the Investigator, 
warranted patient withdrawal. 
• Positive urine drug screen or alcohol breath test result that suggested substance abuse and 
was not explained on the basis of prescription or over-the-counter medication used 
according to instruction. 
• Intercurrent illness or any clinically relevant signs or symptoms which, in the opinion of the 
Investigator, warranted patient withdrawal. 
• Clinically significant AEs which, in the opinion of the Investigator, warranted patient 
withdrawal. 
• In case of an AE, study drug could be stopped for up to 5 days without the patient being 
withdrawn. If deemed safe and justifiable by the Investigator and by the Sponsor’s medical 
representative, study drug could be reinstituted at the previous dose within 5 days of 
discontinuation and the patient continued in the study. If intolerable AEs reappeared after 
reinstituting medication at the previous dose, the patient was to be withdrawn rather than 
undergoing further drug-free periods. 
• If a patient’s corrected QT interval using Bazett’s formula (QTcB) increased > 60 ms 
compared to Baseline or to an absolute QTcB value > 500 ms. In such cases, two repeat ECGs 
were to be immediately obtained, at least 2 minutes apart. A mean QTcB value was 
calculated from the three ECGs; if this mean value confirmed the increase in QTcB, then the 
mean QTcF was calculated for all three ECGs. If the stopping criterion was also met by QTcF, 
then the ECGs were manually read by a cardiologist, to confirm the QTc increase. If 
confirmed, the patient was withdrawn from further dosing (i.e., early termination) and 
would begin the safety Follow-up period. 
• Liver function tests (either AST, ALT, or both) ≥ 4 times ULN reference range. 
• If a patient had severe nausea and vomiting for an extended period. 
• If a patient had severe diarrhoea for an extended period. 
• If during treatment, patients had microscopic haematuria or proteinuria, in two 
uncontaminated samples at two consecutive visits during the study, the patient was to be 
 Early Phase Disease Modification Trials with Selisistat and Optical Coherence Tomography as a Biomarker in Huntington’s Disease 
UCL PhD Submission 
116 
Dr Salman Haider (Student No.: 1054117) 
 
referred for general medical evaluation. If the assessment suggested renal dysfunction 
attributable to another cause, such as infection, treatment with study drug could continue if 
deemed appropriate by the Investigator and the other cause was not to be treated and the 
patient reassessed. If the microscopic haematuria or proteinuria was not attributable to 
another cause and, in the opinion of the Investigator was related to the study drug, the 
patient was discontinued and followed until resolution or an alternative cause was found. 
• A patient was free to withdraw his or her consent to participate in the study, at any time, 
without explanation. In addition, the Investigator could decide, for reasons of medical 
prudence, to withdraw a patient. In either event, the Sponsor was notified and the date and 
reasons for the withdrawal clearly stated in the patient's CRF. If the randomisation code 
needed to be broken for a patient, the date, time and reason was recorded in the patient’s 
CRF. 
• If a patient was withdrawn, or chose to withdraw, the relevant post-study assessment was 
performed wherever possible according to the Schedule of Assessments outlined for the 
safety Follow-up period. 
• Patients who prematurely withdrew from the study were not replaced. 
 
9.2.7 Drug Dosing 
 
The active study drug was orally administered as tablets of either 50 mg or 100 mg in strength with a 
glass of water in the morning. Placebo was administered in the same manner. To maintain blinding, 
each patient took two tablets each day of the study according to the scheme below: 
 
Dose level (mg) selisistat Placebo 
50mg: 1 x 50 mg tablets + 1 (placebo) tablet 
200mg: 2 x 100 mg tablets  
Placebo (0mg) - 2 tablets 
 
Placebo was of identical pharmaceutical composition and appearance aside from containing no 
active drug substance. All tablets were both white, round, bi-convex coated tablets, 10 mm in 
diameter and 5 mm in thickness i.e. identical in size and appearance. 
 
The treatment period was planned to last 12 weeks and comprised 7 visits (Day 1 [Baseline], Day 7 
[Germany only], Week 2 [UK and Italy only], Week 4, Week 6, Week 8, Week 10, and Week 12). The 
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visit on Day 7 was scheduled within a time window of +/- 1 day, and the visits at Weeks 4, 8, and 12 
were scheduled within a time window of +/- 4 days in relation to the intended date of the visit, with 
reference to Day 1. Similarly, the visits at Weeks 2, 6 and 10 should be scheduled within a time 
window of +/- 4 days in relation to the intended date of the visit, with reference to Day 1. 
 
9.2.8 Blinding 
 
An independent, unblinded statistician prepared the randomisation and pack lists based on a 
randomisation scheme. The active and placebo tablets were identical in size and appearance. The 
packaging for each respective preparation was identical with the same labelling (apart from the 
batch number and medication identification number) to ensure that neither the investigator nor the 
patient were aware of the treatment allocated. 
 
Blinding was only to be broken in the case of a medical emergency where drug identification was 
necessary. In such an event, the Investigator was able to obtain details of the treatment assigned to 
an individual patient via the IVRS. Where possible and safe to do so, the Investigator could discuss 
the need to break the blind with the Medical Monitor. If an individual’s treatment was unblinded, 
the patient was withdrawn from the trial. 
 
9.2.9 Drug Group Assignment 
 
Each patient was assigned to one of the three treatment groups (50 mg, 200 mg, or placebo) in a 
1:1:1 ratio. Randomisation to treatment group, according to the patient randomisation list, and 
assignment of the study drug was managed by an interactive voice response system (IVRS). 
 
9.2.10 Prior and Concomitant Therapy 
 
With the exception of HDAC inhibitors (such as Zolinza®/vorinostat, belinostat), concomitant 
medications were allowed during the treatment phase. It was preferred that, whenever possible, the 
doses of concomitant medications remained stable during the trial, in order to prevent confounding 
of results. However, changes in concomitant medications that were medically necessary were not 
prohibited. 
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Medications taken within 21 days before the first dose of trial medication were documented as prior 
medication. Medications taken after the first dose of trial medication were documented as 
concomitant medications. Patients were questioned about concomitant medication at each visit to 
the clinic and the concomitant medication was entered into the CRF. 
 
9.2.11 Treatment Compliance 
 
To enhance treatment compliance, study drug was dispensed and instructions to the patient given 
under the supervision of suitably qualified site staff. Patients were instructed to return all study 
drugs packaging (empty, used and partially used) at each Visit (or End-of-Treatment [EOT] Visit).  
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9.2.12 Schedule of Assessments & Blood Tests 
This is summarised below in Table 14 and 15. 
 
Table 14- Schedule of assessments. Adapted from (Reilmann et al., 2013) 
Period (duration)     Screening  Treatment
a
 (up to 12 weeks)   Follow-up
b 
  (up to       (4 weeks 
  21 days)       +/- 4 days) 
          
Study Day/Week  Days Day 1 Day 7 (+ Week Week  Week 12/ Week 
Activity  -21 to -5 (Baseline) /- 4 (+/- 8 (+/-  EOT
c 
16 (+/- 
    4 days)* 4 days) 4 days)  
(+/- 4 
days) 4 days) 
           
           
Informed 
consent  X         
          
Inclusion/exclusion criteria X         
          
Demographic data X         
          
Medical/medication history X         
          
Urine drugs of abuse screen          
and alcohol breath test X X X X X  X   
          
Urine pregnancy test X X X X X  X  X 
          
CAG repeat length  Xl        
Randomisation (IVRS)  X        
          
Study drug dispensing  X  X X     
          
Concomitant Medications    
X 
     
Recording   X X X  X  X 
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Study drug reconciliation    X X  X  X 
          
Safety Parameters          
           
AE recording   X X X X  X  X 
          
Clinical laboratory tests
d 
X X X X X  X  X 
12-lead ECG
e  X X* X X* X  X  X 
Physical examination X X X X X  X  X 
          
Neurological examination X X X X X  X  X 
           
Vital signs
f  X X X X X  X  X 
UHDRS
g  X X X X X  X  X 
C-SSRS
h  X X X X X  X  X 
Efficacy Parameters          
           
Clinical (GCI)
i  X X  X X  X  X 
UHDRS Total Motor
j 
X X  X X  X  X 
Scale and functional          
Assessments           
          
Cognitive Battery tests
k 
X X  X X  X  X 
Pharmacokinetics  X  X   X   
          
Pharmacodynamic  X  X   X   
           
Abbreviations: CAG = cytosine, adenine, guanine; C-SSRS = Columbia-Suicide Severity Rating Scale; ECG = electrocardiogram; EOT = End of 
Treatment; GCI = Global Clinical Impression; Htt = Huntingtin protein; IVRS = Interactive Voice Response System; and UHDRS = Unified 
Huntington’s Disease Rating Scale. 
** Germany only. 
a Unscheduled visits were possible at the discretion of the Investigator, for reason of safety or evaluation of AEs, or to repeat protocol-
required procedures if necessary. 
b The Follow-up Visit was done 4 weeks (+/- 4 days) after the last dose of study drug. The C-SSRS, 12-lead ECG, clinical laboratory tests 
(serum biochemistry, haematology and urinalysis), and physical and neurological examinations were only performed at the Follow-up Visit 
if there were any clinically significant abnormalities (from Baseline) at Week 12/EOT Visit, as judged by the Investigator. 
c An EOT Visit was to be performed for patients who discontinued prematurely, whenever possible. Patients were instructed to return 
study drug at the EOT Visit. 
d Clinical laboratory tests included haematology (white blood cell count, differential white blood cell count, red blood cell count, 
neutrophils, platelets, haemoglobin, haematocrit, mean cell volume, and mean cell haemoglobin); serum biochemistry (aspartate 
aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma glutamyl transferase, electrolytes, glucose, urea, total 
bilirubin, creatinine, total protein, and albumin); and urinalysis (colour, specific gravity, pH, protein, glucose, ketones, blood, nitrate, and 
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examination of urinary sediment for crystals, casts, red blood cells, white bloods cells, and bacteria or yeast). Additional blood samples for 
serum biochemistry (safety monitoring of liver function tests) were collected and analysed at a local or central laboratory on 3 additional 
visits (UK and Italy) at Week 2 (+/- 4 days), Week 6 (+/- 4 days) and Week 10 (+/- days) (2 additional visits at Week 6 (+/- 4 days) and Week 
10 (+/- 4 days) in Germany). 
e ECGs were recorded after at least 5 minutes supine rest. At Screening, Day 1; at Weeks 4, 8, and 12; and at Follow-up, single recordings 
for safety evaluation were performed. (*) In addition, triplicate ECGs for analysis by central ECG laboratory were to be performed at 
Baseline (pre-dose) and at the Week 4 visit (both pre-dose and 3 hours post-dosing). 
f Vital signs included supine and standing blood pressure and pulse rate, respiration rate, oral or tympanic body temperature and body 
weight. 
g UHDRS tests included motor, cognitive, behavioural, independence, functional and total functional capacity assessments. Those 
individuals determining UHDRS ratings had current valid certification by the EHDN. 
h The C-SSRS was done by certified staff members. 
i GCI included both patient and clinician-based assessments. 
j UHDRS efficacy assessment test consisted of the total motor scale. Those individuals determining UHDRS ratings had current valid 
certification by the EHDN. 
k Cognitive Battery tests consist of the symbol digit modalities, Stroop word, verbal fluency and Mini-Mental State Examination tests. The 
verbal fluency test was described within the UHDRS form. 
l A genetic test using the same Baseline genotyping blood sample was done to assess CYP2C19 and CYP2D6 polymorphisms in samples 
from patients who provided separate written consent for this analysis. Using the same sample, cytochrome (CYP) P450 2C19 and 2D6 
polymorphisms will be assessed in patients that provide separate written consent. 
 
 
Table 15- Blood Tests Schedule. (Reilmann et al., 2013) 
Study Day  Screening Baseline Day 7 Week Week Week Follow-up 
   (Day 1) (+/- 4 days)** 4 (+/- 8 (+/- 12 (+/- (+/- 4 days) 
     4 days) 4 days) 4 days)  
Visit  1 2  3 4 5 6 
       
Assessment    Blood Volume (mL)   
        
CAG repeat length - 6.0
d  - - - - 
Biochemistry
a 
 3.5 3.5 3.5 3.5 3.5 3.5 3.5 
Haematology
a 
 4.0 4.0 4.0 4.0 4.0 4.0 4.0 
Pharmacodynamics        
Soluble Htt
b 
 - 16  8 - 8 8 
Acetylated Htt
b 
 - 16  8 - 8 8 
Pharmacokinetics
c 
- 10  4 - 12 - 
Total  7.5 55.5 7.5 27.5 7.5 35.5 23.5 
      
Abbreviations: CAG = cytosine, adenine, guanine. 
** Germany only. 
a Serum biochemistry and haematology tests were performed pre-dose on Day 1, Day 7 (Germany only), at 4, 8 and 12 weeks and at 
Follow up. For safety monitoring of liver function tests, 2 additional in Germany and 3 in Italy and UK 5-mL blood samples (i.e., an 
additional 10 mL (Germany) or 15 mL (UK and Italy) of blood to that shown in the above table) for serum biochemistry were collected and 
analysed at a local or central laboratory on additional visits at Week 2 (+/- 4 days) (Italy and UK only), Week 6 (+/- 4 days), and Week 10 
(+/- 4 days). 
b Soluble Htt and acetylated Htt blood collection occurred at pre-dose and 4 hours post-dose on Day 1, but only at 4 hours post-dose at 
the visits at 4 and 12 weeks and at the Follow-up Visit. Blood collection was to be as close as possible to the specified timing (± 10 minutes) 
and the actual time of collection with regard to dosing was to be clearly noted in the CRF. No analysis was conducted. Development of a 
GCLP-validated and robust method is ongoing and it is planned that the collected samples will be analysed at a later date. 
c PK blood collections were performed at pre-dose, 1, 2, 3, and 4 hours on Day 1; at pre-dose and 4 hours at Week 4; and at pre-dose, 1, 2, 
3, 4 and 6 hours at Week 12. Blood collection was to be as close as possible to the specified timing (± 10 minutes) and the actual time of 
collection with regard to dosing w be clearly noted in the CRF. Blood samples for soluble HTT and acetylated HTT analysis will be collected 
on Day 1 (Baseline) at pre-dose and 4 hours post-dose, and during the Week 4, Week 12 and Follow-up visits at 4 hours post-dose. 
d A genetic test using the same Baseline genotyping blood sample was done to assess CYP2C19 and CYP2D6 polymorphisms in samples 
from patients who provided separate written consent for this analysis. 
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9.2.13 Safety and Tolerability Assessments 
 
Every effort was made to schedule and perform the procedures as closely as possible to the same 
time of day, giving consideration to appropriate posture conditions, practical restrictions and the 
other procedures to be performed at the same time point. The order of priority for scheduling 
procedures at each time point was: 
 
1. Dosing. 
2. Blood samples. 
3. Urine samples. 
4. Any other procedures. 
 
Electrocardiograms were recorded before vital sign measurements. 
 
9.2.13.1 Adverse Events 
An AE was defined as any untoward medical occurrence in a patient, or clinical 
investigation patient administered a pharmaceutical product and which does not 
necessarily have a causal relationship with this treatment. An AE could, therefore, be 
any unfavourable and unintended sign, symptom, or disease temporally associated 
with the use of a drug (investigation) product, whether or not related to the drug 
(investigational) product. 
 
For the purposes of this study, any detrimental change in the patient’s condition, 
after signing the informed consent form and up to completion of the 4-week Follow-
up period after the last administration of the study drug, could be considered an AE. 
Adverse event recording began on the first day of study drug intake (Day 1, 
Baseline). 
 
All AEs that were on-going at the end of the study were to be followed up for 30 
days after the last administration of the study drug, with the exception of any on-
going study drug related AEs, which were to be followed until resolution, unless, in 
the Investigator’s opinion, the AE was unlikely to resolve due to the patient’s 
underlying disease. All AEs were tracked in the CRF. 
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The Investigator assessed the intensity of AEs based on the following definitions: 
 
• Mild (awareness of sign or symptom, but easily tolerated) 
• Moderate (discomfort sufficient to cause interference with normal activities) 
• Severe (incapacitating, with inability to perform normal activities). 
 
For an AE to be a suspected drug-related event, there had to be at least a reasonable 
possibility of a causal relationship between the study drug and the AE.  
 
 
9.2.13.2 Serious Adverse Events 
An SAE was defined as, but was not limited to, an event that: 
 
• Resulted in death 
• Was life-threatening 
• Required inpatient hospitalisation or prolonged existing hospitalisation 
• Resulted in persistent or significant disability/incapacity 
• Was a congenital anomaly/birth defect 
• Resulted in an important medical event that required medical intervention to 
prevent any of the above outcomes or was a medically important event or reaction 
according to Investigator’s judgement. 
 
Important medical events that did not result in death, were life-threatening or 
required hospitalisation could be considered a serious adverse drug experience, 
when based on appropriate medical judgement, when jeopardising the patient or 
resulting in the patient requiring medical or surgical intervention to prevent one of 
the outcomes listed in this definition. Serious AEs were recorded from the date when 
informed consent was signed if the Investigator considered the event to be related 
to a study procedure. 
 
9.2.13.3 Pregnancy 
Pregnancy itself was not regarded as an AE unless there was a suspicion that the 
study drug may have interfered with the effectiveness of a contraceptive 
medication. However, the outcome of all pregnancies that occurred during paternal 
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or maternal exposure to study drug (spontaneous miscarriage, elective termination, 
normal birth, or congenital abnormality) had to be followed up and documented 
even after the patient had been withdrawn from the study. 
 
All reports of congenital abnormalities/birth defects were to be considered SAEs. 
Spontaneous miscarriages were also to be reported and handled as SAEs. Elective 
abortions without complications were not to be considered as AEs. All outcomes of 
pregnancy were to be reported to the Sponsor’s Drug Safety vendor (Covance DSS) 
on a pregnancy outcomes report form. 
 
9.2.13.4 Laboratory/Vital Sign/ECG Abnormalities 
Laboratory/vital sign/ECG abnormalities were to be reported as AEs if any one of the 
following criteria were met: 
 
• Any criterion for an SAE was fulfilled. 
• The laboratory/vital sign abnormality caused the patient to discontinue study drug 
or discontinue from the study. 
• The laboratory/vital sign abnormality caused the patient to interrupt study drug 
treatment. 
• The laboratory/vital sign abnormality caused the patient to modify the dose of 
study drug. 
• The Investigator believed that the abnormality should be reported as an AE. 
• If an abnormal laboratory value or vital sign was associated with clinical signs and 
symptoms, the sign or symptom was to be reported as an AE and the associated 
laboratory result or vital sign was to be considered additional information that had 
to be collected on the relevant CRF. 
 
In case of accidental overdosing of Selisistat, vital functions were to be monitored 
carefully. Special attention was to be given to cardiovascular (heart rate, blood 
pressure, and ECG parameters) and central nervous system functions. 
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9.2.13.5 Laboratory Safety Assessments 
A central laboratory was used for the analysis of all urine and blood samples. A local 
or central laboratory was used for the additional serum biochemistry blood samples 
collected at Week 2 (the UK and Italy only), Week 6, and Week 10. These were 
collected, processed, and stored according to instructions that were provided to 
sites by the relevant laboratory. 
 
The following clinical laboratory parameters were evaluated: 
 
Haematology: 
• White blood cell count (WBC) 109/L. 
• Differential WBC 109/L & %. 
• Neutrophils 109/L. 
• Platelets 109/L. 
• Red blood cell count (RBC) 1012/L. 
• Haemoglobin (Hb) g/dL. 
• Haematocrit (packed cell volume [PCV]) %. 
• Mean cell volume (MCV) fL. 
• Mean cell haemoglobin (MCH) pg. 
 
Serum biochemistry: 
• AST IU/L. 
• ALT IU/L. 
• Alkaline phosphatase (ALP) IU/L. 
• Gamma glutamyl transferase (GGT) IU/L. 
• Electrolytes (sodium, potassium, chloride, calcium, and inorganic phosphate). 
• Inorganic phosphate mmol/L. 
• Glucose mmol/L. 
• Urea mmol/L. 
• Total bilirubin (total) μmol/L. 
• Creatinine μmol/L. 
• Total protein g/L. 
• Albumin g/L. 
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Urinalysis: 
• Colour. 
• Specific Gravity. 
• pH. 
• Protein. 
• Glucose. 
• Ketones. 
• Blood. 
• Nitrate. 
 
Examination of urinary sediment: 
 
• Crystals, casts, RBC, WBC, and bacteria or yeast. 
 
9.2.13.6 Electrocardiogram Assessments 
The same equipment was to be used to collect standard 12-lead ECG recordings at 
the Baseline Visit and throughout the study. For safety monitoring, 12-lead ECGs 
were recorded at each visit after the patient had been supine for at least 5 minutes. 
A repeat ECG was then be performed after at least 5 additional minutes supine. A 
copy of these recordings was retained in the study site files. 
 
In addition, triplicate ECGs for analysis by the central ECG laboratory were 
performed at Baseline (pre-dose) and at Week 4 (both pre-dose and 3 hours post-
dosing).  
 
A site physician performed a clinical assessment of each 12-lead safety ECG. The ECG 
machine computed the PR, QT and QTcF intervals, QRS duration, and heart rate (HR). 
Reference ranges were applied to all ECG parameters determined throughout the 
study. Patients were to be withdrawn from the study if abnormal QTcF intervals 
were recorded meeting the withdrawal criterion. 
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9.2.13.7 Physical Examination 
A full physical examination (including body weight) was performed by a trained 
physician during each study visit (Screening, Day 1 [Baseline], Week 4, Week 8, and 
Week 12) and during Follow-up. 
 
The physical examination included the following: 
 
• General appearance. 
• Abdomen. 
• Cardiovascular systems. 
• Lungs. 
• Lymph nodes. 
• Musculoskeletal and neurological systems. 
• Skin. 
• Extremities. 
• Head, ears, eyes, nose, throat, mouth. 
• Thyroid gland. 
• Body weight (kg). 
 
 
9.2.13.8 Neurological Examination 
A standard neurological examination by a trained neurologist was performed as 
indicated in the Schedule of Assessments (Table 14). The frequency of the 
assessments could be increased if required in the opinion of the Investigator. 
 
9.2.13.9 Vital Signs 
At the Screening Visit and Baseline Visit (pre-dose), blood pressure, and pulse rate 
were measured in triplicate at approximately 2-minute intervals. The median value 
was used as the baseline value in the data analyses. 
 
Vital signs were also assessed at other times if judged to be clinically appropriate or 
if the on-going review of the data suggested a more detailed assessment of vital 
signs was required. Patients had to be supine for at least 5 minutes before blood 
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pressure and pulse rate measurements. For the standing assessment, patients were 
asked to sit for 1 minute and then stand for 2 minutes prior to the measurement. 
Temperature was measured once either orally or tympanically as detailed. 
 
9.2.13.10 Unified Huntington’s Disease Rating Scale 
The UHDRS, a clinician’s assessment of the capacity to perform in each of five 
functional domains, was carried out for each patient and included the following: 
 
• Motor. 
• Cognitive. 
• Behavioural. 
• Independence. 
• Functional. 
• TFC (including occupation, finances, domestic chores, activities of daily living, and 
care level). 
 
9.2.13.11 Columbia-Suicide Severity Rating Scale 
The C-SSRS is a questionnaire used for suicide assessment (Columbia University 
Medical Centre website [http://cssrs.columbia.edu/]. It was developed by leading 
experts to assess both behaviour and ideation, appropriately assesses and tracks 
suicidal all events, and uniquely addresses the need for a summary measure of 
suicidality (FDA Advisory Committee Meeting, 2007).  
 
9.2.13.12 Drug and Alcohol Screening 
Patients were asked to provide urine samples for drugs of abuse screen, and 
undergo an alcohol breath test at the times indicated in the Schedule of 
Assessments (Table 14). The urine was screened for the presence of the following 
drugs of abuse: methadone, benzodiazepines, cocaine, amphetamines, 
methamphetamines, opiates, and barbiturates. 
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9.2.14 Clinical Assessments 
9.2.14.1 Clinical Impression (Patient and Investigator) 
A clinical impression was performed using a Global Clinical Impression (GCI) scale 
(patient and Investigator based). 
 
9.2.14.2 Cognitive Battery Assessments 
The effect of fatigue was minimised by conducting cognitive assessment as early as 
possible in the study visit day and was controlled for by keeping the time of day of 
the assessments as stable as possible across patients. The cognitive battery included: 
 
• Symbol Digit Modalities Test. 
• Stroop Word Test. 
• Verbal fluency. 
• MMSE. 
 
9.2.14.3 DNA Genotyping 
DNA genotyping samples were collected at Baseline to ascertain HD genotype and to 
identify genetic modifiers of HD, in particular genetic modifiers of age of onset, rate 
of progression, and phenotypic characteristics.  
 
9.2.14.4 Pharmacokinetics 
Blood samples for PK analysis of selisistat were collected at Baseline (Day 1) and 
during the Week 4 and 12 visits. (Only descriptive pharmacokinetic data is presented 
as further detail is beyond the scope of this work.) 
 
9.2.14.5 Pharmacodynamic Measurements 
Blood samples for PD assessments were collected at Baseline (Day 1) and during the 
Week 4, Week 12 and Follow-up visits. Pharmacodynamic samples were processed 
on-site without delay, to extract high quality peripheral blood mononuclear cell 
(PBMC) pellets for freezing. Samples were collected to assess the effect of selisistat 
on candidate pharmacodynamic markers (levels of soluble mutant Htt); however, no 
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analysis was performed as the previously developed methods were found to be 
suboptimal. 
 
9.2.14.6 Biomarker Measurements 
Samples for the PD biomarkers, the level of soluble HTT and the acetylation status of 
mutant HTT, were collected at pre-dose and 4 hours post-dose on Day 1, at 4 hours 
post-dose at both Weeks 4 and 12, and at the follow-up visit. 
 
9.2.14.7 Genetic Assessments 
The HD genotype and genetic modifiers of HD, and CYP2C19 and CYP2D6 isoenzymes 
will be listed by treatment and patient based on the safety analysis set. 
 
9.2.14.8 Data Quality Assurance (QA) 
The Investigators were provided with standardised CRFs and ensured that all data 
from patient visits were promptly entered into the CRFs in accordance with the 
specific instructions given. Investigators had to sign each CRF to verify the integrity 
of the data recorded. The Investigators maintained source documents, such as 
laboratory reports, X-rays, ECGs, consultation reports and complete medical history 
and physical examination reports. 
 
The Sponsor/ICON implemented and maintained QC and (QA) procedures with 
written standard operating procedures (SOPs) to ensure that the study was 
conducted and data were generated, documented and reported in compliance with 
the protocol, GCP, and applicable regulatory requirements. 
 
9.2.15 Statistical and Analytical Plans 
 
The study sponsor indicated that due to the exploratory first in disease nature of the study, no 
formal statistical comparisons were planned or performed. Further comparative statistical sub-
analysis of change in clinical parameters between treatment groups was undertaken using an 
unpaired t-test, by myself with oversight from Dr Mariam Shoai, UCL, where indicated. 
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9.2.15.1 Data Handling 
For safety parameters, an end of treatment visit was defined as the last non-missing 
post-baseline record for each patient. There was no imputation for partial dates or 
times. However, imputation of partial dates was used to determine the treatment-
emergent flag for AEs and the previous/concomitant flag for medications. 
 
For efficacy analyses, and in case of missing post-baseline records occurring during 
the treatment, the last non-missing post-baseline observation was carried forward. 
If the first post-baseline observation was missing, a missing value was imputed. 
Records occurring after the end of the treatment date/ time were not imputed. 
Patients who withdrew from the study were summarised by treatment group 
according to their reason for withdrawal. 
 
9.2.15.2 Demographic and Baseline Characteristics 
All demographic and baseline characteristic data recorded at the Screening Visit 
were summarised by treatment group. Patient disposition was also summarised.  
 
9.2.15.3 Drug Compliance 
Compliance was calculated as: 100% * [(sum of Number of tablets dispensed – sum 
of Number of tablets returned) / (overall exposure*2)]. Compliance was assessed 
both between visits and overall. 
 
9.2.15.4 Safety Analysis 
The primary objective was to assess the safety and tolerability of selisistat in HD 
patients following treatment for 12 weeks. 
 
Adverse events volunteered throughout the study were classified per the Medical 
Dictionary for Regulatory Activities (MedDRA 14.0). Treatment-emergent adverse 
events (TEAEs) were defined as signs or symptoms that emerged during treatment or 
within 30 days of the last dose of study drug, including those signs and symptoms 
absent at pre-treatment or those that had worsened relative to pre-treatment 
status. No formal statistical comparisons were conducted. 
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Laboratory parameters were described by time point and treatment using 
descriptive statistics for continuous data. The change from baseline was summarised 
for each post baseline visit with descriptive statistics by treatment and time.  
 
Vital signs (including supine and standing blood pressure), pulse rate, respiratory 
rate, body temperature, weight, height (Screening only), and body mass index [BMI]) 
were summarised descriptively by treatment and time point.  
 
All data from the physical and neurological examinations were presented in a listing. 
ECG parameters (HR, PR, QRS interval, QT, QTcF) were summarised descriptively by 
treatment and time point. Changes from baseline were summarised for all scheduled 
post baseline visits. Summary statistics also included the number and percentage of 
patients with Normal, Abnormal non-clinically significant (NCS) or Abnormal clinically 
significant (CS), by parameter and visit. 
 
Continuous variables were summarised with the following descriptive statistics: n 
(Number of observations), mean, standard deviation (SD), median, minimum, and 
maximum. Categorical data were summarised with frequencies and percentages. 
Summary statistics were presented for each question of the C-SSRS separately at 
each time point. 
 
9.2.15.5 Efficacy Analysis 
All efficacy summaries were presented by treatment group and visit/time point not 
including the EOT visit.  
 
Unified Huntington’s Disease Rating Scale 
Scores and changes from baseline scores (for post-baseline visits only) for each 
domain were summarised by treatment group using descriptive statistics at every 
planned visit.  
 
Global Clinical Impression 
The GCI scores (assessed by the patient and the clinician) for each of the three items 
(“How ill is the subject at this time”, “GCI assessed by clinician”, “GCI assessed by 
subject”) were summarised for each assessor by treatment group using categorical 
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descriptive statistics at every planned visit. The same analysis were performed 
separately for each of the TFC subgroups (defined above) using the FAS only. 
 
Mini-Mental State Examination 
The MMSE score, as well as the change from baseline, were summarised at every 
planned Visit. The same analysis were performed separately for each of the TFC 
subgroups (defined above) using the FAS only. 
 
The PD variables were: 
 
• Change from Baseline levels of soluble HTT 
• Change from Baseline in acetylation status of mutant HTT 
 
The variables for genetic assessments are: 
 
• HD genotype and genetic modifiers of HD 
• CYP2C19 and CYP2D6 isoenzyme genotype 
 
9.2.15.6 Determination of Sample Size 
The sample size of 120 patients (40 patients per treatment group) was based on 
clinical judgement and/or practical considerations and not on statistical 
considerations. However, with 40 patients per treatment group, there was an 80.0% 
probability of detecting an AE with an underlying incidence rate of 0.04. The 
proposed number of patients was also chosen to generate PD data to support dose 
selection for further studies. 
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9.3 Results (Reilmann et al., 2013) 
9.3.1 Study Summary 
161 patients were screened and 144 randomised to the three treatment arms, placebo, 50mg and 
200mg of the study drug with 125 patients (86.8%) completing the study (Figure 16). The dropout  
 
rate between these different arms did not reach statistical significance though one notes that the 
percentage of patients completing the study in the higher dose group was lower than the others. 
This dropout was related to higher incidence of adverse effects though again this did not reach 
statistical significance.  
 
9.3.2 Demography 
Patient demography data collected at the Screening Visit are presented below (Table 16 & 
Figure 17). 
  
Figure 16- Study Recruitment Summary  
Screening  
n=161 
Randomised 
n=144 
Placebo 
n=50 
50mg  
n=49 
200mg  
n=45 
Completed 
n=47 
Completed 
n=42 
Completed 
n=36 
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Table 16- Demographic characteristics at screening visit. Adapted from (Reilmann et al., 2013) 
 
Placebo 
SEN0014196 
50 mg 
SEN0014196 
200 mg Total 
N=50 N=49 N=45 N=144 
Age (years)
a 
n 
Mean (SD)  
 
50 49 45 144 
50.9 (10.29) 52.4 (9.98) 48.0 (7.50) 50.5 (9.50) 
Sex 
Male 
Female 
 
32 (64.0) 24 (49.0) 24 (53.3) 80 (55.6) 
18 (36.0) 25 (51.0) 21 (46.7) 64 (44.4) 
Race
b 
Asian 
White
 
 
1 (2.0) 0 (0.0) 1 (2.2) 2 (1.4) 
49 (98.0) 49 (100.0) 44 (97.8) 142 (98.6) 
Height (cm) 
n 
Mean (SD) 
 
50 49 45 144 
172.29 (9.063) 169.85 (10.093) 172.24 (9.322) 171.44 (9.508) 
Weight (kg) 
n 
Mean (SD) 
 
49 49 45 143 
70.09 (11.954) 73.03 (13.841) 71.94 (11.986) 71.68 (12.613) 
BMI (kg/m
2
)
c 
n 
Mean (SD) 
 
49 49 45 143 
23.61 (3.423) 25.23 (3.766) 24.18 (2.949) 24.34 (3.451) 
Abbreviations: BMI = Body mass index; SD = standard deviation. 
a Age was defined as the integer value of the number of years between the date of screening and the date of birth, divided by 
365.25. 
b Multi-racial patients were counted in each race category they listed. 
c BMI was calculated as weight (kg) / [(height (cm)/100)2]. 
 
While no major differences were seen between treatment arms in relation to age, race, 
height, weight or BMI, one notes that a higher proportion of males were present in the study 
(55.6% to 44.4%) with this most pronounced in the placebo group (64% to 36%). Additionally 
only two non-Caucasian patients were enrolled.  
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9.3.3 Other Baseline Characteristics 
 
All patients had a CAG repeat length of ≥ 36. The most frequent medical history was surgical 
and medical procedures (125 patients [86.8%] in total). The most frequent procedures were 
appendectomy (23 patients [16.0%] in total), tonsillectomy (11 patients [7.6%] in total) and 
hysterectomy and vasectomy (both nine patients [6.3%] in total). There were no notable 
differences between the treatment groups.  
 
Figure 17- Boxplot of Selected Demographic Data across Treatment Groups 
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The next most frequently experienced medical history was the psychiatric disorders, 
affecting 85 patients (59.0%) in total, of which 36 patients were in the placebo group, 
compared to 25 patients and 24 patients in the selisistat 50 mg and 20 mg groups, 
respectively. The most frequent disorders were depression (50 patients [34.7%] in total) and 
sleep disorder (11 patients [7.6%] in total). There were no other notable differences 
between the treatment groups. 
 
 
9.3.4 Prior and Concomitant Medications 
 
Prior medications were those medications taken within 21 days before the first dose of study 
drug. The most frequently taken of these medications were antidepressants, pain relief 
medications and dietary supplements. Concomitant medications taken during the treatment 
period by more than 5% of patients in any treatment group are summarised below (Table 
17). 
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Table 17- Prior and concomitant medications. Adapted from (Reilmann et al., 2013) 
   Placebo SEN0014196 SEN0014196 Total 
     50 mg 200 mg    
   N=50 N=49 N=45 N=144 
 
Any 
concomitant  48 (96.0) 
4
6 (93.9) 42 (93.3) 136 (94.4) 
 Medication           
 Citalopram  16 (32.0) 9 (18.4) 12 (26.7) 37 (25.7) 
 Vitamins, other 9 (18.0) 7 (14.3) 7 (15.6) 23 (16.0) 
 Combination          
 Tetrabenazine  10 (20.0) 5 (10.2) 6 (13.3) 21 (14.6) 
 Tiapride hydrochloride 10 (20.0) 5 (10.2) 6 (13.3) 21 (14.6) 
 Mirtazapine  7 (14.0) 3 (6.1) 7 (15.6) 17 (11.8) 
 Olanzapine  7 (14.0) 5 (10.2) 4 (8.9) 16 (11.1) 
 Etizolam  4 (8.0) 3 (6.1) 7 (15.6) 14 (9.7) 
 Lorazepam  5 (10.0) 4 (8.2) 4 (8.9) 13 (9.0) 
 Paracetamol 2 (4.0) 7 (14.3) 4 (8.9) 13 (9.0) 
 Risperidone  5 (10.0) 3 (6.1) 3 (6.7) 11 (7.6) 
 Levothyroxine sodium 2 (4.0) 4 (8.2) 4 (8.9) 10 (6.9) 
 
Ascorbic 
acid  5 (10.0) 3 (6.1) 2 (4.4) 10 (6.9) 
 Ubidecarenone 4 (8.0) 4 (8.2) 2 (4.4) 10 (6.9) 
 Ibuprofen  4 (8.0) 4 (8.2) 1 (2.2) 9 (6.3) 
 Sertraline  3 (6.0) 3 (6.1) 3 (6.7) 9 (6.3) 
 Sulpiride  3 (6.0)  0 6 (13.3) 9 (6.3) 
 Acetylsalicylic acid 3 (6.0) 3 (6.1) 2 (4.4) 8 (5.6) 
 
Anti-depressant medications in the form of Citalopram and anti-chorea drugs in the form of 
Tetrabenazine and tiapride were the most common class of medications used in the study, 
alongside multivitamins. Tetrabenazine and tiapride hydrochloride occurred more commonly 
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in the placebo group (both 20.0%) than in the selisistat 50 mg group (10.2%) or the selisistat 
200 mg group (both 13.3%). There was no notable difference between the proportions of 
patients taking vitamins in each treatment group. 
 
In terms of potential impact of concomitant drugs on the study drug, there were no patients 
taking drugs with a similar mode of action to the study drug or on enzyme inducing 
medications. 
 
Both Citalopram and Tetrabenazine were taken more frequently within the placebo arm of 
the trial and a difference here could affect comparative analysis of motor and mood 
readouts. However on sub-analysis via unpaired t-test, no statistically significant difference 
in concomitant medication use was found between the various arms of the trial (Table 18 & 
19).  
 Table 18- Comparative Analysis of Citalopram Use across treatment groups 
 
Table 19- Comparative Analysis of Tetrabenazine/Tiapride Use across treatment groups 
 
 
 
  
Test |Difference of percentage| Std Error t-value p-value 
placebo vs 50mg 9.8 0.0712 1.376 0.1704 
placebo vs 200mg 6.7 0.0734 1.21 0.2278 
200 vs 50mg 3.3 0.0666 -0.47 0.6406 
Test |Difference of percentage| Std Error t-value p-value 
placebo vs 50mg 9.8 0.0712 1.376 0.1704 
placebo vs 200mg 6.7 0.0734 1.21 0.2278 
200 vs 50mg 3.3 0.0666 -0.47 0.6406 
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9.3.5 Treatment Compliance 
Table 20- Treatment Compliance. Adapted from (Reilmann et al., 2013) 
   Placebo SEN0014196 SEN0014196 Total 
    50 mg 200 mg  
   N=50 N=49 N=45 N=144 
 
Compliance 
(%)      
 N  50 49 45 144 
 Mean (SD)  100.31 (2.360) 99.73 (1.465) 99.66 (2.714) 99.91 (2.232) 
 
Compliance 
(%)      
 80% - 120%  50 (100.0) 49 (100.0) 45 (100.0) 144 (100.0) 
 
Compliance with all arms was above 90% in all groups with no apparent significant 
differences between groups (Table 20). 
 
9.3.6 Efficacy Analysis 
 
9.3.6.1 Introduction 
Data is presented here using descriptive statistics carried out by the study sponsor as 
per study report (Reilmann et al., 2013). Further comparative statistical sub-analysis 
of change in means scores between treatment groups was undertaken by myself 
using an unpaired t-test where indicated.  
 
9.3.6.2 United Huntington’s Disease Motor Rating Scale  
The UHDRS ’99 Motor score is a clinical assessment widely employed by HD clinicians 
to quantify to motor burden of disease (Appendix 13.1). 
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Table 21- Change in UHDRS across treatment groups and time-points. Adapted from (Reilmann et al., 2013) 
 
On a descriptive level, the scores were generally comparable across treatment 
groups and time-points (Table 21 & Figure 18). 
Figure 18- Mean UHDRS Motor Score across Treatment Groups and Time-points 
  
Visit Descriptive 
Measure 
Placebo SEN0014196 (50 mg) SEN0014196 (200 mg) Total 
N=50 N=49 N=45 N=144 
Value at 
visit ΔUHDRS 
Value at 
visit ΔUHDRS 
Value at 
visit ΔUHDRS 
Value at 
visit ΔUHDRS 
B
as
el
in
e
 N 50 - 49 - 45 - 144 - 
Mean (SD) 41.2 (16.69) - 40.9 (19.26) - 39.7 (16.51) - 40.6 (17.44) - 
W
ee
k 
4
 N 49 49 48 48 43 43 140 140 
Mean (SD) 41.8 (16.48) 0.4 (4.88) 41.8(18.78) 0.3 (4.58) 41.4 (16.49) 0.8 (5.17) 41.7 (17.18) 0.5 (4.84) 
W
e
e
k 
8
 N 49 49 48 48 43 43 140 140 
Mean (SD) 42.3 (17.51) 0.9 (5.49) 42.3 (19.51) 0.8 (6.59) 41.2 (17.20) 0.7 (6.44) 42.0 (18.01) 0.8 (6.13) 
W
e
e
k 
1
2
 N 49 49 48 48 43 43 140 140 
Mean (SD) 42.9 (17.98) 1.5 (7.15) 42.3 (19.21) 0.8 (5.67) 41.4 (18.38) 0.8 (6.99) 42.2 (18.41) 1.0 (6.59) 
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 Table 22- Comparative analysis of difference in UHDRS Score in treatment groups at Baseline and Week 12 
 
A sub-analysis performed confirms that there were no significant differences in 
UHDRS motor score of the three arms of the trial at baseline. Unfortunately, there 
were also no significant changes in the motor symptoms of those treated for 12 
weeks with either 200mg or 50mg of selisistat (Table 22).   
 
9.3.6.3 Cognitive Assessment 
Although the verbal fluency test score improved modestly from Baseline to Week 12 
in all treatment arms, this did not reach significance.  
 
The SDMT tests visuomotor integration, visual scanning, tracking and motor speed. 
The  examinee  is  given  90  seconds  to  match  symbols  and  digits  as  quickly  as  
possible.  The  key  (specifying  which  number  corresponds  to  each  symbol)  is  
located at the top of the page. There was no discernibly significant change in symbol 
digit modality score (Table 23 & 24 & Figure 19) between treatment groups and 
across time-points with sub-analysis not revealing any significant differences.  
  
t Test Difference of means Std Error t-value p-value 
B
as
el
in
e
 
placebo vs 50mg 0.30000000 3.62511809 0.08275592 0.93422065 
placebo vs 200mg 1.5000000 3.4100524 0.4398759 0.6610569 
200 vs 50mg -1.2000000 3.6915708 -0.3250649 0.7458734 
W
ee
k 
12
 
placebo vs 50mg 0.6000000 3.7796245 0.1587459 0.8742086 
placebo vs 200mg 1.5000000 3.8018338 0.3945464 0.6941332 
200 vs 50mg -0.9000000 3.9426366 -0.2282736 0.8199595 
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Table 23- Change in SDMT scores across treatment groups and timepoints.  
Adapted from (Reilmann et al., 2013) 
 
 
 
 
 
Visit  Placebo  SEN0014196 SEN0014196 Total 
     50 mg 200 mg   
  N=50  N=49 N=45 N=144 
  
Value at 
visit 
Change 
from  
Value at 
visit 
Change 
from 
Value at 
visit 
Change 
from 
Value 
at visit Change from 
   Baseline   Baseline  baseline  Baseline 
Symbol Digit Modalities Test 
Baseline           
N  50   49  43  142  
Mean 
(SD)  21.2 (11.64)   24.3 (15.10)  25.5 (10.97)  23.6 (12.80)  
Week 4           
N  49 49  48 48 41 41 138 138 
Mean 
(SD)  21.8 (11.66) 0.8 (3.73)  23.4 (13.80) -0.3 (4.03) 24.0 (10.38) -0.7 (3.84) 23.0 (12.05) -0.0 (3.89) 
Week 8           
N  49 49  48 48 41 41 138 138 
Mean 
(SD)  21.9 (11.83) 0.8 (4.27)  23.8 (16.01) 0.0 (4.95) 24.1 (11.79) -0.7 (4.53) 23.2 (13.36) 0.1 (4.60) 
Week 12           
N  49 49  48 48 41 41 138 138 
Mean 
(SD)  21.7 (10.65) 0.6 (4.37)  24.4 (15.88) 0.6 (4.23) 24.3 (12.41) -0.4 (5.10) 23.4 (13.14) 0.3 (4.54) 
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Table 24- Comparative Analysis of change in SDMT between treatment groups at baseline and week 12 
 
The  Stroop  Test  has  three  conditions  that  require  visual  scanning,  cognitive  
control  and  processing  speed. Subjects are given a card on which the names of 
colours are printed in black ink and must read as many words as they are able in 45 
seconds. The sub- analysis confirms that there were no significant differences in 
stroop word test of the three arms of the trial at baseline. However, the results do 
suggest that the two treatment arms of the trial are tending towards significance. 
That is, those treated had a higher score than those in the placebo arm at baseline. 
t Test Difference of means Std Error t-value p-value 
B
as
e
lin
e
 
placebo vs 50mg -3.1000000 2.7134954 -1.1424379 0.2562951 
placebo vs 200mg -4.30000000 2.32035218 -1.85316696 0.06703632 
200 vs 50mg 1.2000000 
 
2.7069369 
 
0.4433055 
 
0.6586390 
 
W
ee
k 
1
2
 
placebo vs 50mg -2.7000000 2.7510686 -0.9814368 
 
0.3292656 
 
placebo vs 200mg -2.600000 2.462720 -1.055743 0.294287 
200 vs 50mg -0.10000000 
 
3.00064614 
 
-0.03332616 
 
0.97349141 
Figure 19- SDMT Score between treatment groups across time-points 
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However, after 12 weeks, their scores are less different (unpaired t-test). There were 
no significant changes in the score for those treated for 12 weeks with either 200mg 
or 50mg of selisistat (Table 25 & 26 & Figure 20). 
Table 25- Change in Stroop scores across treatment groups and time-points.  
Adapted from (Reilmann et al., 2013) 
 
 Table 26- Comparative Analysis of change in Stroop Score in treatment groups at Baseline and 12 weeks 
Visit 
Descriptive 
Measure 
Placebo SEN0014196 (50 mg) SEN0014196 (200 mg) Total 
N=50 N=49 N=45 N=144 
Value at 
visit 
Δstroop 
Value at 
visit 
Δstroop 
Value at 
visit 
Δstroop 
Value at 
visit 
Δstroop 
B
as
el
in
e N 50 - 49 - 45 - 144 - 
Mean (SD) 52.0 (21.04) - 57.9 (24.75) - 58.8 (21.51) - 56.1 (22.56) - 
W
ee
k 
4
 N 49 49 48 48 43 43 140 140 
Mean (SD) 53.1 (20.76) 1.7 (8.89) 56.1 (22.96) -1.4 (9.47) 54.6 (21.28) -2.5 (6.89) 54.6 (21.57) -0.7 (8.66) 
W
ee
k 
8
 N 49 49 48 48 43 43 140 140 
Mean (SD) 51.0 (22.17) -0.4 (12.47) 54.8 (25.87) -2.7 (13.08) 55.1 (20.54) -1.9 (9.44) 53.6 (22.96) -1.7 (11.81) 
W
ee
k 
12
 
N 49 49 48 48 43 43 140 140 
Mean (SD) 50.3 (21.47) -1.1 (11.97) 53.3 (24.59) -4.2 (11.06) 54.4 (22.63) -2.6 (9.17) 52.6 (22.84) -2.6 (10.86) 
t Test Difference of means Std Error t-value p-value 
B
as
el
in
e
 
placebo vs 50mg -5.9000000 4.6211370 -1.2767421 0.2048411 
placebo vs 200mg -6.8000000 4.3744042 -1.5544974 0.1235185 
200 vs 50mg 0.9000000 4.7731599 0.1885543 0.8508586 
W
ee
k 
12
 
placebo vs 50mg -3.0000000 4.6909079 -0.6395350 0.5240513 
placebo vs 200mg -4.1000000 4.6170402 -0.8880148 0.3769802 
200 vs 50mg 1.1000000 4.9504492 0.2222021 0.8246661 
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9.3.6.4 Problem Behaviours Assessment 
The  goal  of  the  Problem  Behaviours  Assessment  (PBA)  is  to  assess  the  
following  ten  symptoms:  low  mood  (i.e.  depression),  suicidal  ideation,  anxiety,  
irritability,  angry  out-bursts  and  aggressive  behaviour,  lack  of  motivation  
(apathy,  social  and  household  activities,  enthusiasm/spontaneity),  perseveration,  
paranoid  thinking/delusions,  hallucinations and behaviour suggesting 
disorientation. Each symptom is rated for severity and frequency on a scale from 0 
(absent and never) to 4 (severe and always).  
 
The behavioural assessment scores at Baseline were comparable cross-sectionally, 
and were modestly better longitudinally from Baseline to Week 12 (Table 27). 
 
 
 
 
 
  
Figure 20- Stroop Score between treatment groups and across time-points. 
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Visit 
Placebo 
SEN0014196 
              50 mg 
SEN0014196 
200 mg Total 
N=50 N=49 N=45 N=144 
Value at 
visit 
Change 
from 
baseline 
Value at 
visit 
Change 
from 
Baseline 
Value at 
visit 
Change 
from 
Baseline 
Value at 
visit 
Change 
from 
Baseline 
Problem Behaviour Assessment 
Baseline 
n  50  49  45  144  
Mean 
(SD)  10.8 (9.72)  11.3 (10.50)  8.3 (8.24)  10.2 (9.59)  
Week 4 
n  49 49 48 48 43 43 140 140 
Mean 
(SD)  9.6 (8.60) -0.9 (4.83) 10.4 (10.19) -1.1 (4.44) 7.8 (7.36) -0.7 (5.03) 9.3 (8.84) -0.9 (4.73) 
Week 8 
n  49 49 48 48 43 43 140 140 
Mean 
(SD)  9.8 (8.95) -0.7 (4.46) 9.9 (9.95) -1.7 (6.43) 6.7 (7.17) -1.8 (5.55) 8.9 (8.87) 
-1.4 
(5.51) 
Week 12 
n  49 49 48 48 43 43 140 140 
Mean 
(SD)  10.0 (8.90) -0.4 (5.07) 10.1 (10.15) -1.4 (5.87) 7.7 (7.39) -0.9 (6.10) 9.4 (8.94) -0.9 (5.65) 
 
A sub-analysis of PBA scores across treatment groups at baseline and week 12 failed 
to identify at statistically significant difference (Table 28). 
 
  
Table 27- Change in Problem Behaviour Assessment across treatment groups and time-points.  
Adapted from (Reilmann et al., 2013) 
 Early Phase Disease Modification Trials with Selisistat and Optical Coherence Tomography as a Biomarker in Huntington’s Disease 
UCL PhD Submission 
148 
Dr Salman Haider (Student No.: 1054117) 
 
Table 28- Comparative analysis of difference of PBA score across treatment groups at baseline and week 12 
 
9.3.6.5 Independence & Functional Assessment 
The independence and functional assessment scale is a percentage based 
assessment of independence- 100% representing complete independence, looking 
specifically at performance in 25 areas of daily life (Appendix 13.5). There was no 
apparent change in the mean independence scale and functional assessment scores 
from Baseline to Week 12 (Table 29 & 30 & Figure 21). 
 
 
 
 
 
 
 
 
 
 
t Test Difference of means Std Error t-value p-value 
B
as
el
in
e
 
placebo vs 50mg -0.5 2.03459 -0.2451 0.806 
placebo vs 200mg 2.5 1.8434 1.3561 0.17835 
200 vs 50mg -3 1.9387 -1.547 0.125 
W
ee
k 
12
 
placebo vs 50mg -0.1 1.9398 -0.05155 0.95899 
placebo vs 200mg 2.3 1.689 1.3537 0.1792 
200 vs 50mg -2.4 1.848 -1.298 0.1976 
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Table 29- Change in Independence Scale across treatment groups and time-points.  
Adapted from (Reilmann et al., 2013) 
 Visit  Placebo SEN0014196 SEN0014196 Total 
 
  50 mg 200 mg   
N=50 N=49 N=45 N=144 
Value at 
visit 
Change 
from 
Value at 
visit 
Change 
from 
Value at 
visit 
Change 
from 
Value 
at visit Change from 
 Baseline  Baseline  baseline  baseline 
Independence Scale Assessment 
 Baseline          
 n  50  49  45  144  
 
Mean 
 (SD)  5.1 (2.89)  5.0 (3.25)  4.3 (2.28)  4.8 (2.85)  
 Week 4          
 N  49 49 48 48 43 43 140 140 
 
Mean 
(SD)  5.0 (2.80) 
 
0 (0.87) 5.0 (3.31) 0 (0.71) 4.3 (2.33) -0.1 (0.78) 4.8 (2.85) -0.1 (0.78) 
 Week 8          
 n  49 49 48 48 43 43 140 140 
 
Mean 
(SD)  5.2 (2.92) 0.1 (1.08) 4.9 (3.23) -0.1 (0.76) 4.3 (2.23) -0.1 (0.86) 4.8 (2.85) -0.0 (0.91) 
 Week 12          
 n  49 49 48 48 43 43 140 140 
 
Mean 
(SD)  5.0 (2.94) -0.1 (0.97) 4.9 (3.20) -0.1 (0.81) 4.4 (2.31) 0.0 (0.95) 4.8 (2.85) -0.1 (0.90) 
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Table 30- Change in Functional Assessment Scores across treatment groups and time-points.  
Adapted from (Reilmann et al., 2013) 
 
 
 
 
     Visit 
Placebo SEN0014196 SEN0014196 Total 
   50 mg 200 mg   
 N=50 N=49 N=45 N=144 
 
Value at 
visit 
Change 
from 
Value at 
visit 
Change 
from 
Value at 
visit 
Change 
from 
Value at 
visit 
Change 
from 
  baseline  baseline  baseline  baseline 
 Functional Assessment 
 Baseline          
 n  50  49  45  144  
 
Mean 
(SD)  19.2 (5.60)  19.2 (5.97)  20.5 (4.55)  19.6 (5.43)  
 Week 4          
 n  49 49 48 48 43 43 140 140 
 
Mean 
(SD)  19.0 (5.79) -0.2 (1.60) 19.3 (5.97) 0.2 (0.87) 20.4 (4.50) 0.0 (0.65) 19.5 (5.49) 0.0 (1.14) 
 Week 8          
 n  49 49 48 48 43 43 140 140 
 
Mean 
(SD)  19.0 (5.98) -0.3 (1.73) 19.5 (5.72) 0.4 (1.20) 19.6 (5.48) -0.7 (3.44) 19.3 (5.71) -0.2 (2.30) 
 Week 12          
 n  49 49 48 48 43 43 140 140 
 
Mean 
(SD)  19.1 (5.80) -0.1 (1.74) 19.3 (5.79) 0.2 (1.21) 20.3 (4.37) -0.0 (0.91) 19.6 (5.38) 0.0 (1.35) 
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9.3.6.6 Total Functional Capacity Assessment 
This is a clinical staging tool based on functional ability and scored out of a maximum 
of 13 (Table 2 Page 24). The functional capacity assessment scores were comparable 
from Baseline to Week 12 (Table 31 & Figure 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21- Functional Assessment Score between treatment groups and across time-points 
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Sub-analysis of difference between means of TFC scores across treatment arms at baseline and week 
12 failed to identify any statistically significant change (Table 32). 
 
 
 
 
 
 
           Visit 
Placebo 
SEN0014196 
             50 mg 
SEN0014196 
200 mg Total 
N=50 N=49 N=45 N=144 
Value at 
visit 
Change 
from 
baseline 
Value at 
visit 
Change 
from 
baseline 
Value at 
visit 
Change 
from 
baseline 
Value at 
visit 
Change 
from 
baseline 
Total Functional Capacity 
Baseline 
n 
Mean (SD) 
50  49  45  144  
8.6 (3.27)  9.2 (2.96)  9.4 (2.63)  9.0 (2.98)  
Week 4 
n 
Mean (SD) 
49 49 48 48 43 43 140 140 
8.5 (3.25) -0.1 (0.62) 9.2 (3.05) 0.0 (0.62) 9.2 (2.59) -0.0 (0.67) 9.0 (2.99) -0.0 (0.63) 
Week 8 
n 
Mean (SD) 
49 49 48 48 43 43 140 140 
8.4 (3.28) -0.2 (0.79) 9.2 (2.97) 0.0 (0.83) 9.0 (2.49) -0.2 (0.89) 8.9 (2.95) -0.1 (0.83) 
Week 12 
n 
Mean (SD) 
49 49 48 48 43 43 140 140 
8.5 (3.23) -0.1 (0.62) 9.1 (2.94) -0.0 (0.77) 9.1 (2.45) -0.2 (0.92) 8.9 (2.90) -0.1 (0.77) 
Table 31- Total Functional Capacity change from baseline at each visit. Adapted from (Reilmann et al., 2013) 
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Table 32- Comparative analysis of difference of TFC scores across treatment groups at baseline and week 12 
 
 
 
 
 
 
 
 
t Test Difference of means Std Error t-value p-value 
B
as
el
in
e
 
placebo vs 50mg -0.6 0.6266 -0.9575 0.3407 
placebo vs 200mg -0.8 0.606 -1.3195 0.19027 
200 vs 50mg 0.2 0.5766 0.3468 0.7295 
W
ee
k 
12
 
placebo vs 50mg -0.6 0.62689 -0.957 0.34096 
placebo vs 200mg -0.6 0.5937 -1.0105 0.3149 
200 vs 50mg 0 0.5639 0 1 
Figure 22- TFC Score between treatment groups and across time-points 
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9.3.6.7 GCI Assessment 
Throughout the study, the GCI did not alter to a meaningful extent.  
Clinician Assessment 
Overall there was no change in the clinician assessment of most of the patients 
during the course of the study. 
 
Patient Assessment 
The majority of patients themselves overall reported no change to their condition. 
 
9.3.6.8 MMSE 
Similar MMSE scores were noted across treatment groups and timepoints (Table 33).  
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Table 33- Change in MMSE score across treatment groups and time-points.  
Adapted from (Reilmann et al., 2013) 
 
 
9.3.6.9 Pharmacokinetic Data 
Rapid peak concentrations were achieved after 1 to 2 hours post dosing at both drug 
doses.  Higher drug levels were noted in females versus males across time at both 
dose levels on Day 1 and Week 12.  
 
 Visit  Placebo SEN0014196 SEN0014196 Total 
     50 mg 200 mg   
   N=50 N=49 N=45 N=144 
   
Value at 
visit 
Change 
from 
Value at 
visit 
Change 
from 
Value at 
visit 
Change 
from 
Value at 
visit 
Change 
from 
    baseline  baseline  baseline  baseline 
 Baseline          
 n  50  49  45  144  
 
Mean 
(SD)  25.2 (3.70)  25.2 (4.85)  26.3 (2.88)  25.5 (3.93)  
 Week 4          
 n  49 49 48 48 43 43 140 140 
 
Mean 
(SD)  25.9 (4.21) 0.7 (2.20) 25.6 (4.38) 0.5 (1.40) 26.5 (3.26) 0.3 (2.38) 26.0 (3.99) 0.5 (2.02) 
 Week 8          
 n  49 49 48 48 43 43 140 140 
 
Mean 
(SD)  25.4 (3.73) 0.2 (1.85) 25.4 (4.55) 0.3 (1.82) 26.4 (3.05) 0.2 (2.33) 25.7 (3.85) 0.2 (1.99) 
 Week 12          
 n  49 49 48 48 43 43 140 140 
 
Mean 
(SD)  26.1 (3.90) 0.9 (1.72) 25.3 (4.69) 0.2 (2.10) 26.4 (3.11) 0.2 (2.53) 25.9 (3.98) 0.5 (2.14) 
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9.3.6.10 Safety 
Table 34- Adverse Events. Adapted from (Reilmann et al., 2013) 
   Placebo 
N=50 
SEN0014196  SEN0014196   Total  
   50 mg    200 mg      
   N=49    N=4
5 
  N=144  
   Events  Patients Events  Patients Events  Patients Events  Patients 
                   
 Any 
TEAEs 
 54  25 (50.0) 87  37 (5.5) 64  32 (71.1)         205  94 (65.3) 
 TEAEs leading 
to 
1  1 (2.0) 7  7 (14.3) 12   8 (17.8) 20  16 (11.1) 
 study 
discontinuation 
                
 Any related 
TEAEs 
8  5 (10.0) 25  16 (32.7) 29  18 (40.0) 62  39 (27.1) 
 Any SAEs  3  2 (4.0) 3  3 (6.1) 3  3 (6.7) 9  8 (5.6) 
Abbreviations: SAE = serious adverse event; TEAE = treatment-emergent adverse event. Data source: TEAEs were defined as signs or symptoms 
that emerged during treatment or within 30 days of the last dose of study drug, including those signs and symptoms absent pre-treatment or that 
worsened relative to pre-treatment status. 
 
Descriptively a trend to an increased number of adverse events were noted in the active drug 
treatment arms versus placebo- 25 patients (50.0%) patients in the placebo group, 37 patients 
(75.5%) in the selisistat 50 mg group, and 32 patients (71.1%) in the selisistat 200 mg group (Table 
34).  A statistically significant difference was noted in the percentage difference of adverse events 
occurring in the active treatment groups versus placebo, confirming the above observation (Table 
35).  
 
Table 35- Comparative Analysis of Difference in Percentage of Adverse events across treatment groups 
Test |Difference of percentage| Std Error t-value p-value 
placebo vs 50mg 25.5 
0.0937 
 
-2.723 0.0074 
placebo vs 200mg 21.1 0.0978 -2.159 0.0334 
200 vs 50mg 4.5 0.0913 -0.482 0.6316 
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In terms of sub-typing the adverse events into organ systems, infections (27 
patients), abnormalities in investigations (27 patients) and gastrointestinal disorders 
(24 patients) were the most common TAEs reported. 
 
For infections and infestations, there was not a clear difference across treatment 
groups, while for investigational abnormalities a significantly greater preponderance 
of patients receiving active compound was noted with 9 patients in 50mg and 12 
patients in 200mg group respectively afflicted. This pattern was repeated for 
gastrointestinal side-effects with 13 patients in the 50mg group, 7 in the 200mg and 
4 in the placebo group. Diarrhoea was reported by 12 patients in the active 
treatment group and one in the placebo group. 
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Table 36- Adverse Events leading to withdrawal by system organ class.  
Adapted from (Reilmann et al., 2013) 
 System Organ Class  Placebo       SEN0014196 SEN0014196  Total 
 Preferred Term     50 mg  200 mg    
    N=50  N=49   N=45  N=144 
   Events Patients Events  Patients Events  Patients Events  Patients 
               
 Gastrointestinal disorders 0  0 0   0 1  1 (2.2) 1  1 (0.7) 
 Diarrhoea  0  0 0   0 1  1 (2.2) 1  1 (0.7) 
 Hepatobiliary disorders 0  0 1  1 (2) 0  0 1  1 (0.7) 
 Hepatitis  0  0 1  1 (2) 0  0 1  1 (0.7) 
 
Infections and 
infestations 0  0 1  1 (2) 0  0 1  1 (0.7) 
 Gastroenteritis 0  0 1  1 (2) 0  0 1  1 (0.7) 
 Investigations 0  0 5  5 (10.2) 9  6 (13.3) 14  11 (7.6) 
 ALT increased 0  0 0   0 4  4 (8.9) 4  4 (2.8) 
 AST increased 0  0 0   0 2  2 (4.4) 2  2 (1.4) 
 GGT increased 0  0 0   0 1  1 (2.2) 1  1 (0.7) 
 
Hepatic enzyme 
increased 0  0 3  3 (6) 1  1 (2.2) 4  4 (2.8) 
 
Liver function test 
abnormal 0  0 2  2 (4) 1  1 (2.2) 3  3 (2.1) 
 Psychiatric disorders 1  1 (2.0) 0   0 2  2 (4.4) 3  3 (2.1) 
 Apathy  0  0 0   0 1  1 (2.2) 1  1 (0.7) 
 Depression 0  0 0   0 1  1 (2.2) 1  1 (0.7) 
 Suicide attempt 1  1 (2.0) 0   0 0  0 1  1 (0.7) 
 
9.3.6.11 Safety Conclusions 
20 events in 16 patients prompted withdrawal from the drug trial, with one patient 
in the placebo, 7 in the 50mg and 8 in 200mg group (Table 36), with rise in ALT and 
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hepatic enzymes the most commonly occurring event, which was only in the active 
drug arms. A dose dependency was suggested as ALT & AST increases were seen only 
in 200mg group (Figure 23). 
 
Individual descriptions of serious adverse events can be found in Appendix 13.10. In 
summary however, the one death and one suicide attempt that occurred was not 
thought to related to study drug as both patients were in the placebo group. In 15% 
(n=22) of patients abnormalities in liver function disturbance were observed, with 20 
patients in the active drug arm, 50mg (n=9) and 200mg (n=11) while three were in 
the placebo group. All patients recovered aside from one, in whom blood tests 
deteriorated despite previous serial improvements 9 weeks following cessation of 
study drug. This patient had to be followed up outside the end of the study window 
by the local investigator. 
 
Figure 23- Hepatic Enzyme (ALT/AST) Changes in Treatment Groups 
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9.3.7 Clinical Laboratory Evaluation 
9.3.7.1 Haematology, Biochemistry & Urinalysis 
While there were elevations in monocytes, basophils and neutrophils through the course of the 
study, none reached statistical significance. No other haematological abnormalities were noted. 
Liver function disturbance is covered elsewhere and there were no changes in renal function 
and electrolytes. No significant changes in urinalysis parameters were noted. 
 
 
9.3.7.2 Vital Signs, Physical Findings and Electrocardiogram  
There were no significant abnormalities noted in these assessments throughout the study. 
 
 
9.3.7.3 Columbia-Suicide Severity Rating Scale 
Aside from one serious adverse event with a suicide attempt, only transient suicidal ideation 
was noted in the study. Overall the intensity of suicidal ideation was low and no treatment 
initiation related severe suicidal ideation.   
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9.4 Discussion 
 
Selisistat, a Sirtuin and selective inhibitor of silencing information regulator T1 (SirT1), may have a 
therapeutic role in preventing deacetylation of mutant Htt thereby enabling its extrusion.  
 
The aim of the present study was to assess safety and tolerability of 12 weeks of treatment with 
selisistat at doses of 50 mg and 200 mg in HD patients, and secondarily to assess short-term clinical 
effects, modulation of candidate pharmacodynamic markers and the pharmacokinetic profile of 
Selisistat. 
 
In summary the average age of the study participants was 50.5 years and a BMI of 24.34 kg/m2 with 
a preponderance of Caucasian patients. An unequal gender distribution was noted but this was not 
statistically significant. The most commonly declared medical history was depression (50 patients) 
and sleep disorder (11 patients). In terms of the drug history the most frequent medications were 
antidepressants, dietary supplements and chorea suppressing medications. Compliance of 80-120% 
was achieved across all treatment groups. Nineteen patients were excluded with the most common 
reason being that they did not complete the study due to abnormal liver function test results. There 
were no statistically significant effect of disease relevant clinical parameters such as motor score, 
stroop, PBA and TFC scores. 
 
9.4.1 Demographics 
 
Two clear differences between treatment groups were apparent. Firstly there is a significant under-
representation of Asian or other racial groups. It is established that there can be racial differences in 
bio-absorption of drugs and therefore evidently the applicability of this research to other racial 
groups would need to be investigated further (Bjornsson et al., 2003;Chen, 2006).  
 
9.4.2 Adverse Event Profile 
 
The mean exposure to the study drug was 80.2 days (SD 15.79 days), with no apparent difference 
between the treatment arms. Of the 205 treatment related adverse events TEAEs, there were 177 
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deemed of mild severity, 24 moderate and 4 were severe. More events were recorded in active 
treatment groups, 37 patients in 50mg group and 32 in the 200mg group.  
 
ALT increase was the most frequent treatment related adverse event with all 8 patients occurring in 
the active drug arms. AST increase was seen in 6 patients again with no patients in the placebo 
group affected. There were 9 serious adverse events in total, with 2 in the placebo group (aspiration 
leading to death, and suicide attempt) and 3 patients in 50mg (hepatitis, liver function test 
abnormality, and choking) and 200mg groups (furuncle, clavicle fracture and liver function test 
abnormality) respectively.   
 
It was notable that adverse events concerning abnormal liver function tests occurred as the most 
frequent related TEAEs, and with the exception of elevated gamma-glutamyltransferase, occurred 
only in the selisistat groups, suggesting that this is a drug related effect. 
 
These results suggest that selisistat may cause abnormalities in liver function. Bi-weekly monitoring 
of LFTs allowed timely identification of these events, which were all reversible, except in one case. 
For related TEAEs, there was a tendency for more liver function-related TEAEs to occur in the higher 
selisistat dose group. Additionally one notes this was a 12 week study. It is not clear whether liver 
function disturbance would have occurred over a longer duration. An escalating dose design study 
could answer this question.   
 
Most patients had no suicidal thoughts throughout the study. As mentioned above, one patient in 
the placebo group made a suicide attempt that was considered not related to the study drug. Up to 
two patients in each of the placebo and selisistat 50 mg groups and no patients in the selisistat 
group had suicidal thoughts at any visit, suggesting that these thoughts did not have a relationship 
with selisistat. 
 
9.4.3 Comparison to Phase 1B Study 
 
There were also no treatment related changes to clinical efficacy parameters in the shorter 14 day 
Phase 1B study. Interestingly, despite the much shorter duration, one patient did experience 
disturbance in ALT levels. This emphasises the merited concern over potential hepatic enzyme 
derangement. 
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9.4.4 Efficacy  
 
Although there were some minimal changes to the parameters throughout the study, there were no 
clinically significant results. In this short term study, no effect of selisistat was seen on clinical 
parameters in the patient population. The study was not powered to reveal any efficacy readouts 
and moreover, in this 12 week study, finding a statistically significant effect would be less probable.  
 
 
9.4.5 Pharmacokinetics 
 
Pharmacokinetic data has already suggested that the drug reaches higher concentrations in females 
than males which itself may be a reflection of the relative difference in body mass index. Thus the 
larger number of male subjects in the placebo groups could potentially skew pharmacokinetic 
comparisons between groups. However this difference did not reach statistical significance on sub-
analysis. 
 
9.4.6 Pharmacodynamics- Target Engagement 
 
Levels of soluble mutant huntingtin in peripheral blood mononuclear cells showed borderline 
statistically significant (p = 0.058, p = 0.075) increases of similar magnitude at 12 weeks compared to 
placebo in the 50mg and 200mg groups respectively, that reverted to levels consistent with the 
placebo group at follow-up (Reilmann et al., 2014). The clinical significance of mutant Huntingtin 
levels in PBMCs is not clear and thus the effect of any modulation thereof is not known. The effect 
on CSF mutant Huntingtin levels, which would evidently be more relevant to a potential CNS effect 
of the compound, is also not known.  
 
9.4.7 Summary 
 
While the compound does appear generally safe and tolerated, two major concerns exist. To date no 
validated clinical data has been published to demonstrate pharmacodynamic efficacy and as such 
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leaves large question marks over the future of the compound. This may well be largely due to the 
closure of this arm of drug development by the study sponsor.  
 
Secondly there remains significant disquiet about the liver function disturbance observed despite 
the relatively short study period. The prohibitive cost of phase III studies, which could potentially last 
two years, may have effectively curtailed critical pharmacodynamic work that could have addressed 
both these concerns.  
 
At the time of writing therefore, further work on selisistat for Huntington’s disease has been 
discontinued although the compound has been recently acquired by AOP Orphan Pharmaceuticals 
who do focus on rare diseases, though no clear plans have been announced at present. 
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 Characterisation of Motor Phenotypes in Huntington’s disease 10
and Correlation with Imaging Measures of Regional Atrophy 
This study conception and motor segregation methodology was developed by myself with supervisory 
input from Professor Tabrizi, UCL & Dr Ralf Reilmann, University of Munster. Statistical advice was 
given by Ruth Keogh, London School of Hygeine & tropical Medicine. The VBM analysis parameters 
were suggested by myself but finalised following discussions between myself, Ruth Keogh, Dr Rachel 
Scahill, UCL and Dr Elin Rees, UCL. Dr Rees kindly performed the VBM analysis. Secondary analysis 
was discussed with and carried out by Dr Mariam Shoai, UCL. The Study was carried out using 
subjects from TRACK-HD and PADDINGTON studies, both of which followed the Helsinki protocol 
(Ethical Principles for Medical Research Involving Human Subjects), with local research ethics 
committee approval and all study members were trained in good clinical practice.  
 
10.1 Introduction 
 
There is well-established consensus amongst experts that distinct motor phenotypes exist in HD. 
While the classical adult onset motor presentation is that of a hyperkinetic movement disorder with 
chorea predominating over bradykinesia and rigidity, in juvenile HD subjects bradykinesia, rigidity 
and dystonia are clearly more prominent, described as the Westphal variant. This more parkinsonian 
phenotype has also been noted in a minority of adult onset subjects. A further significant percentage 
fall into a mixed motor phenotype with both hypokinetic and hyperkinetic features. Finally, a 
minority group are those who appear to have clearly symptomatic disease but with relatively lower 
motor scores, though care must be taken to control for disease stage. A classification system for the 
subdivision of these varying phenotypes has not been established and thus the spectrum of motor 
features in HD while clinically evident, remains uncharacterised formally.  
 
The underlying neuroanatomical and pathological basis for these phenotypes also remains 
unexplored. With the advent of imaging biomarker studies, they can be tested for the first time in 
HD. The importance of such a correlation resides in the ability to fully reflect the heterogeneity that 
exists in HD, which will in turn facilitate accurate, relevant biomarkers tailored to the patient group 
in question. It would also facilitate a more detailed understanding of the natural history of the 
evolution of motor symptoms in HD. There is a valid impression based on clinical experience, that 
after years of hyperkinetic movements, in the moderate to latter stages of disease, a more akinetic 
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picture images, reflecting presumably more widespread degeneration. Such a rating system would 
better facilitate sub-analysis of this motor evolution, an individualised disease pathway for the 
patient, and in the setting of an effective intervention, form part of longer-term efficacy measures. 
 
The Unified Huntington’s Disease Rating Scale (UHDRS) is a multi-item assessment tool  used in HD 
patients, which includes motor evaluations- Total Motor Score (TMS) and functional tools- Total 
Functional Capacity (TFC) (Huntington Study Group, 1996;Huntington Study Group, 1999). Although 
the TMS does suffer from floor and ceiling effects, at either end of disease states, it has shown a 
trend to distinguish between disease stages (Franciosi et al., 2013) and remains the sole motor 
rating scale in HD. A natural history study of HD over 3 years, demonstrated that the TMS worsened 
by 3 points per year and TFC by 0.6 per year (Dorsey et al., 2013).  
 
Indeed recent work utilised the TMS to develop a means of segregating patients into these distinct 
motor phenotypes. Interestingly, choreic subjects performed better on functional and cognitive 
measures than akinetic ones. For the choreic subtype, chorea subscore were used totalling 28 and 
for hypokinetic-rigidity, finger taps, pronate-supinate hands, bradykinesia, rigidity, items measuring 
speed of movement and rigidity, out of 28. A 4 point difference between the two subtype scores was 
required to be assigned to either group. If this was not met the mixed motor type was used (Hart et 
al., 2013). 
 
A sub-analysis of cortical thickness in HD patients found that compared to controls, subjects with 
hypokinetic features showed greater cortical loss in anterior frontal, pre-motor and supplementary 
motor areas compared to those subjects whose motor phenotype was more hyperkinetic.  
Interestingly, striatal volumes did not differ between the two phenotypes (Rosas et al., 2008). 
 
In Parkinson’s disease, cognitive impairment seems to be associated with the akinetic rigid 
phenotype, tremor dominant disease correlates with a slower course of disease and gait failure with 
rapid disease progression (van Rooden et al., 2009;Jankovic et al., 1990).  
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Although the JHD group represents arguably the phenotypically purest grouping, unfortunately, 
imaging studies using Juvenile HD populations are rare and no direct comparison with adult onset 
imaging has ever been carried out. There is a suggestion from cases reports and small case series, of 
cerebellar atrophy, as well more florid putaminal atrophy alongside the cortical and subcortical 
volumetric loss amongst JHD patients (Comunale, Jr. et al., 1995;Ribai et al., 2007;Ruocco et al., 
2006). 
 
Thus using specific sub-scores of the TMS, segregation criteria were developed for the major motor 
groups outlined above. Using these HD motor phenotypes, a whole brain VBM analysis was 
undertaken for the first time in HD research, to see whether regional differences in atrophy exist 
between these groups that might, based on their neuroanatomical function, plausibly explain the 
clinical heterogeneity seen in HD. 
 
10.2 Methods 
 
10.2.1 Participants 
 
A combined PADDINGTON Imaging biomarker study and TRACK-HD cohort of 147 early stage HD 
subjects were utilised for this study. Initially COHORT subjects, from the London longitudinal study 
were included raising total number to 191. However due to the technical differences in imaging 
between this group and the PADDINGTON and TRACK-HD subjects, that would prevent VBM 
analysis, they had to be excluded.  
 
10.2.2 Development of Motor Classification System 
 
A motor classification system was developed based on sub-scores of the UHRDS Total motor score 
(Appendix 13.1) to segregate HD patients. The development of this classification system and 
scientific rationale is covered in the results sections.  
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10.2.3 VBM Analysis 
 
A voxel-wise structural brain image analysis was conducted, in SPM8 on a Matlab 2012b platform, to 
examine between-phenotype volumetric differences, using Unified segmentation (Ashburner & 
Friston, 2005) and a study-specific DARTEL template (Ashburner, 2007). Results were adjusted for 
multiple comparisons using False Discovery Rate (FDR) correction at the p<0.05 level.  
 
10.3 Results 
10.3.1 Development of Motor Phenotype Criteria 
 
Clinical experience in managing early stage HD patients would indicate that there would be far more 
hyperkinetic adult patients than hypokinetic. However, perhaps the greatest portion would 
constitute those with so called mixed motor phenotypes encompassing bradykinesia as well as 
chorea. One must make a clinical distinction here between true bradykinesia with decrement, 
bradyphrenia and motor slowing, which the UHDRS is not sophisticated enough to detect. For 
pragmatic reasons therefore, bradykinesia is used hereafter to define slowness of movement which 
may arise from extra-pyramidal, pyramidal and inter-pyramidal sources. Dystonia unless fixed is 
classified as a hyperkinetic movement disorder. However, due to the fact that is notoriously difficult 
to gain consensus on the presence and/or extent of dystonia, this score was left out of the 
hyperkinetic group. 
 
The UHDRS motor score was thus sub-divided into those calibrating hyperkinetic and akinetic clinical 
signs. The starting composition was as follows: Hyperkinetic= chorea subscore from all 4 limbs, face, 
mouth and trunk + finger tapping + pronation/supination from upper limbs; Akinetic= Bradykinesia 
subscore from all 4 limbs. It is important to note that leg tapping does not form part of the 
assessment of leg bradykinesia whereas finger tapping is assessed in upper limb assessments.  
 
From preliminary review of motor scores data, a number of helpful observations emerged that could 
inform segregation criteria. Firstly, it was apparent that patients could score in both groups to 
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differing extents, or not at all, giving rise to hyperkinetic, akinetic, mixed motor and minimal motor 
groups. Additionally a small score in either hyperkinetic or akinetic or both probably would be 
unlikely to reflect a truly hyperkinetic or akinetic state. Therefore a minimum score in each of these 
scores, hyperkinetic and akinetic, must be reached in order to be classified as one or the other or 
mixed motor. If that minimum score was not met or there was a low total motor score, this could be 
assumed to reflect a low motor burden consistent with the minimal motor group.  
 
Criteria 1 
In the further development of the scoring system, finger-tapping and pronation/supination were 
removed from the hyperkinetic score, as although they do assess speed of movement, they are not 
as definitively extra-pyramidal as bradykinesia and rigidity are, as they probably tap into 
corticospinal and cerebellar pathology as much as they do striatal/basal-ganglia. 
 
Alongside the clinically established hyperkinetic and akinetic groups, when examining the raw data, 
mixed motor and minimal motor groups emerged. In retrospect these groups probably reflect the 
predominant clinical experience. Moreover, there were subjects with high and low mixed motor 
burdens, which prompted a further subdivision of mixed motor into severe and mild groups. 
 
In order to obtain maximum discriminatory value, a stricter segregation method was applied, 
removing finger tapping and pronation, and increasing the cut-offs in the various groups. To ensure 
better separation in seemingly mixed motor groups, I also subtracted the AkR score from the HK 
score (Hk-AkR) to better identify predominantly hyperkinetic groups or akinetic groups or truly 
mixed groups, and worked this into the definitions below.  
 
If the TMS score was greater than 28 this merited admission into the mixed motor group and there 
was clearly a high motor burden. 
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Methods: 
 
TMS subscores: 
 
Hyperkinetic (Hk): Chorea scores from 7 body parts; max score of 28 
 
Akinetic Rigid (AkR): Bradykinesia & Rigidity (Left & Right); max score of 12 
 
Segregation Criteria: 
 
191 participants were divided into groups by the following criteria: 
 
Hyperkinetic: HK score (total chorea) ≥ 14 & HK-AkR score ≥7 & total motor score (TMS) >10 & ≤ 28.  
 
Akinetic Rigid: AkR ≥4 & HK-AkR score ≤ -4 & TMS > 10 & ≤ 28. 
 
Mixed Motor Severe (MixMtrSev): TMS >28.  
 
Mixed Motor Mild (MixMtrMld): TMS ≤ 28 and Hk-AkR score ranges from -3 to 7. 
 
Minimal Motor (MinMtr): TMS ≤ 10.  
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Results: 
 
 
Conclusion: 
 
Overall it was felt that these criteria utilised too many groups and thus may leave too few numbers 
in either extremes to render an analysis viable. It was also felt that the higher total score for the 
hyperkinetic group versus akinetic group may also skew data analysis.  
 
Criteria 2a: 
 
Rationale 
The small numbers of akinetics in criteria 1 prompted consideration to re-introduce finger taps and 
pronation into this assessment. The bradykinesia assessment could similarly have components not 
only of extra-pyramidal pathology but evidently pyramidal and cerebellar. Ultimately they are all 
motor pathways. The comparative assessment also seemed more mathematically eloquent given 
both groups was now being scored out of 28, as opposed 28 vs 12. 
 
In order to select out any clear hyperkinetics and akinetics from the large mixed motor group, the 
criteria were revised by seeking to quantify the proportion that the Hk or AkR score contributes to 
the total motor score, using the Hk/TMS and AkR/TMS method. 
 
e.g. Hk score 4, TMS 10, therefore Hk/TMS= 0.4 
 
Group Hyperkinetic Akinetic Rigid Mixed Motor 
Severe 
Mixed Motor 
Mild 
Minimal 
Motor 
Number 
(%TOT) 
9 (5%) 7 (4%) 72 (38%) 82 (43%) 20 (10%) 
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In order to tease out from those with a high total motor score (>28) into those who are truly mixed 
and those where HK or AkR is responsible for a significant part of the high total motor score, I 
employed a cut-off of ≥ 0.4, whereby the Hk or AkR score must comprise  ≥0.4 of the TMS. 
 
Regarding the Hyperkinetics, I also decided to remove the absolute score ≥14 also and focus solely 
on the difference between the phenotypes i.e. the Hk-AkR score. 
 
From the end goal point of view, which is imaging correlation, there did not seem to be much value 
in subdividing the mixed motor group and thus, this was abandoned. 
 
Methods: 
 
TMS subscores: 
 
Hyperkinetic (HK): Chorea scores from 7 body parts; max score of 28 
 
Akinetic Rigid (AkR): Finger Taps, Pro/Sup, Bradykinesia & Ridigity (left & Right); max score of 28 
 
(Finger-tapping and pro/supination re-added) 
 
Segregation Criteria: 
 
191 participants were divided into groups by the following criteria: 
 
Hyperkinetic: HK-AkR score ≥ 7 & TMS >10. If TMS>28, then Hk/TMS must be >0.4 (to 1 decimal 
space).  
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AkR (re-includes finger taps and pronation supination): HK-AkR score ≤ -4. If TMS >28 then AkR/TMS 
must be ≥ 0.4 (to 1 decimal space).  
 
Mix Mtr (merging of Max and Mild Mix Motor): TMS >10 and Hk-AkR score ranges from -3 to 6. Or 
does not fit in any other group. 
 
Min Mtr: TMS ≤ 10.  
 
Results 
 
 
Conclusions 
Hyperkinetics and akinetic numbers have risen further as expected but is not really reflective of true 
clinical experience as there are more akinetic patients than hyperkinetic. 
 
Criteria 2b 
 
Rationale 
In light of the above, it was decided to relax the Hk-AkR criteria to ≥4 for the hyperkinetic group, to 
the same parameter as one uses in AkR criteria, which is also more appropriate from an analytical 
perspective. 
 
Methods: 
 
TMS subscores: 
 
Group Hyperkinetic Akinetic Rigid Mixed Motor Minimal Motor 
Number (%TOT) 14 (8%) 18 (9%) 139 (72%) 20 (10%) 
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Hyperkinetic (HK): Chorea scores from 7 body parts; max score of 28 
 
Akinetic Rigid (AkR): Finger Taps, Pro/Sup, Bradykinesia & Ridigity (left & Right); max score of 28 
 
(Finger-tapping and pro/sup re-added) 
 
Segregation Criteria: 
 
191 participants were divided into groups by the following criteria: 
 
Hyperkinetic: HK-AkR score ≥ 4 & TMS >10. If TMS>28, then Hk/TMS must be >0.4 (to 1 decimal 
space).  
 
AkR (re-includes finger taps and pronation supination): HK-AkR score ≤ -4. If TMS >28 then AkR/TMS 
must be ≥ 0.4 (to 1 decimal space).  
 
Mix Mtr (merging of Max and Mild Mix Motor): TMS >10 and Hk-AkR score ranges from -3 to 3. Or 
does not fit in any other group. 
 
Min Mtr: TMS ≤ 10.  
 
Results 
 
 
Conclusion 
 
Further increase in Hyperkinetic numbers. 
Group Hyperkinetic Akinetic Rigid Mixed Motor Minimal Motor 
Number (%TOT) 26 (14%) 18 (9%) 127 (66%) 20 (10%) 
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Criteria 3a 
 
Rationale 
Previously, we have used the Hk/TMS and AkR/TMS calculations to sift further patients out from the 
larger mixed motor group. However, a fair part of the TMS cannot be attributed to either of the 
phenotypes and it could be argued therefore, masks the true proportions. 
 
Therefore I developed the phenotype motor score (pMS) which is Hk and AkR scores combined and 
applied the Hk/pMS and AkR/PMS calculation in those subjects with a high TMS, using a higher cut-
off of ≥ 0.8. 
 
Methods 
 
TMS Subscores: 
 
Hyperkinetic (HK): Chorea scores from 7 body parts; max score of 28 
 
Akinetic Rigid (AkR): Finger Taps, Pro/Sup, Bradykinesia & Rigidity (left & Right); max score of 28 
 
Phenotype Motor Score (pMS) is the combination of the above two scores, out of 56. 
 
Segregation Criteria: 
 
191 participants were divided into groups by the following criteria: 
 
Hyperkinetic: HK-AkR score ≥ 7 & TMS >10. If TMS>28, then Hk/pMS must be ≥ 0.8 (to 1 decimal 
space).  
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AkR (re-includes finger taps and pronation supination): HK-AkR score ≤ -4. If TMS >28 then 
AkR/pMS must be ≥ 0.8 (to 1 decimal space).  
 
Mix Mtr (merging of Max and Mild Mix Motor): TMS >10 and Hk-AkR score ranges from -3 to 6. Or 
does not fit in any other group. 
 
Min Mtr: TMS ≤ 10.  
 
Results 
 
 
Conclusion 
A corresponding reduction in group numbers has occurred, so I go on to refine this further below. 
 
Criteria 3b 
 
Rationale 
Criteria 3a but relax Hk criteria to ≥ 4 and Hk or AkR/pMS to 0.7 
 
Methods 
 
TMS Subscores: 
 
Hyperkinetic (HK): Chorea scores from 7 body parts; max score of 28 
Group Hyperkinetic Akinetic Rigid Mixed Motor Minimal Motor 
Number (%TOT) 11 (6%) 9 (5%) 151 (79%) 20 (10%) 
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Akinetic Rigid (AkR): Finger Taps, Pro/Sup, Bradykinesia & Ridigity (left & Right); max score of 28 
 
Phenotype Motor Score (pMS) is the combination of the above two scores, out of 56. 
 
Segregation Criteria: 
191 participants were divided into groups by the following criteria: 
 
Hyperkinetic: HK-AkR score ≥ 4 & TMS >10. If TMS>28, then Hk/pMS must be >0.7 (to 1 decimal 
space).  
 
AkR (re-includes finger taps and pronation supination): HK-AkR score ≤ -4. If TMS >28 then 
AkR/pMS must be ≥ 0.7 (to 1 decimal space).  
 
Mix Mtr (merging of Max and Mild Mix Motor): TMS >10 and Hk-AkR score ranges from -3 to 3. Or 
does not fit in any other group. 
 
Min Mtr: TMS ≤ 10.  
 
Results 
 
Conclusion 
This looks like the best of the various criteria, representing a fair compromise in seeking signal over 
noise. A difference of 4 between the Hk-AkR probably takes into account reasonably intra-rater 
Group Hyperkinetic Akinetic Rigid Mixed Motor Minimal Motor 
Number (%TOT) 31 (16%) 19 (10%) 121 (63%) 20 (10%) 
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variability, given this is a cross-sectional study. The change from 0.8 to 0.7 results in 13 extra 
hyperkinetics and 5 extra AkRs.  
 
Final Classification System 
 
However as the actual distribution of motor phenotypes in HD had never been formally studied and 
was based on clinical impression, which can be inaccurate and subject to unconscious bias, an 
alternative final method was proposed. As an illustration, motor raters typically have better 
correlation for hyperkinetic scores than akinetic scores i.e. it can be easier to identify and score a 
patient that moves more than one that moves less.  This is in itself inherent bias within the input 
data to our analysis. 
 
A histogram based distribution plot of motor phenotypes scores would allow firstly visualisation of 
the spread of the phenotypes scores to see if they complement the clinical perception. Secondly, 
using centiles within that spread to segregate groups seemed ultimately a more rigorous, repeatable 
and objective approach. As discussed above, only participants from PADDINGTON and TRACK-HD 
imaging biomarker studies were included in the final analysis. 
 
Hyperkinetic (HK) score 
 
This is constituted of the chorea subscore from 7 body parts (right and left upper and lower limbs, 
face, mouth and trunk), giving a total score of 28. 
 
The Akinetic Rigid (AkR) score 
 
This comprised of the finger taps, pronation/supination and bradykinesia & rigidity (right & left 
upper limb) subscores, also giving a total score of 28.  
 
A composite ratio of the HK/(HK + AkR) score was then calculated to determine the relative  
contribution of each score to the motor phenotype. The HK + AkR is the phenotype motor score 
(pMS) and seeks to more accurately select out the hyperkinetics and Akinetic.  
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A histogram of these scores was then created (Figure 24) and based on the distribution frequency of 
scores seen, a percentile based division of phenotypes was carried out.  
 
All those with a total motor score of 10 or less were assigned automatically to the minimal motor 
group 0. Clinical convention suggests that a TMS of 10 or less is a reasonable threshold below which 
signs are considered fairly mild. 
 
Those subjects within the 37.5th percentile and below constituted the akinetic motor group (1), 
62.5th percentile and above, the hyperkinetic motor group 3 and those in between, the mixed motor 
group 2. 
 
 
 
Figure 24- Histogram of hyhperkinetic score/hyperkinetic + akinetic Rigid Score (HK/(HK+AkR), with 
percentile based division into motor phenotype groupings. 
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10.3.2 Group Characteristics 
Table 37- Group characteristics of PADDINGTON and TRACK-HD cohort 
Group Age 
V1 
Number 
(M:F) 
CAG Disease Burden 
Score 
SDMT_correct Stroop 
WR_correct 
TMS 
Akinetic  25 
(17:8) 
     
Mean 45.9  43.5 353.4 32.9 74.7 21.8 
SD 9.3  2.2 69.7 11.4 21.8 9.7 
Min motor  17 
(11:6) 
     
Mean 45  43.6 332.8 45.2 95.2 8.1 
SD 11.4  3.3 50.7 12.8 9.8 1.8 
Mixed motor  78 
(42:36) 
     
Mean 48.5  44.0 382.7 31.0 73.9 26.6 
SD 10.4  3.49 79.1 9.0 18.7 9.6 
Hyperkinetic  25 
(11:14) 
     
Mean 49.6  43.9 389.4 34.1 80.1 24.5 
SD 10.1  2.9 63.2 8.9 17.1 9.9 
 
There was a reasonable consistency of age & CAG size amongst the four groups, though the gender 
distribution was far more skewed (Table 37).  
 
10.3.3 VBM Analysis 
 
Given the possibility of varying disease onset amongst these groups, and cognitive dysfunction that 
occurs in HD, age, gender, CAG, disease burden and Stroop score were considered as co-variates in 
the analysis. Further co-variates included the total intracranial volume to correct for any size related 
confounding and the TMS (minus the phenotype motor score).  The TMS was included because the 
pMS score is a composite of a few though not all subscores within the TMS. Thus it could be argued 
that any differences seen on VBM, might be explained by motor deficits in other areas, not 
encompassed by the segregation method.  
A VBM based analysis of GM and WM covarying for age, gender, scanner, CAG, disease burden, TIV, 
Stroop score and TMS (minus phenotype motor score) was undertaken. One subject did not have a 
SDMT score so they were excluded. With adjustment for multiple comparisons (FWE and the less 
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stringent FDR) there were no significant between group differences in brain volumes. A second 
analysis was undertaken using age, gender, scanner, disease burden, total intracranial volume, 
Stroop score but this was also not significant (Figure 25). 
 
10.3.4 Secondary Analysis 
 
Previous work has explored the possibility of relationships between disease characteristics and 
phenotypes.  Here we looked at whether there were any differences in age, gender, CAG, SDMT, 
stroop and disease burden scores between patients. 
 
Figure 25- Representative VBM analysis of grey matter in four different motor groups, hyperkinetic, 
akinetic, mixed motor and minimal motor. 
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In the following analysis multinomial logistic regression was performed with phenotype groups as 
the outcome with hyperkinetic phenotype as the chosen reference level (Table 38). 
 
Table 38- Multinomial Logistic regression looking for differences in clinical characteristics between akinetic, 
minimal and mixed motor groups.  
(Hyperkinetic group used as reference.) 
Coefficient (Intercept) AgeV1 Sex1M2F StroopWR_ 
correct 
SDMT_ 
correct 
CAG DBS 
Akinetic 24.179399 -0.11615 -0.44719 -0.02121 -0.02034 -0.34877 -0.02065 
Minimal -6.409309 1.04310 7.596393 0.596729 -0.7347 7.149499 -36.5339 
Mixed 10.757425 -0.05224 -0.16605 -0.00957 -0.02516 -0.13446 0.018392 
 
p-value 
for: 
(Intercept) AgeV1 Sex1M2F StroopWR_ 
correct 
SDMT_ 
Correct 
CAG DBS 
akinetic 0.0142769 0.0323 0.45682 0.277334 0.598513 0.04851 0.6134 
minimal 0 0.3524 0 0.748547 0.407626 0 0 
mixed 0.1672909 0.2459 0.72353 0.546116 0.425349 0.31290 0.5611 
 
Prior to interpretation, it is important to note the small sample size as this limits the efficacy and 
generalisability of multinomial logistic regression analysis. Correction for multiple comparisons 
means that results must again be taken with extreme caution. 
 
Using the hyperkinetic phenotype as the reference, in this worked example, a one-unit increase in 
the variable AgeV1 is associated with a decrease in the log odds of being in akinetic vs. hyperkinetic 
group by 0.12. This change in log off odds is significant on testing suggesting that akinetics are 
apparently more likely to be younger than the hyperkinetics. However, the clinical relevance of this 
is unclear and the actual effect is likely to be negligible, given the small sample size. 
 
In the gender analysis and in simpler terms, being female and a higher CAG size is more of a risk 
factor for the minimal movement category compared to hyperkinetic. There is a hint of an effect 
suggesting lower CAG being seen in akinetic groups versus hyperkinetics. Neither of these findings 
equates to clinical experience and may reflect low numbers in the groups.  
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A lower DBS is apparently more likely to be found in the minimal motor group i.e. they are less 
afflicted than hyperkinetic groups which meets the clinical experience and is consistent with their 
lower TFC. There does not appear to be any correlation with cognitive scores in the form of SDMT 
and the various motor phenotypes. 
 
10.4 Conclusion 
 
A novel, potentially clinically relevant, repeatable HD phenotype segregation method has been 
developed here to objectively identify the well-established clinical phenotypes seen in HD, 
hyperkinetic, akinetic, mixed motor and minimal motor.  
 
However it must be acknowledged that the UHDRS is an imprecise instrument, not designed for such 
a purpose. Bradykinesia encompasses a variety of pathologies and is not adequately assessed in the 
lower limbs. Dystonia is also not included and therefore the true hyperkinetic state may be 
underrepresented. Moreover, although the heterogeneity of motor phenotypes in HD is clinically 
apparent, the proposed groupings have not ever been evidenced. Thus in the development of the 
segregation method, criteria were adjusted to ensure enough numbers were present in each group 
to reflect clinical experience, which itself has never been formally ratified. In doing so, there may 
also be a danger of moving away from a priori hypothesis approach. A cluster based statistical 
analysis of motor phenotypes in HD is an alternate approach therefore, as it would not be based on 
what may be an inaccurate clinical presumption. 
 
Subsequent VBM analysis of grey and white matter structures in 146 PADDINGTON and TRACK-HD 
patients looking for correlation with HD motor phenotypes however failed to reveal any significant 
differences. Correlation between minimal motor group and female gender and higher TFC scores 
was noted, while correspondingly lower TFC score i.e. greater functional impairment was seen in the 
akinetic group versus hyperkinetic or mixed motor groups but statistical significance was not 
reached. It is possible that functional and independence scale measures which broaden and deepen 
the functional performance derived from the TFC may have been a more sensitive comparator. 
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Multinomial logistic regression analysis confirmed the clinical impression that the minimal motor 
group is associated with a lower disease burden score.  
 
These negative VBM findings could be explained by the relatively early stage of the subjects and 
studying moderate stage subjects and juvenile HD (pure akinetic rigid) may be helpful in this regard. 
The total motor score may not be sensitive enough to detect enough difference to make arbitrary 
phenotypic separation viable. Using quantitative measures like Q-motor testing as a representative 
of bradykinesia for example, would seem to be a far more reliable assessment than subjective 
clinical measures.  
 
Furthermore, this data, controlled for age, cognitive scores and other co-variates, may reveal a more 
authentic distribution of motor phenotypes from which global and regional brain volumetric 
correlations can be sought. Indeed a recent regression analysis was employed to determine the 
association between regional atrophy and motor and cognitive measures. Diminution in 
Quantitative-motor performance correlated with lower grey matter volume in the left superior 
parietal cortex (Minkova et al., 2018). 
 
The failure to find any regional atrophy correlating with differing motor phenotypes may relate to 
the possibility that the origin of motor phenotypes is the net result of dysfunction across multiple 
motor and cognitive networks. Functional motor studies and connectivity analyses may be a more 
appropriate analytical tool as atrophy may be too crude and non-specific a measure. 
 
Some clinicians would argue that the largest group are those with co-existing chorea and 
bradykinesia (Thompson et al., 1988;Girotti et al., 1988;Sanchez-Pernaute et al., 2000). It may 
therefore be the case that identifying extremes on this distribution, the hypo and hyperkinetic, 
would require far higher numbers to enable a detectable difference to be appreciated. In previous 
work over 1800 subjects were present resulting in a significantly better powered study compared to 
191 in this work (Hart et al., 2013). 
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The effect of medication must also be carefully considered, as anti-chorea agents such as 
tetrabenazine and olanzapine can have significant impacts on motor scores and through 
dopaminergic inhibition, result in parkinsonian type symptoms.  It may be that on a one-off analysis 
that previously hyperkinetic patients are now rendered akinetic by medications for example. There is 
evidence that anti-psychotic use is associated with a greater decline in TFC (Desamericq et al., 2014). 
Additionally, long-term anti-psychotic use in mental health populations is associated with brain 
atrophy, cognitive impairment, apathy and the effect of this on an already degenerating brain is not 
known (Torres et al., 2016). This was not taken into account in this work. 
 
An open VBM based methodology was employed here. A regional atrophy based hypothesis as used 
by Rosas et al. 2008 was originally considered. This initial hypothesis stated that hyperkinetic HD 
phenotypes demonstrate greater caudate atrophy than Parkinsonian HD phenotypes (UHDRS 2 out 
of 3 of rigidity, bradykinesia and dystonia >2). A sub-analysis of total striatal and composite caudate 
and putaminal measures was also planned to look for further correlations. A further hypothesis was 
that a prominent motor HD phenotype (high balance impairment/chorea/inco-ordination scores) 
may correlate with greater motor cortex, striatal, cerebellum, brainstem atrophy. Conversely, a 
prominent non-motor HD phenotype presentation (low mood, cognitive/behavioural change) may 
correlate more with frontal lobe and cingulate atrophy. 
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 Optical Coherence Tomography in Huntington’s disease 11
This study was my own idea conceptually and methodologically. I recruited the patients, carried out 
the clinical and neurophthalmological assessments, undertook the OCT scans, tabulated and 
conducted initial analysis of the data. Training on and use of OCT machine was provided by Dr Rhian 
Raftoupoulos and Dr Raj Kapoor. I formulated the hypotheses to be tested and carried out statistical 
tests. I received statistical advice from Zoe Scott at the ION Education Unit and Dr Mariam Shoai, UCL 
and where indicated, they carried out more detailed statistical analyses. 
 
11.1 Introduction 
 
The eye in neurological practice is often termed the ‘window into the CNS.’ This is because it allows 
direct visualisation of the retina and optic nerve through a variety of qualitative and quantitative 
modalities, ranging from bedside fundoscopy to electrophysiological studies and OCT. Optical 
coherence tomography allows the real time retinal substructures to be quantified and measured and 
has been in use since 1995 largely in ophthalmological practice. It is a non-ionising imaging modality 
of the retinal nerve fibre layer (RNFL) at micrometre resolution, with rapid, consistent data 
acquisition. The speed of sampling, the order of a few minutes, confers a considerable advantage 
over MR scanning. OCT is analogous to sonar techniques or ultrasound with light waves substituted 
for sound waves. Novel Spectral-domain OCT machines are able to image the retina and RNFL at 
extremely high resolution. Constituting part of the anterior visual pathway, the retina contains non-
myelinated peripapillary retinal nerve fibre layer (RNFL), retinal ganglion cells (RGCs) and inner 
retinal layers amongst several other layers (Figure 26).  
Figure 26- Retinal Architecture (NFL- Nerve Fibre Layer, GCL- Granular Cell Layer, IPL- Inner Plexiform Layer, 
INL- Inner Nuclear Layer, OPL- Outer Plexiform Layer Layer, ONL- Outer Nuclear Layer, PRL- Photoreceptor 
Layer, RPE- Retinal Pigmentary Epithelium 
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Retinal ganglion cells are neurons located in the retinal ganglion cell layer and have a soma from 
which the originating axon runs initially in the retinal nerve fibre layer.  These axons then converge 
turning into the optic disc, cross the lamina cribrosa at the optic nerve head and constitute the optic 
nerve. They are particularly sensitive to neurodegenerative damage due to defective mitochondrial 
dynamics and axonal transport, as well as oxidative stress and energy depletion, given the high 
metabolic demand and performances typical of these cells, mostly as a consequence of their patchy 
myelination (La et al., 2017). OCT facilitates access to and quantification of these unmyelinated 
neuronal populations. Thus their potential as surrogate markers of intracranial neuronal pathology is 
highlighted and has led to their employment in clinical trials (Petzold et al., 2010).  
 
11.1.1 The Retina in Neurodegenerative Diseases 
 
Studies in Alzheimer’s disease (AD) patients have demonstrated evidence of significant loss of RFNL 
even in subjects with mild cognitive impairment (Valenti, 2011;Danesh-Meyer et al., 2006), as well as 
structural and functional impairment, despite normal ophthalmological examination (Moschos et al., 
2012). Clear differences in RNFL thickness were also found between healthy controls and early AD 
(Kirbas et al., 2013). In Parkinson’s disease, a temporal loss of retinal nerve fibre layer thickness was 
identified by OCT (Kirbas et al., 2013).  
 
There also appears to be differential pattern of RNFL depending on the specific neurodegenerative 
disorder. The magnocellular RGCs are predominantly affected in AD and multiple system atrophy 
consistent with those changes found in glaucoma.  In  PD  and  Huntington’s  disease,  the  
parvocellular  RGCs  are  more  affected, which is similar to the pattern seen in mitochondrial  optic 
neuropathies (La et al., 2017). Furthermore, in Multiple Sclerosis (MS), meta-analysis has shown a 
reliable difference in the RNFL thickness between MS subjects and controls and some prognostic 
potential in optic neuritis (Petzold et al., 2010).  
 
Visual impairment is a non-motor feature of PD that may be due to the loss of dopaminergic neurons 
located in the inner nuclear layer and inner plexiform layer of the retina. Secondary involvement of 
the retinal amacrine cells, which provide input to retinal ganglion cells, may also be expected. 
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Dopamine has been established as a major neurotransmitter in the retina, so areas that contain 
dopaminergic cells (such as higher visual areas, LGN, and the visual cortex) may also be responsible 
for visual impairment in PD. Absolute sensitivity, spatial contrast sensitivity, temporal sensitivity, and 
colour vision are visual functions mediated by dopamine and affected in PD (La et al., 2017). 
Thinning of RNFL, particularly in the inferotemporal area of the optic disc, is a possible explanation 
for the arcuate superior visual field defect commonly seen in Parkinson’s disease (Inzelberg et al., 
2004). Reduced RNFL, macular thickness, and volume but not in the fovea, despite normal visual 
function has also been found (Altintas et al., 2008).  
 
In a recent study, one hundred two eyes from 52 patients affected by PD were compared with 97 
eyes from 50 age-comparable controls. In all patients, peripapillary RNFL thickness was measured by 
OCT. Eyes from patients with PD had a statistically significant decrease in average peripapillary RNFL 
thickness compared with control eyes (P < 0.001). This reduction was observed in every quadrant 
(inferior, superior, nasal (P < 0.001), and temporal (P = 0.017)) in patients with PD. As the evolution 
and severity of PD progress, the peripapillary RNFL layer thickness, as evaluated by OCT, gradually 
diminishes (Jimenez et al., 2014).  
 
11.1.2 Retina in Huntington’s disease 
 
Although visual loss has not been formally reported by patients with Huntington’s disease, the 
evidence for retinal pathology in HD comes from a number of sources. Retinal increment thresholds  
were impaired to foveally directed blue light (Paulus et al., 1993). In drosophila models 
photoreceptor degeneration is reported (Jackson et al., 1998). In R6/1 and R6/2 HD mouse models 
loss of rod and cone function, photoreceptor degeneration, deficit in cone response on 
electroretinography and loss of cone opsin and transducin protein expression is seen (Batcha et al., 
2012;Helmlinger et al., 2002). In a pre-symptomatic HD mouse model (HdhQ150), retinal intra-
nuclear neuronal inclusions were demonstrated (Young et al., 2013). In an R6/2 mouse model, 
retinal  dysfunction  and  lower  b-wave  amplitudes  as  measured  by electroretinogram  (ERG)  and  
pathology was noted (Ragauskas et al., 2014). Later in the disease, rod dysfunction, retinal 
remodelling, gliosis and apoptosis occurs. Amacrine cells, which are retinal inter-neurones, are also 
lost as part of inner retinal degeneration (Batcha et al., 2012;Helmlinger et al., 2002;Johnson et al., 
2014).  
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A post-mortem histological study however, of one human HD retina, failed to reveal any significant 
abnormalities (Petrasch-Parwez et al., 2005). From a therapeutic perspective, pre-clinical research 
has shown improvement of retinal dysfunction in R6/2 mice following intra-vitreal administration of 
a Rho-associated kinase (ROCK) via reduction in Huntingtin aggregation (Li et al., 2013), implying that 
the presence of mutant Htt within the retina itself may be directly responsible for the retinal 
neurodegenerative phenotype.   
 
In related polyglutamine triplet expansion disorders, retinal degeneration is well established 
clinically in Spinocerebellar Ataxia 7 patients. Similarly, a recent OCT study of nine Spinocerebellar 
Ataxia 1 (SCA1) patients, a polyglutamine triplet expansion disorder like HD with known cerebellar 
and brainstem volume loss, did demonstrate significant RNFL loss versus controls (Stricker et al., 
2011). Complimentary work has shown that Spinocerebellar ataxia types 1, 2, 3, and 6, also caused 
by polyglutamine expansions, were associated with reduced thickness of the RNFL and/or macular 
region (Pula et al., 2011). 
 
11.1.3 Visual Pathway in Huntington’s disease 
 
Various pathological ophthalmological signs can be found in both preclinical and clinical stages of 
HD. Specific retinal damage, namely, abnormal proteins formation, photoreceptor degeneration and 
retinal remodelling, has been studied in animal models as described above. Functional changes in 
occipital lobe activity and its atrophy as well as degeneration of visual pathways can already be 
present in the early stages of the disease.  
 
Oculomotor symptoms of HD include disturbed visual fixation, slower tracking eye movements and 
saccades, and suppressed vestibulo-ocular reflex. Visual perceptual disorders, such as visuospatial 
difficulties, problems of stimulus identification and motion perception, along with decreased 
contrast sensitivity, have also been described (Svetozarskiy et al., 2015).  
 
Circadian deficits in HD are seen in both R6/2 and Q175 mouse models. Light detected by the retina 
by retinal ganglion cells that express the photopigment melanopsin, but also receive input from the 
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suprachiasmatic nuclei in the hypothalamus, which regulates circadian rhythms. In turn, they also 
mediate a range of non-image forming responses to light including circadian entrainment and the 
pupillary light response (PLR). Using an R6/2 and Q175 mouse model, the PLR was found to be 
attenuated in both lines and reduced levels of cone opsin and melanopsin expression were noted, 
implying involvement of the anterior visual pathway in HD (Ouk et al., 2016).  
 
The posterior part of the visual pathway may also be involved. Occipital volume loss is seen in both 
pre-manifest and symptomatic individuals (Nopoulos et al., 2010;Rosas et al., 2008;Tabrizi et al., 
2013) while in HD patients, visuomotor & visuospatial deficits in visuomotor and visuospatial 
functioning is established (Say et al., 2011). A recent study did suggest that the executive 
dysfunction seen in HD may be contributed to by deficits in visual processing pathways. HD patients 
demonstrated occipito-temporal atrophy, impaired visuomotor and visuospatial function versus 
controls and association between SDMT performance and left fusiform activity on functional 
neuroimaging (Wolf et al., 2014).  
 
A study examining cortical thickness across four occipital regions in premanifest, early HD groups 
and controls, revealed that the occipital cortex in premanifest and early HD participants was reduced 
compared to controls. Regions associated with higher level visual processing (e.g., lateral occipital, 
lingual regions), highlight the potential visual deficits associated with occipital atrophy seen in 
multiple studies (Johnson et al., 2015). 
 
11.1.4 OCT as a biomarker in Huntington’s disease 
 
Considerable recent work has been carried out to identify candidate biomarkers in Huntington’s 
disease, as clinical assessment alone lacks sensitivity over shorter time-spans. Amongst potential 
biomarkers, longitudinal MR imaging has identified atrophy of whole brain, white and grey matter as 
well as regional atrophy in premanifest and early HD subjects (Tabrizi et al., 2012).  
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To the best of our knowledge, OCT had never been performed previously in HD patients (correct at 
time of study) and data presented below represents a pilot study investigating the potential of 
neuroretinal measurements as a biomarker in HD (Haider S, 2014). 
11.2 Methods 
The Study were carried out following the Helsinki protocol (Ethical Principles for Medical Research 
Involving Human Subjects), with local research ethics committee approval and clinical research 
organisation supervision including site initiation, monitoring and final visits. All study members were 
trained in good clinical practice.  
 
11.2.1 Group Characteristics 
 
Forty two genetically confirmed premanifest, early, moderate and juvenile HD patients,  segregated 
based on Shoulson and Fahn  total functional capacity criteria (Shoulson et al., 1989) were selected 
for analysis. They were recruited from the multidisciplinary clinic at the National Hospital of 
Neurology and Neurosurgery and the PADDINGTON (Pharmacodynamic Approaches to 
Demonstrating Disease Modification in Huntington’s disease) study. Twenty eight age matched 
healthy controls were also recruited. Any significant ophthalmological history of note prompted 
exclusion. The data underwent standard quality control measures including duplicate detection. Two 
were excluded as retinal registration was not possible due to difficulties with fixation and head 
chorea. Two subjects were excluded due to diabetes. In a further two subjects, measurements from 
one eye only were suitable. 
 
11.2.2 Assessments 
 
All participants underwent a neuro-ophthalmological assessment of colour vision (Ishihara testing), 
visual acuity (Snellen chart), visual field assessment by confrontation and pupillary reflexes. Optical 
coherence tomography (Spectralis 99165, Heidelberg Engineering) was carried out on all subjects, 
which involved macular volume and peri-papillary RNFL measurement of both eyes. 
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Inclusion Criteria 
- Able to provide informed consent 
- Able to tolerate OCT exam 
- Gene positive Early, Moderate Stage or Juvenile HD or Controls 
Exclusion Criteria 
- Significant head or truncal chorea 
- Diabetes, Glaucoma or other neuro-ophthalmological disease 
- Advanced stage HD 
 
11.2.3 Automated Data Analysis 
Peripapillary RNFL thickness was measured and automated data readouts were produced as shown 
below (Figure 27). The RNFL is automatically compared to a normal distribution and colour coding 
applied to indicate this relationship. 
 
Figure 27- Example of circumferential peripapillary RNFL thickness, with colour coding representing values 
compared to the normal distribution. G- global; NS- nasal-superior; N- nasal; NI- nasal-inferior; N/T- nasal-
temporal ratio; TI- temporal-inferior; T- temporal; TS- temporal-superior; ON- optic neuritis; PMB- papillo-
macular bundle; RNFL- retinal nerve fibre layer. 
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The macular volume was also measured with the automated readout obtained as described in Figure 
28.  
 
11.2.4 Statistical Analysis 
 
For the purposes of analysis and given the small sample size, early and moderate stage HD patients 
were combined in a symptomatic HD group for some analyses. Statistical analyses were performed 
in R on segmented retinal data, looking at RNFL and macular volumes in order to determine if there 
are significant differences in the pathology of left and right eyes. RNFL and macular volumes were 
consistent across both eyes and thus right and left eye results were combined. However, some 
regions of the retina showed a trend towards difference between the eyes and thus each eye was 
treated as a separate independent variable.  
Figure 28- Example Macular Volume Readout 
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The null hypothesis that "the samples come from a normal distribution" against the alternative 
hypothesis "the samples do not come from a normal distribution" was tested using the Shapiro-Wilk 
normality test using the stats package in R. The results confirm that the null hypothesis of normal 
distribution cannot be rejected for RNFL and macular volumes. RNFL and macular volumes between 
symptomatic HD groups (early, moderate and juvenile stage) were compared to suitably age-
matched controls using the student’s t-tests as the data fulfils the assumption of normality.  
 
Segmented retinal data did show a trend towards non normality, and in the case of one region at 
least, PMBR, rejected the null hypothesis of normality. In order to allow for possible lack of normal 
distribution in some segmented retinal regions, samples from the aforementioned HD groups and 
controls were tested for deviation from the null hypothesis using the Mann-Whitney test (also 
known as Wilcoxon rank sum test). The null hypothesis being tested is that the true difference 
between HD group and control is zero.  
 
In order to test for association whilst controlling for age and gender, logistic and ordinal logistic 
regressions were performed using stats and MASS packages in R respectively. Due to small sample 
numbers logistic regression (controls versus all symptomatic HD) was conducted on segmented 
retinal data, whilst ordinal logistic regression was performed with RNFL and macular volume data.  
 
11.3 Results 
11.3.1 Group Characteristics  
Group demographics are shown below (Table 39), including CAG size. Aside from refractive errors, 
there were no significant abnormalities found on neurophthalmological assessment. 
Table 39- Group Demographics 
 
Characteristic 
Adult Controls 
N=16 
Premanifest HD 
N=9 
Early HD 
N=14 
Moderate HD 
N=6 
Age; mean yrs (SD) 49.3 (9.1) 40.1 (6.6) 52.8 (9.5) 53.7 (6.7) 
Gender; n male (%) 8 (50.0%) 5 (55.6%) 3 (21.4%) 4 (66.7%) 
CAG; median (IQR)  - 44 (41.5, 44.5) 43.5 (40, 45) 44.5 (44, 45) 
DBS; mean (SD) - 307.9 (75.2) 361.1 (96.5) 461.3 (62.0) 
TFC; median (IQR) 13 (13, 13) 13 (13, 13) 12 (11, 13) 6 (5, 6) 
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TMS; median (IQR) 0 (0, 0) 0 (0, 3) 17 (13, 24) 45.5 (37, 55) 
 
A smaller number of moderate subjects (n=6) and premanifest subjects (n=9) are noted. The average 
age between early and moderate stage HD subjects was relatively similar, though the control group 
was slightly younger. There were a larger number of female participants in the early HD group than 
controls. Importantly CAG size is well matched between all HD groups. DBS and functional scores 
(TFC) and TMS are all consistent with advancing disease stages. 
Table 40- Juvenile HD and Controls group demographics 
 
Characteristic 
Juvenile HD 
N=4 
Young Controls 
N=12 
Age; mean yrs (SD) 29.8 (4.3) 28.7 (4.5) 
Gender; n male (%) 2 (50.0%) 4 (33.3%) 
CAG; median (IQR)  57.5 (53, 59) - 
DBS; mean (SD) 598.6 (82.8) - 
TFC; median (IQR) 8.5 (6, 11) 13 (13, 13) 
TMS; median (IQR) 39.5 (23.5, 59.5) 0 (0, 0) 
 
Small numbers are noted in the juvenile group due to difficulties in recruitment, though ages are 
well matched. A larger percentage of female subjects were noted in the control group versus males 
(Table 40). 
 
11.3.2 Macular Volume & Retinal Nerve Fibre Layer 
Macular Volume is Reduced in HD patients versus controls but not RNFL; no effect in Juvenile HD 
 
An initial analysis looking for differences between affected (HD) populations and controls did 
demonstrate reduced macular volume in the symptomatic HD group (early and moderate stage 
combined) versus controls (p<0.01). There was no effect noted with Juvenile HD subjects or with an 
RNFL analysis as a whole (Table 41). 
 Controls Pooled HD 
(Early & Moderate 
Stage) 
Juvenile HD Juvenile Controls 
 Early Phase Disease Modification Trials with Selisistat and Optical Coherence Tomography as a Biomarker in Huntington’s Disease 
UCL PhD Submission 
198 
Dr Salman Haider (Student No.: 1054117) 
 
Table 41- Summary table of macular volume and retinal nerve fibre layer thickness in controls versus 
symptomatic HD groups (Student’s T-test) 
 
11.3.3 Macular Volume 
Reduced macular volume in Early and Moderate Stage HD participants 
 
There was a statistically significant difference noted between controls and symptomatic HD groups 
(p= 0.015). In the premanifest HD group, there was no clear evidence of macular volume loss versus 
controls, though the lack of tightly age-matched controls may confound this interpretation. Between 
early and moderate stage HD subjects, a difference is seen which approaches the threshold of 
statistical significance (P= 0.06 for both groups respectively). Comparison of juvenile subjects with 
appropriate controls failed to reveal anything of significance. 
 
 
 
 
 
 
Age 48.7 53.1 28.1 29.8 
SD 9.2 8.9 4.35 4.34 
Average Macular 
Volume mm
3
 
(Combined) 
8.71 8.47 
 
 
8.95 8.83 
SD 0.22 0.31 0.30 0.14 
P-value versus 
Controls 
(*Young controls) 
n/a 0.015 n/a *0.41 
Average RNFL μm 
(Combined) 
94.2 92.7 102.5 103.7 
SD 7. 5 9.64 7.5 2.8 
P-value versus 
Controls (*Young 
Controls) 
n/a 0.47 n/a *0.58 
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A boxplot distribution analysis of macular volumes between disease stages suggests there may be 
lowering of macular volume as disease advances (Figure 29). 
It is noted that both age and gender are possible confounders in macular and RNFL readouts and 
thus the quoted p-values may be misleading. Moreover there was some asymmetry in gender 
distribution amongst the groups, particularly juvenile HD versus young controls. In order to address 
this, ordinal logistic regression was performed on symptomatic HD patients versus controls, where 
disease stage is ordered by moderate > early > controls and where age and gender are treated as co-
variables. For the juvenile HD versus young controls comparison, a student’s t-test did not suggest 
that gender was significantly different between the groups. 
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Figure 29- Boxplot Distributions of Macular Volume by Group suggesting reduced MV as disease 
progresses.  4 Juvenile HD subjects versus 12 age matched young controls show no clear effect. 
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Macular Volume & Disease Stage  
Table 42- Ordinal Logistic Regression of Macular Volume by Disease Stage, corrected for possible age and 
gender confounding, maintains statistical significance 
 Value Lower 95% Upper 
95% 
Std. 
Error 
t value p value 
Macular volume -3.043 -5.507 -0.580 1.257 -2.422 0.015 
Age at Visit 0.037 -0.037 0.110 0.038 0.972 0.331 
Gender -0.409 -1.783 0.965 0.701 -0.583 0.560 
Controls to Early Cut -25.177 - - 11.366 -2.215 0.027 
Early to Moderate Cut -22.977 - - 11.209 -2.050 0.040 
 
Corrected ordinal logistic regression analysis of macular volume by disease stage, suggest that with 
an increase in disease severity, a reduction in macular volume is seen. That is to say 1 unit increase 
in macular volume decreases the disease stage severity, on a log of odds scale, by 3.04.  However, 
one notes the large confidence interval for this variable. An increase in sample size will narrow this 
range and give a more stable log of odds. Addition of premanifest samples, improves the p value to 
0.013 with a log of odds of -2.694. Importantly, despite correction for possible effect of age at visit 
and gender on macular volume, significance is maintained (Table 42).  
 
11.3.4 Retinal Nerve Fibre Layer  
RNFL Thickness is Unaffected 
 
70
80
90
10
0
11
0
12
0
R
N
FL
 th
ic
kn
es
s
Ad
ult
 co
nt
ro
ls
Pr
em
an
ife
st 
HD
Ea
rly
 st
ag
e 
HD
M
od
er
at
e 
sta
ge
 H
D
Ju
ve
nil
e 
HD
Yo
un
g 
co
nt
ro
ls
Figure 30- Boxplot Distributions of RNFL by Group suggesting no clear differences between Adult 
Controls and Premanifest groups. 
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While there was a trend for lower RNFL values in affected individuals versus controls this did not 
reach statistical significance (Figure 30). This was confirmed by ordinal logistic regression models, 
both excluding and including premanifest group, where no association with disease stage was 
observed for RNFL thickness (Table 43). 
 
Table 43- Ordinal Logistic Regression of RNFL by Disease Stage, corrected for possible age and gender 
confounding, with premanifest group excluded still shows no statistical significance 
 
Inclusion of premanifest samples produces a worse model with p value of RNFL thickness increasing 
to 0.4 with log of odds reducing to -0.03.  
 
11.3.5 Change in Whole Brain and Caudate Volume Correlation  
 
Given the hypothesis that intra-retinal pathology could be a surrogate marker of intracranial 
pathology in HD, and the fact that 27 of the subjects in the OCT study had longitudinal volumetric 
MRI data as part of the PADDINGTON imaging biomarker project, a correlation between MV and 
RNFL and change in whole brain/caudate volumes over 15 months was sought. However, this 
analysis did not produce any results of statistical significance (Figure 31) (carried out by Zoe Scott, 
ION). 
 
 
 
Value Lower 95% Upper 95% Std. Error t value p value 
RNFL thickness -0.056 -0.134 0.023 0.040 -1.381 0.167 
Age at Visit 0.041 -0.033 0.116 0.038 1.088 0.277 
Gender 0.299 -1.087 1.685 0.707 0.423 0.672 
Controls to Early Cut -2.678 - - 4.364 -0.614 0.540 
Early to Moderate 
Cut -0.350 - - 4.329 -0.081 0.936 
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Figure 31- Regression Co-efficient of change in caudate and whole brain (over 15 months) with macular 
volume and RNFL thickness with no evidence of significant correlation. 
            Caudate changes (N=18)                       Whole Brain changes (N=19) 
Characteristic Regression coefficient (95% CI) P-
value 
Regression coefficient (95% CI) P-
value 
MV; per unit 
higher 
-0.00 (-0.02, 0.01) 
 
0.79 -0.42 (-1.48, 0.64) 
 
0.42 
RNFL; per unit 
higher 
-0.00 (-0.00, 0.00) 
 
0.99 0.01 (-0.04, 0.05) 
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11.3.6 Retinal Segmentation 
 
The retina can be subdivided as outlined in Figure 27 into specific regions of interests which in 
different neurological as well as neurophthalmological disorders can be affected differentially. An 
analysis aimed at determining whether regional retinal susceptibility exists in HD subjects versus 
controls was initially performed using Mann-Whitney test. The results were corrected for multiple 
testing using Bonferoni as well as Benjamini-Hochberg corrections. However, Benjamini-Hochberg 
correction was deemed to be most appropriate as the variables exhibited mild correlation with one 
another (Figure 32). 
 
 
Figure 32- Rank-based measure of association correlation matrix in symptomatic HD and control groups 
showing mild and moderate correlation of retinal segments with one another. Blue colour indicates positive 
correlation; red-brown negative correlation. 
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Descriptive retinal data for each segment compared to controls is presented below. 
 
RFNL Nasal Superior and Temporal Superior Regions 
Figure 33- RFNL Thickness by retinal segments NS- Nasal Superior TS Temporal Superior.  
Standard Deviation bars shown. 
 
There does not appear to be any significant difference between the groups in the nasal superior and 
temporal retinal regions (Figure 33). 
  
Con Early Mod JHD
Mean NS Right 92 84.14444444 76.55555556 100.0833333
Mean NS Left 95.17777778 95.54761905 82.44444444 107.6666667
Mean TS Right 129.2666667 122.9333333 115.6666667 141.875
Mean TS Left 126.1222222 127.047619 117.7777778 136.2916667
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RFNL Thickness Papillomacular bundle, Nasal and Temporal Regions 
 
There does not appear to be any significant difference between the groups in the papillomacular 
bundle, nasal and temporal retinal regions (Figure 34). 
 
 
 
 
 
 
 
 
Con Early Mod JHD
Mean PMB Right 54.54444444 56.13333333 55 54.54166667
Mean PMB Left 53.91111111 54.9047619 59.88888889 51.04166667
Mean N Right 73.45555556 73.37777778 55.22222222 83.875
Mean N Left 69.12222222 73.0952381 49 81.58333333
Mean T Right 69.73333333 69.86666667 72.55555556 67.95833333
Mean T Left 67.67777778 70.38095238 77.44444444 65.125
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Figure 34- RFNL Thickness by Retinal Segments PMB- Papillomacular bundle N- Nasal T Temporal.  
Standard Deviation Bars shown. 
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RFNL Thickness Nasal Inferior and Temporal Inferior Regions 
 
There does not appear to be any significant difference between the groups in the nasal and temporal 
inferior retinal regions (Figure 35). 
 
 
 
 
 
 
 
 
 
Con Early Mod JHD
Mean TI Right 136.6555556 131.1555556 124.2222222 158.625
Mean TI Left 139.4111111 132.0952381 125.6666667 148.5416667
Mean NI Right 118.4333333 111.4888889 82 131
Mean NI Left 113.8555556 104.6190476 70.55555556 121
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Figure 35- RFNL Thickness by retinal segments NI- Nasal Inferior TI Temporal Inferior.  
Standard Deviation bars shown. 
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There does not appear to be any significant difference in all retinal regions between juvenile HD and 
young controls (Figure 36). 
 
JHD CON
NS R Av 100.0833333 106.5151515
NS L Av 107.6666667 110.2121212
TS R Av 141.875 140.3939394
TS L Av 136.2916667 140.2272727
N/T R Av 1.233333333 1.144242424
N/T L Av 1.257916667 1.114393939
N R Av 83.875 80.03030303
N L Av 81.58333333 76.90909091
G R Av 104.4583333 102.5454545
G L Av 102.9583333 102.0909091
T R Av 67.95833333 72.96969697
T L Av 65.125 76.71212121
PMB R Av 54.54166667 54.63636364
PMB L Av 51.04166667 54.34848485
NI R Av 131 112.7575758
NI L Av 121 117.6212121
TI R Av 158.625 151.7575758
TI L Av 148.5416667 154.4090909
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Figure 36- RFNL Thickness by all retinal segments in Juvenile HD patients versus controls. Standard deviation 
bars shown. G- global; NS- nasal-superior; N- nasal; NI- nasal-inferior; N/T- nasal-temporal ratio; TI- temporal-
inferior; T- temporal; TS- temporal-superior; ON- optic neuritis; PMB- papillo-macular bundle; RNFL- retinal 
nerve fibre layer. 
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In order to test the hypothesis that there is selective retinal segment loss in HD populations versus 
controls, a Wilcoxon rank sum test was performed with results summarised below in Table 44. 
 
Table 44- Retinal segments are not significantly associated with HD subtypes on Wilcoxon rank sum test 
Group Significant after BH correction Approaching Significance 
after BH correction 
Premanifest Nil Nil 
Early  Nil Nil 
Moderate Nil NIL, NIR, NTL, NL, GL 
Juvenile Nil Nil 
Symptomatic HD Nil Nil 
 
There was no evidence of an association between retinal segment loss and HD subtypes, although in 
moderate HD group, several variables approached significance. Of note, the NI region approaches 
significance on both right and left sides, indicating a potential genuine effect that may be detectable 
with a larger sample size.  However the correlation matrix (Figure 32) indicates that this cluster of 
variables are in fact positively correlated with each other, suggesting that there may be one true 
signal, which again would require larger sample sizes, to determine definitively. 
 
11.4 Conclusion 
 
In this pilot biomarker study, an OCT based analysis of macular and RNFL measures has been carried 
out for the first time in Huntington’s disease patients. Macular volume appears to be reduced in 
symptomatic HD groups versus age-matched controls, to a statistically significant level. No 
statistically significant differences in RNFL thickness is noted however, between controls and 
symptomatic HD groups. Intriguingly, the juvenile HD population, the most aggressive HD 
phenotype, does not display any positive findings on macular volume and RNFL readouts versus a 
young control group. Retinal segmentation analysis also failed to reveal any significant findings. No 
clear correlation between change in whole brain and caudate volume over 15 months and either MV 
or RNFL is apparent. 
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Despite suggestive mouse model data and the macular volume loss noted here, HD patients do not 
complain of symptoms suggestive of colour vision loss, nor is there any suggestion anecdotally of 
higher rates of maculopathy for example in this patient group, although epidemiological data to 
answer this question accurately is not available.  
 
The visual system in HD itself is not well studied either, though recent work using cognitive testing, 
structural MRI and fMRI has shown that HD patients have significantly inferior visuomotor and visual 
object performance compared to controls, with accompanying volumetric loss in occipitotemporal 
regions. Decreased activity was also noted in fusiform cortex, an area known to be involved in visual 
processing and facial recognition (Wolf et al., 2014). Visuo-spatial memory as determined by the 
Visual Spatial Learning Test (VSLT), was impaired in HD patients compared to both control and 
premanifest populations (Pirogovsky et al., 2013).  
 
A sub-clinical level effect may be more plausible and one notes that despite full clinical recovery 
from optic neuritis, deficit on ERG testing can still be seen in MS sufferers (Petzold et al., 2010). In 
the R6/1 model, ERG has demonstrated deficits present prior to histological abnormalities, indicating 
neural dysfunction is occurring prior to formation of intra-nuclear neuronal aggregates. An 
electroretinogram (ERG) study of HD patients and controls designed to gauge any correlation 
between ERG measurements and stage of disease revealed statistically significant increased 
amplitudes in HD patients compared to controls at light-adapted (photopic) 24.2 and 60.9 cd.sec/m2 
intensities, and dark-adapted (scotopic, red flash) 0.22 cd.sec/m2 intensity. This implies that the 
enhanced response in HD patients is specific to the cone photoreceptor pathway dysfunction (Pearl 
et al., 2017). However, neurophthalmological assessment on our participants was not suggestive of 
abnormalities in colour vision via Ishihara testing. Given the above and the cone dysfunction seen 
both in terms of opsin expression and ERG abnormalities in previous studies (Ouk et al., 2016;Batcha 
et al., 2012), more sensitive testing of colour vision using FM100 Hue test could be undertaken in 
follow-up studies. It should be noted that the major limiting factor of this study, in particular with 
respect to brain volume and retina segmentation analysis is the small sample numbers.  
 
The macula is made up of large numbers of densely packed retinal ganglion cells which are 
intimately associated with cones. Thus it may be that the ganglion cells themselves are affected 
more so than cones. Direct testing of cone function to explore this hypothesis could be attempted in 
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the future as well as comparative analysis of the contribution of each of the nerve fibre layers to the 
overall volume loss noted. Indeed, in Parkinson’s disease, there is evidence that examination of the 
pre-ganglionic layers is a better indicator of retinal pathology (Shrier et al., 2012;Spund et al., 2013). 
Furthermore, the absence of a clear RNFL thinning may also be explained by a relative increased 
susceptibility of cones to the effect of mutant Huntingtin. 
 
Complimentary work carried out independently in 26 HD patients and 29 controls who underwent  
spectral domain OCT scans showed Temporal RNFL thickness was significantly reduced in the HD 
group (62.3 vs. 69.8 lm, p = 0.005), and significant negative correlation between temporal RNFL 
thickness and disease duration (R2 = -0.51, p = 0.04).  There was a significant negative correlation 
between macular volume and disease duration (R2 = -0.71, p = 0.002), and motor scores (R2 = -0.56, 
p = 0.01). Interestingly and in contrast to other work, colour vision was significantly poorer in the HD 
group. They propose that the preferential temporal RNFL loss in HD patients may implicate 
mitochondrial dysfunction as the temporal RNFL is reduced similarly in patients with some 
mitochondrial disorders, including Leber’s hereditary optic neuropathy (Kersten et al., 2015).  
 
In contrast to work presented here, no difference between absolute values of macular volume 
between cases and controls was observed, macular volume did significantly correlate with UHDRS 
motor scores and disease duration. The sample size between both studies is comparable (22 HD eyes 
to 24) and small, limiting interpretation. Additionally, there were non-contemporaneous/absent 
ocular and motor assessments in this external work. 
 
In a later study using spectral domain OCT, a significant reduction in macular choroidal thickness was 
found in HD patients when compared with controls. In addition, several retinal macular thickness 
measurements were inversely correlated with TMS-UHDRS, suggesting that the macular choroid may 
be altered early in the progression of the disease and that retinal macular thickness may decrease 
with increasing motor severity of the disease. Hence, both the choroidal and retinal macula may be 
affected in HD pathology (Andrade et al., 2016). As a major vascular structure, choroidal thickness 
may change in volume either because of structural changes or abnormal perfusion status. Recent 
studies have highlighted neurovascular dysfunction and blood–brain barrier dysfunction in the 
brains of mice and humans with HD may contribute to the pathophysiology of the disease (Drouin-
Ouellet et al., 2015;Lin et al., 2013). 
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The relatively small numbers of both juvenile and moderate HD subjects (4), the gender difference 
between juvenile and control subjects and the overall small numbers in the study must be 
considered. Both macular volume and RNFL can be influenced by age and sex which could impact on 
both positive results in the case of macular volume, and negative findings in the case of absence of a 
readout in the juvenile HD group. However, there was no evidence of a statistically significant 
difference in gender between the juvenile HD and young control groups. Additionally, it may be that 
there is relative greater durability of neuro-retinal neurones than elsewhere in brain but this is 
importantly not obviously seen in the equivalent mouse models. Paradoxically this is supported by 
the lack of correlation noted between macular volume and change in whole brain and caudate 
volume data.  
 
Technical limitations with OCT must also be considered. Retinal layers are not evenly distributed in 
the macula with inner retinal layers absent in the foveola (macular centre) and gradually emerging 
toward the macular periphery. Therefore, radial distance to the foveola may be a more relevant 
measure than macular segmentation. Indeed this was evident in PD with analysis of an annular zone 
surrounding the foveola improving readout between patients and controls (Andrade et al., 
2016;Spund et al., 2013). 
 
The JHD phenotype is noted to be the most aggressive form and the lack of a clear effect, despite 
age matched controls is unusual. Firstly, the low number of JHD subjects significantly reduces the 
ability of study to detect a difference. However, it is clear that retinal nerve fibre layer thickness and 
macular volume diminish with age, as do corresponding neuronal populations do in the brain. It is 
therefore possible that because of a combination of their relatively young age combined with 
relatively resistant neuro-retinal neurones versus those intracranially, no clear effect is seen. Testing 
and comparing relative expression of mutant Htt in retinal tissues versus the brain could provide 
valuable supplementary data to better answer this question.  
 
In support of this theory, one notes the absence of an effect in the premanifest population, despite 
evidence of active brain neurodegeneration from imaging and clinical studies, showing volumetric 
loss and cognitive deficits respectively. This could indicate that retinal neurodegeneration at the 
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macula and peripapillary RNFL, may occur later on in the evolution of HD pathology. The peripheral 
retina however has not been explored in this study and may therefore be worth investigating. 
However, neuropathological, clinical and imaging studies in JHD indicate far more severe 
neuropathological changes than in adult onset disease. Thus it may be that in contrast to affected 
neuronal populations in the brain, retinal neurones may be more resistant to the early cellular 
insults of pathogenic mutant Huntingtin. With further ageing, susceptibility of this population may 
increase, rendering adult onset HD subjects more liable to show detectable change within the retina. 
Longitudinal follow-up of this juvenile HD cohort as well as increasing its numbers would be helpful 
in resolving this question. Finally, juvenile HD does represent a clinically distinct phenotype to adult 
onset HD and it may be therefore that a retinal phenotype is not seen in this grouping and indeed 
may never be so, despite the larger CAG size.  
 
Interpretation of OCT can also be influenced by pre-existing ophthalmological disease, particularly 
glaucoma, cataracts, retinal disease and high myopia (Leung et al., 2006). All patients had a carefully 
taken ophthalmic history but did not undergo pressure testing to exclude glaucoma. As a relatively 
novel imaging modality, OCT may also lack from large cohort normative data to discern any clear 
effects of gender, ethnicity and age on readouts. All participants were Caucasian in origin and the 
group demographics indicate reasonable age-matching. A higher proportion of female subjects are 
noted in the early stage HD groups and literature does suggest that OCT is influenced by gender, 
body mass, height or weight. Recent work has shown statistically significant differences in retinal 
thickness between subjects of different race, gender, and age. When compared to Caucasians and 
Hispanics, African-American race is a predictor of decreased mean foveal thickness while male sex 
regardless of race, is a significant predictor of increased mean foveal thickness (Kashani et al., 2010). 
A sub-analysis was undertaken to determine the extent of influence of age and gender in this work 
which did not reveal it to be a factor in the correlation of macular volume with the presence of HD 
phenotype. 
  
Given the chorea and eye movement abnormalities that occur in HD, including difficulties with 
fixation, at the outset of study it was not clear how patients of different stages would tolerate the 
procedure. Dual beam eye tracking technology helped to correct for microsaccadic unintended 
deviations. FoDi- fovea-to-disc alignment also automatically orients the anatomy for PMB 
measurement accuracy. In general only 2 subjects out of 65 found the procedure too difficult to 
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complete. One notes with great interest also the development of hand held OCT devices for 
paediatric populations though in this study children were sedated (Avery et al., 2014b;Avery et al., 
2014a) meaning assessments could be carried out at home.  
Data presented here suggests that macular volume is reduced in symptomatic HD groups compared 
to controls and to the best of our knowledge, is the first such demonstration of an ocular 
neurodegenerative phenotype in human HD retina. If longitudinal change as measured by OCT can 
be proven, its value as a biomarker would rise significantly and further study is warranted. 
 
Finally, statistical measurements in small sample size cohorts, are extremely sensitive to small 
changes in sample numbers. Thus, we note that definitive results cannot be obtained without 
collaborative studies to incorporate larger data sets thus raising the possibility of meta-analysis of 
published data as future work. 
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 Conclusions  12
12.1 Disease Modification and Clinical Trial Design 
 
The need for a truly disease modifying strategy for neurodegenerative disroders in general and HD 
specifically is readily apparent. Thus far no therapeutic approach that was successful in animals has 
translated to success in human trials (Mestre et al., 2009). Trials have utilised re-purposed 
compounds without established mode of action. Despite several promising approaches found in 
animal models, and over twenty five years since the discovery of the responsible gene, even a truly 
promising potential therapy remained elusive, until the recent Ionis-HTTRx trial. 
 
 In part this reflects, the lack of commutability of animal model research to its human counterpart, 
but also the inherent complexity of targeting a primarily neurodegenerative disease process (Mestas 
& Hughes, 2004). The validity of preclinical research has also been questioned with many studies 
unable to be replicated independently, suggesting that methodological considerations, publication 
bias, statistical concerns may be impeding translation of therapies (Munafo et al., 2014;Menalled & 
Brunner, 2014). Furthermore, in spite of recent advances in molecular genetics and shared 
pathogenic mechanisms with other more common neurodegenerative diseases, specific 
Huntington’s disease research arms within pharmaceutical companies were not prioritised until 
recently, largely due to its rarity compared to other neurological diseases e.g. Alzheimer’s and 
cerebrovascular disease, heart disease and cancer.  Takeda, Roche and TEVA now have established 
programmes in Huntington’s disease. 
 
Indeed, tetrabenazine is still currently the only medicine licensed within the European Union (EU) for 
symptomatic control of chorea. Other therapies in use range from anti-psychotics, for irritability, 
behavioural and chorea management, selective serotonin re-uptake inhibitors (SSRIs) for depression 
and anxiety, mood stabilisers, are in routine use by HD specialists but have not been ratified formally 
in specific studies (Reilmann et al., 2013). 
 
Selisistat demonstrated impressive pre-clinical data with two postulated mechanisms of action, 
acetylation of mutant HTT to drive autophagy and amelioration of transcriptional dysregulation. It 
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was safe in healthy volunteers. Phase 1 and 2B data demonstrated reasonable safety and tolerability 
with no clear change in clinical efficacy parameters. However significant concern over liver function 
disturbance requires further clarification which unfortunately due to financial constraints will not be 
forthcoming. The putative mode of action has not been definitively evaluated nor published to be 
subjected to scrutiny from the scientific community.  
 
Modern pharmaceutical development especially for neurological diseases, despite considerable 
investment and evident need, yields a relatively low number of novel compounds. Even when they 
do reach Phase III trials, they often fail to demonstrate efficacy. For example, over the last twenty 
years, 99 clinical trials have been undertaken in HD utilising 41 different therapeutic compounds but 
only 3.5% have transitioned to the next stage of drug development (McColgan & Tabrizi, 2018). To 
ensure that the transition to proof of concept trials is well founded, a valid pharmacodynamic 
interaction must be demonstrated. This is elaborated further into the “three pillars of survival,” as 
outlined (Morgan et al., 2012): 
 
1. Exposure at the target site of action over a desired period—required concentration of drug 
in the right compartment. If substituted by plasma levels, there needs to be adequate 
pharmacokinetic (PK) modelling and evidence that barriers such as the blood–brain barrier 
(BBB) are crossed. 
 
2. Binding to the pharmacological target in line with proposed mode of action—PET studies, 
namely, occupancy studies, are helpful here. 
 
3. Expression of pharmacological activity commensurate with the demonstrated target 
exposure and target binding- pharmcokinetic/pharmacodynamic (PD) studies with 
biomarkers that reflect the expression of primary pharmacology at the site of action. The 
phase II trial should produce sufficient evidence that the drug is safe and has efficacy in the 
target population. Defining what constitutes sufficient evidence to support a “Go” decision 
to phase III is difficult to articulate, but there have been several attempts to quantify the 
process.  
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12.2 Disease Modification 
 
A consensus of what constitutes disease modification is also lacking. It is reasonable to propose that 
to demonstrate disease modification an intervention must: 
 
1. Impede the underlying pathological processes of disease that lead to cell death and dysfunction. 
 
2. Lead to an improvement in the phenotype. 
 
It can be argued that symptomatic therapies affect the pathology of disease, or indeed may access 
compensatory pathways, that underpin a clinical improvement. Therefore, for a given therapeutic 
strategy to be termed truly disease modifying, it becomes fundamental to connect retardation of 
pathology and functional amelioration/dysfunctional slowing, with retardation of disease. Neither of 
the therapeutic studies presented here meet the criteria above and this acid test, and how best to 
carry it out must be kept at the forefront from bench to bedside in future drug trials. 
 
It may prove important to distinguish disease modification from a curative therapy, which might be 
defined as an intervention which removes the underlying the disease process entire from the 
organism; restorative therapy e.g. stem cell transplantation, where the underlying disease pathology 
is not directly impacted, rather supplanted by healthy tissue; rescue therapy, aimed at salvaging at 
risk populations of neurones and compensatory therapy, to boost compensatory networks, which is 
currently being studied via a novel brain-training neurofeedback and fMRI paradigm (Papoutsi et al., 
2018). Combinations of these approaches may in fact be the most effective in the treatment of 
complex, progressive neurogenetic and degenerative disease  
 
Mechanistically, recovery may be underpinned by activation of compensatory pathways such as 
those well-known following cerebrovascular events for example, plasticity and recovery of neuronal 
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circuits that were salvageable. In an fMRI study of premanifest HD subjects, as atrophy increased 
performance-related activity was enhanced in the right parietal cortex during a working memory 
task. Increased functional coupling between the right dorsolateral prefrontal cortex and a left 
hemisphere network predicted better cognitive performance as atrophy increased (Kloppel et al., 
2015). In the future one can envisage the simultaneous administration of a disease arresting 
treatment with therapy designed to boost compensatory pathways. 
 
12.3 Biomarker Development 
 
Alongside biologically sound therapies, sensitive, reliable, objective readouts or genuine biomarkers 
to demonstrate the potential for disease modification were lacking until recent studies. These 
biomarkers have focussed on neuroimaging, clinical assessments and quantitative motor strategies. 
However in neurologically impaired subjects long, arduous and mentally taxing assessments are far 
from ideal. The innate immune system is postulated as a modifier in Huntington’s disease while 
Sirtuins are known to modulate the immune system. A proposed mechanism for selisistat might be 
via an interaction with the immune system in HD patients but unfortunately no evidence of this 
effect was seen. However it is unclear what proportion, indeed if any, of the dysfunction of the 
innate immune system is driving disease progression. 
 
Optical coherence tomography represents a relatively novel retinal nerve fibre layer imaging 
modality that is well tolerated, with scan times of the order of a few minutes and an automated 
analysis generated within a few seconds. Furthermore for multi-centre studies, as long as the same 
machine is employed, inter-site consistency is far easier to achieve compared to MR based 
techniques. 
 
12.4 Future Work 
 
It is clear that further validation of the mechanism of action of selisistat in terms of modulation of 
peripheral and central HTT levels and its role in the innate immune system is required. With the 
 Early Phase Disease Modification Trials with Selisistat and Optical Coherence Tomography as a Biomarker in Huntington’s Disease 
UCL PhD Submission 
219 
Dr Salman Haider (Student No.: 1054117) 
 
availability of novel methods of accurately quantifying HTT species both in blood and CSF potentially, 
there is an opportunity to demonstrate true abrogation of the pathogenic process. Restoration of 
normal transcriptional function in HD patients must also be demonstrated. Given the hepatotoxicity 
observed in selected subjects with selisistat, a wider dosing range and period, enzymatic, 
pharmacodynamic and susceptibility studies may help to clarify the source of this disturbance. If the 
drug is shown to prevent pathobiology in HD, then liver function monitoring regimens can be 
introduced. Finally, if and when true target engagement with HTT species is demonstrated, phase III 
studies can be conducted to look for changes in imaging, clinical (TMS & quantitative motor) as well 
as functional outcomes. However with the completion from HTT lowering therapies drugs such as 
selisistat are ultimately no longer attractive options.  
 
Although the VBM analysis failed to show anything of significance, developing an easy, quantifiable 
and repeatable method to define motor phenotypes in HD or indeed wider phenotypes beyond pure 
motor symptomatology, captures the true heterogeneity of disease. The UHDRS assessment tool is 
not suited to this. In turn this would allow research to determine what underpins these differences 
with the potential to target more focussed therapies if and when they become available. By way of 
example, this technique of histogram based segregation if applied to dystonia or oculomotor 
function, or more widely to gait and balance using tandem gait and retropulsion test measures, 
could facilitate creation of motor, cognitive and psychiatric domains to better define and refine 
disease burden. Alternatively, a cluster analysis could be employed to determine if HD patients 
segregate easily into phenotypic groups.   
 
Alternatively, more direct neuro-anatomically based hypotheses could be tested using volumetric 
and DTI based modalities expressing functional connectivity measures, looking for more 
caudate/putaminal volume loss for example in the hyperkinetic group phenotype versus more 
corticospinal/sub-cortical and motor and supplementary motor area loss in the akinetic grouping. 
This would mirror the clinical observation that bilateral lesions of the putamen such as stroke 
(particularly subthalamic nucleus), space-occupying lesions or indeed in hyperglycaemic states result 
in chorea; similarly that those patients with vascular dementia have significant subcortical 
hypertensive and atherosclerotic small vessel disease. 
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Optical coherence tomography would benefit from longitudinal assessments as well as increasing of 
sample size. For future work, in order to detect a difference in MV between early stage HD and 
moderate stage HD, using estimates from current work in order to detect a difference with 80% 
power and a two-sided significance level of 5% we would need to obtain macular volume data on 55 
patients in both groups. Similarly, in order to detect a difference in RNFL between adult controls and 
early stage HD /moderate stage HD combined with 80% power and a two-sided significance level of 
5%, we would need to obtain RNFL data on 102 patients in both groups. 
 
In the case of the macular volume loss, it would be important to determine the contribution the 
choroidal macula as this has been implicated in subsequent work. A sub-segmental analysis would 
be essential to confirm more recent work and determine the origin of the neurodegeneration 
occurring. Indeed a recent cross-sectional study used spectral domain optical coherence tomography 
with automatic segmentation to measure peripapillary retinal nerve fibre layer (pRNFL) thickness 
and retinal layers in foveal scans was carried out in 15 patients with HD and 15 age- and sex-
matched controls. In complement to results presented above, Temporal pRNFL, macular RNFL 
(mRNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer and outer 
plexiform layer thicknesses and IPL, retinal pigment epithelium and outer macular volume were 
found lower in HD compared to controls, while outer nuclear layer and outer retinal layer thickness 
were increased (p<0.05) (Gulmez et al., 2018). Correlation with occipital lobe and visual tracts via 
volumetric techniques and tractography (DTI) could also shed light on the anatomical substrate for 
this neurodegeneration. Clinical correlation with more dedicated ERG based methods of assessing 
cone function as well as better bedside testing of colour vision would seem sensible. 
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 Appendix 13
13.1 Unified Huntington’s Disease Rating Scale ’99 (Motor) (Huntington Study 
Group 1999) 
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13.2 Total Motor Score Tabulated Data  
Visit Statistic Group A- 10mg 
(N=17) 
Group B- 100mg 
(N=19) 
Group C- Placebo 
(N=19) 
Observed Change 
from 
Baseline 
Observed Change 
from 
Baseline 
Observed Change 
from 
Baseline 
Baseline       
Mean (SD) 29.5 
(14.50) 
 32.6 (10.3)  32.1 (11.55)  
Median (Min, 
Max) 
28.0 (8, 
64) 
 32.5 (17, 56)  33.0 (14, 53)  
Day 14       
Mean (SD) 26.1 
(14.68) 
-3.4 32.7 (10.91) 0.1 31.6 (12.07) -0.5 
Median (Min, 
Max) 
25.0 (8, 
62) 
-3.0 33.5 (16, 56) 1.0 32.0 (10, 52) -1.0 
Day 28       
Mean (SD) 27.1 
(16.42) 
-2.4 31.4 (10.78) -1.2 32.1 (12.87) -0.1 
Median (Min, 
Max) 
25.0 (8, 
71) 
-3.0 29.5 (19, 58) -3.0 32.0 (10, 62) -2.0 
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13.3 Chorea Score Tabulated Data  
Dose Group A- 10mg Group B- 100mg Group C- Placebo 
Time Baseline Day 7 Day 14 Baseline Day 7 Day 14 Baseline Day 7 Day 14 
Mean 9.35 8.94 8.7 8.38 8.38 8.44 9.31 9.31 9.21 
SD 5.13 4.95 4.42 4.84 4.23 4.59 3.93 3.74 3.64 
 
13.4 Total Functional Capacity Tabulated Data  
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13.5 Functional Assessment Score & Independence Scale 
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13.6 MMSE 
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13.7 MMSE Tabulated Data  
 
13.8 Symbol Digit Modalities Test 
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13.9 Symbol Digit Modalities Data 
 
 
13.10 Phase 2 Study- Serious Adverse Events Description (Reilmann et al., 
2013) 
Patient 3030003 (liver function tests abnormality) was a 49-year-old white female with a body 
weight of 56 kg and a height of 162 cm (BMI 21.6 kg/m2). She had no relevant medical history, and 
no history of alcohol abuse or viral hepatitis. No concomitant medications were reported. The 
patient commenced study treatment with selisistat 50 mg once daily on 22nd February 2012. 
Elevation of LFTs was noted on 21st March 2012 (Study Day 29) after four weeks of treatment, with 
AST 234 U/L (ULN 37) and ALT 428 U/L (ULN 47). The patient was without symptoms; the event was 
assessed as mild, possibly related and classified as a serious adverse event based on medical 
importance of the event. The study drug was discontinued on 23rd March 2012 (Study Day 31). 
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During follow-up, LFTs improved and were normal at the latest visit on 24th May 2012, approximately 
9 weeks after termination of study treatment. Bilirubin and eosinophils were normal throughout the 
study and follow-up visits. The event resolved on 24th May 2012 (Study Day 93), and was considered 
to be possibly related to the study drug. 
 
Patient 3040006 (hepatitis) was a 48-year-old white male with a body weight of 87 kg and a height of 
184 cm (BMI 25.6 kg/m2). Besides minor surgery, medical history included episodes of depression 
but no alcohol abuse or viral hepatitis. No concomitant medications were reported. The patient 
commenced study treatment with selisistat 50 mg once daily on 3rd April 2012. At Baseline, AST (41 
U/L; ULN 37) and ALT (67 U/L; ULN 47) were slightly elevated. On 19th April 2012 (Study Day 17) the 
patient felt anxious, feverish, and had a temperature. Laboratory results demonstrated markedly 
elevated LFTs with eosinophilia. The patient’s symptoms continued on the subsequent days and he 
felt tired and experienced nausea. On 22nd April 2012 (Study Day 20), the patient experienced 
nausea all day with vomiting in the evening. The patient discontinued the study drug on this day. 
Repeat laboratory assessment on 24th April 2012, confirmed markedly elevated LFTs with ALT 776 
U/L (ULN 47), AST 190 U/L (ULN 37), GGT 81 (ULN 51) and eosinophils 7.5% (ULN 7.0%), with normal 
bilirubin. The patient also had diarrhoea and was hospitalised. He was diagnosed with severe 
hepatitis. Further laboratory abnormalities included low potassium, reduced phosphate, elevated 
glucose, urine ketones and bacteria. During hospitalisation, the patient was treated with 500 mg 
paracetamol orally every 4 to 6 hours for temperature and the patient was feeling better with no 
nausea on the following day. The patient improved rapidly and was discharged from hospital on 27th 
April 2012 (Study Day 25). Investigations from the admission did not reveal viral hepatitis and no 
evidence of autoimmune disease. Hepatitis A IgM and hepatitis B surface antigen were reported as 
normal. On 12th June 2012 (Study Day 71), all values were within normal range and the event was 
considered resolved. The event was considered to be related to the study drug. 
 
Patient 3050002 (liver function test abnormal) was a 46-year-old white female with a body weight of 
51 kg and a height of 163 cm (BMI: 19.2 kg/m2). The patient had a medical history of hysterectomy 
and oophorectomy, fracture of right wrist, irritability in relation to Huntington’s disease and pelvic 
inflammatory disease. There was no reported medical history of alcohol abuse or viral hepatitis. Her 
concomitant medication included carbamazepine 300 mg daily and Ellese solo (hormonal 
replacement). The patient commenced study treatment with selisistat (selisistat) 200 mg once daily 
on 08th December 2011. At Baseline, all LFTs were normal with GGT close to the ULN (screening GGT 
34 U/L; baseline 32 U/L; ULN 33). After 4 weeks of treatment, the patient did not report any 
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emerging, new symptoms but LFTs were slightly elevated with AST 49 U/L (ULN 47) and GGT 41 U/L 
(ULN 33), with all other values normal. The patient was therefore seen at an extra visit 9 days later 
(on 13th January 2012). The patient was still without symptoms but LFT were now elevated with AST 
216 U/L (ULN 37), ALT 321 (ULN 47) and GGT 99 U/L (ULN 33). Bilirubin and eosinophils were normal. 
On 16th January 2012 (Study Day 40), the patient was diagnosed with the mild SAE of liver function 
tests abnormal, which was also considered to be medically important. Study treatment was 
discontinued on this day and the patient was followed until normalisation of LFTs. On 08th February 
2012, ALT was still elevated to 93 U/L (local lab ULN 41) while on 10th April 2012, all values were back 
to normal with GGT 45 U/L (local lab ULN 45) and ALT 14 U/L. Viral titres for hepatitis B and C were 
negative. The event of liver function tests abnormal was ongoing at the time of last follow up and 
was considered to be possibly related to the study drug. 
 
Adverse events assessed as non-serious 
 
Patient 1020004 was a 64-year-old white female with a body weight of 72 kg and height of 158 cm 
(BMI: 28.6 kg/m2). She had a medical history including erythema nodosum and partial 
thyroidectomy. Her concomitant medication included olanzapine 5 mg once daily, Tiaprid 600 mg 
3+2+1+0 daily, Venlafaxine 150 mg daily, ASS 100 mg daily and L-thyroxine 75 mg daily. The patient 
commenced study treatment with selisistat (selisistat) 200 mg once daily on 24th February 2012. At 
Baseline, ALP was elevated (148 U/L; ULN 135) and GGT was at the ULN (33 U/L; 43 U/L at screening; 
ULN 33). After 1 week of treatment, all values were normal. At the Week 4 visit, LFTs were elevated 
with AST 60 U/L (ULN 37), ALT 101 U/L (ULN 47) and GGT 50 U/L (ULN 33). The patient was 
continued on study treatment. On 18th April 2012 (Study Day 55), the patient’s LFTs were slightly 
more elevated and the patient was diagnosed with the mild AE of hepatic enzyme increased. Study 
treatment was discontinued on 20th April 2012 (Study Day 57) and the patient was discontinued 
from further treatment. At this visit, ALP was 176 U/L (ULN 135), AST 72 U/L (ULN 37), ALT 158 U/L 
(ULN 47) and GGT 194 U/L (ULN 33); bilirubin and eosinophils were normal throughout. The patient 
was asymptomatic and did not receive any treatment for the elevated LFTs. During subsequent 
follow-up visits values normalised to the same level as before the study with slightly elevated GGT 
(55 and 47 U/L; ULN 33 on 16th May 2012 and 14th June 2012, respectively). The AE was considered 
to be resolved on 16th May 2012 (Study Day 83) and was considered to be related to the study drug. 
 
Patient 1020013 was a 49-year-old white male with a body weight of 83 kg and height of 190 cm 
(BMI: 22.7 kg/m2). He had a medical history including facial dermatitis and episodes of depression; 
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there were no reported concomitant medications. The patient commenced study treatment with 
selisistat (selisistat) 200 mg once daily on 1st March 2012. At Baseline and at the Week 1 visit, all 
laboratory values were within normal range. On 29th March 2012 (Study Day 29), the patient 
experienced the mils AEs of alanine aminotransferase increased and aspartate aminotransferase 
increased (AST 89 U/L [ULN 37] and ALT 175 U/L [ULN 47]). Study treatment was discontinued on 9th 
April 2012 (Study Day 40). Bilirubin and eosinophils were normal throughout and the patient was 
asymptomatic and did not receive any treatment for the elevated LFTs. During subsequent follow-up 
visits one and two weeks after discontinuation, LFTs were still elevated but were then normalised 3 
weeks after study drug termination. The AEs were considered resolved on 26th April 2012 (Study Day 
57). Both AEs were considered to be related to the study drug. 
 
Patient 1020018 was a 54-year-old white male with a body weight of 96 kg and a height of 180 cm 
(BMI 29.5 kg/m2). His medical history included glaucoma. No concomitant medications were 
reported. The patient commenced study treatment with selisistat (selisistat) 50 mg once daily on 20 
March 2012.At both Baseline and Screening, ALT was slightly elevated (55 and 63 U/L; ULN 47), but 
other values were normal. After one and four weeks of treatment, values were unchanged with ALT 
48 and 61 U/L, with all other normal. At the Week 8 visit, elevated LFTs were noted with AST 100 U/L 
(ULN 37), ALT 241 U/L (ULN 47), GGT 63 U/L (ULN 51) and eosinophils 8.1% (ULN 7.0%). On 18th May 
2012 (Study Day 60), the patient was diagnosed with the mild AE of hepatic enzyme increased. Study 
treatment was withdrawn on 22nd May 2012 (Study Day 64). The patient was asymptomatic and did 
not receive any treatment for the elevated LFTs. At a follow-up, on May 30th, LFT values had 
improved but remained slightly elevated with AST 43 U/L (ULN 37), ALT 93 U/L (ULN 47) and GGT 69 
U/L (ULN 51). At the end-of-treatment visit and one week later, all values except ALT, which had 
returned to baseline levels (57 U/L and 57 U/L, ULN 47), were normalised. At the time of last follow-
up, the AE was ongoing, and was considered to be related to the study drug. 
 
Patient 1030007 was a 39-year-old white male with a body weight of 83 kg and a height of 185 cm 
(BMI 24.4 kg/m2). The patient had no relevant medical history and his concomitant medication 
included Lyrica 75 mg daily. The patient commenced study treatment with selisistat (selisistat) 200 
mg once daily on 07 December 2011. At Baseline, bilirubin was at the ULN (19 μmol/L); other values 
were normal. On 14 December 2011 (Study day 8), the patient experienced the moderate AE of 
hepatic enzyme increased: elevated LFTs were noted with AST 99 U/L (ULN 37), ALT 215 U/L (ULN 
47) and GGT 59 U/L (ULN 51). Bilirubin and eosinophils were normal. The patient was asymptomatic 
and did not receive any treatment for the elevated LFTs Study treatment was continued. After four 
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weeks of study treatment, LFTs were improved with normal AST, ALT 54 U/L (ULN 47) and GGT 63 
U/L. At Week 8, ALT remained slightly elevated to 58 U/L, with all other values normal. At Week 12, 
after completion of the full duration of study treatment, ALT was further elevated (178 U/L), AST 78 
(ULN 37), GGT 90 U/L (ULN 51); other values normal. At the follow-up visit, four weeks later ALT and 
AST were again slightly elevated (69 and 39 U/L, respectively). The patient completed the full 
duration of study treatment and LFTs were normal at Week 12/EoT visit. At the time of last follow-
up, the AE of hepatic enzyme increased was ongoing. The AE was considered to be possibly related 
to the study drug. 
 
Patient 1030027 was a 45-year-old white female with a body weight of 81 kg a height of 162 cm 
(BMI 30.7 kg/m2), without notable relevant medical history. Her concomitant medication included 
amisulpride 150 mg daily and various dietary supplements. The patient commenced study treatment 
with placebo once daily on 3rd May 2012. At Screening and Baseline, slightly elevated GGT values 
were noted (40 and 33 U/L; ULN 33) and on 04 June 2012 (Study Day 33), a mild AE of hepatic 
enzyme increased with GGT 54 was recorded. The patient continued on study treatment and GGT 
values were 49 and 48 U/L at the Week 8 and Week 12/EoT visits. Other LFTs, bilirubin and 
eosinophil were normal. At the time of last follow-up, the AE was ongoing, and considered to be 
possibly related to the study drug. 
 
Patient 1040003 was a 49-year-old white female with a body weight of 51 kg and a height of 162 cm 
(BMI: 10.5 kg/m2). Her medical history included hypertension, allergic rhinitis, episodes of 
depression and elevated GGT values without known cause. Her concomitant medication included 
citalopram 20 mg daily, metoprolol 50 mg daily, amitriptyline 50 mg daily and Valoron 40 mg daily. 
The patient commenced study treatment with selisistat 50 mg once daily on 31 January 2012. At 
Baseline and screening, GGT was elevated to 121 and 133 U/L (ULN 33). On 07 February 2012 (Study 
Day 8) GGT was somewhat higher (181 U/L) and AST was just above ULN (48 U/L; ULN 47); other 
values were normal. The patient was diagnosed with the mild AEs of alanine aminotransferase 
increased and gamma glutamyl transferase increased. Study treatment was continued. The patient 
completed the full study duration and GGT value ranged from 108 to 209 U/L (ULN 33) with all other 
values normal. At the follow-up visit, 4 weeks after the last treatment visit, GGT was at the same 
level as at baseline (110 U/L). All other values including eosinophils were normal throughout the 
study; the patient was asymptomatic. At the time of last follow-up, the AEs of alanine 
aminotransferase increased and gamma glutamyl transferase increased were ongoing. The AEs were 
considered possibly related to the study drug. 
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Patient 1040014 was a 48-year-old white male with a body weight of 97 kg and height of 193 cm 
(BMI: 26.1 kg/m2). His medical history included hypertension, electrocardiographic signs of left 
ventricular hypertrophy and episodes of depression. His concomitant medication included atenolol 
50 mg daily, lercanidipine 10 mg daily, valsartan 80 mg daily, hydrochlorothiazide 12.5 mg daily, 
nortriptyline 200 mg daily and green tea capsules 340 mg TID. The patient commenced study 
treatment with selisistat (selisistat) 200 mg once daily on 28 February 2012. All values were normal 
at Baseline and at Screening. On 23 April 2012 (Study Day 56) elevated LFTs were noted with AST 
163 U/L (ULN 37) and ALT 287 U/L (ULN 47) and normal GGT, bilirubin and eosinophils. The patient 
was diagnosed with the moderate AEs of alanine transferase increased and aspartate transferase 
increased. The patient was asymptomatic throughout the episode. Study treatment was 
discontinued on 25th April 2012 (Study Day 58). After discontinuation of study treatment, LFT values 
quickly normalised and all values were within normal range at the latest follow-up visit, 1 month 
after withdrawal of study treatment. The AEs were considered to be resolved on 25th May 2012 
(Study Day 88). The events were considered to be possibly related to the study treatment. 
 
Patient 1060007 was a 58-year-old white female with a body weight of 64 kg and height of 163 cm 
(BMI: 24.0 kg/m2), without relevant medical history and with no reported concomitant medication. 
The patient commenced study treatment with selisistat (selisistat) 200 mg once daily on 30th January 
2012. At Baseline and Screening, all values were normal and remained within normal ranges after 
one week of treatment. At the Week 4 visit, markedly elevated LFTs were noted with AST 334 U/L 
(ULN 37), ALT 289 U/L (ULN 47), GGT 63 U/L (ULN 33) and slightly elevated ALP to 139 U/L (ULN 135). 
The patient was diagnosed on 27th February 2012 (Study Day 29) with the mild AEs of alanine 
aminotransferase increased, aspartate aminotransferase increased and gamma glutamyl transferase 
increased. Bilirubin and eosinophils were normal. The patient did not experience any symptoms 
suggestive of liver disease during the study. Study treatment was discontinued on 28th February 
2012 (Study Day 30). Follow-up samples one week after discontinuation showed essentially 
unchanged values, whereas all values were within normal with the exception of a slightly elevated 
GGT to 51 U/L (ULN 33) range 4 weeks after withdrawal of study treatment. The AEs of alanine 
aminotransferase and aspartate aminotransferase abnormalities resolved on 29th March 2012 (Study 
Day 30) and the AE of gamma glutamyl transferase increase resolved on 19 June 2012 (Study Day 
142). All three AEs were considered possibly related to the study drug. 
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Patient 2040013 was a 40- year-old white male with a body weight of 65 kg and a height of 176 cm 
(BMI 21.0 kg/m2), with no relevant medical history. His concomitant medication included Zyprexa 5 
mg daily, Pasaden 10 drops daily, Laroxyl 5 drops daily and dietary supplement. A mild AE of 
elevated LFTs was noted at the screening visit (Day -20) and remained ongoing. The patient 
commenced study treatment with placebo once daily on 10th January 2012. At Screening and at 
Baseline, ALT was increased to 113 and 111 U/L (ULN 47) and AST to 58 and 49 U/L (ULN 37). Study 
treatment was initiated and LFT values remained essentially unchanged, with ALT and AST values 
somewhat lower on treatment. All other values were normal. On 1st March 2012 (Day 52), the 
patient experienced a mild AE of hepatic steatosis, which was ongoing at the time of last follow-up. 
The AE was not considered to be related to the study drug. 
 
Patient 2040016 was a 30-year-old white female with a body weight of 51 kg and height of 165 cm 
(BMI: 24.6 kg/m2). She had no relevant medical history. Her concomitant medication included 
citalopram 20 mg daily, Pasaden 7 drops twice daily and dietary supplement. The patient 
commenced study treatment with placebo once daily on 12th March 2012. At Baseline and 
Screening, all LFT values normal and remained normal until the last study visit (Week 12) on 6th June 
2012 (Study Day 87), at which an elevated GGT of 62 U/L (ULN 33) was noted as a mild AE. All other 
LFTs, including bilirubin and eosinophils were normal. The AE resolved on 27th June 2012 (Study Day 
108) and was considered to be possibly related to the study drug. 
 
Patient 2040021 was a 54-year-old white male with a body weight of 78 kg and height of 178 cm 
(BMI: 24.6 kg/m2). The patient had no relevant medical history and his concomitant medication 
included Pasaden 10 drops twice daily and dietary supplement. The patient commenced selisistat 
200 mg once daily on 19th March 2012. At Baseline, all values were within normal range. At Week 4, 
GGT of 52 U/L (ULN 51) was noted. On 16th May 2012 (Study Day 59), at the Week 8 visit, mild 
adverse events of alanine aminotransferase increased and aspartate aminotransferase increased 
were recorded with ALT 144 (ULN 47), AST 65 (ULN 37) and GGT 52 U/L (ULN 51). Dosing with study 
treatment was continued and values remained at similar levels 2 weeks later and at the Week 12 
visit. At follow-up 5 weeks later, all values were back to normal, except GGT (60 U/L). The AEs were 
considered resolved on 16th June 2012 (Study Day 120) and were considered to be possibly related 
to the study drug. 
 
Patient 2040024 was a 37-year-old white male with a body weight of 92 kg and a height of 172 cm 
(BMI 31.1kg/m2). He had no relevant medical history. His concomitant medications included 
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paroxetine 20 mg daily, valproate 400 mg daily, clozapine 50 mg daily, clonazepam 20 mg daily and 
vitamins. The patient commenced study treatment with selisistat (selisistat) 50 mg once daily on 11th 
April 2012. At Baseline, all values were within normal range. At Week 4, and 8, values remained 
normal. On 20th June 2012 (Study Day 71), at the 10 week visit, mild AEs of alanine aminotransferase 
increased and aspartate aminotransferase increased were noted: AST 38 U/L (ULN 37) and ALT 53 
U/L (ULN 47). Study treatment was continued with essentially unchanged LFT values: at week 12 
(last treatment visit) AST was 46 U/L (ULN 37) and ALT 60 U/L (ULN 47). At follow-up, three weeks 
later, a higher ALT value of 114 U/L (ULN 47) was however observed and values remained elevated 
at an additional follow up at the local laboratory in September with AST 65 U/L (ULN 37) and ALT 118 
U/L (ULN 47). The site will continue to follow the patient with repeat samples. The AE of alanine 
aminotransferase increase was considered to be not related to the study drug and the AE of 
aspartate aminotransferase increase was considered to be possibly related to the study drug. 
 
Patient 2040025 was a 56-year-old white female with a body weight of 64 kg and a height of 160 cm 
(BMI: 25.0 kg/m2). Her medical history included bronchitis and urinary tract infection one month 
before start of study treatment. Her concomitant medication included citalopram 7 mg daily, 
Pasaden 7 drops daily. The patient commenced study treatment with selisistat 200 mg once daily on 
10 May 2012. LFT values were normal at Screening and at Baseline. On 7th June 2012 (Study Day 29), 
after 4 weeks of study treatment, mild adverse events of alanine aminotransferase increase and 
aspartate aminotransferase increase were noted with ALT 69 U/L (ULN 47) and AST 44 U/L (ULN 37). 
Study treatment was continued and LFT values remained on the same level with ALT 55 U/L at Week 
12/EoT. Bilirubin, GGT and eosinophils were normal throughout the study. The AEs were ongoing at 
the time of last follow-up and were considered to be related to the study drug. 
 
Patient 3020005 was a 68-year-old white male with a body weight of 69 kg and a height of 177 cm 
(BMI 21.9 kg/m2). His medical history included recurrent erysipelas and mildly reduced vibration 
sense in lower extremities. His concomitant medication included paracetamol 500 mg as needed. 
The patient commenced study treatment with selisistat (selisistat) 50 mg once daily on 21st February 
2012. At Baseline and after 4 weeks of treatment, all values were normal. After 8 weeks of 
treatment, elevated LFTs were seen with AST 113 U/L (ULN 37), ALT 271 U/L (ULN 47) and GGT 84 
U/L (ULN 51); other values including bilirubin and eosinophils were normal. The patient was 
diagnosed with the mild AE of hepatic enzymes increased on 15th April 2012 (Study Day 53). The 
event was assessed as a non-serious adverse event of mild intensity and as unlikely related and 
study treatment was withdrawn on 20 April 2012 (Study Day 60). The patient was asymptomatic and 
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did not experience any symptoms suggestive of liver disease during the study. Two weeks later (on 
April 27th) , values were somewhat improved and at the latest follow-up, on May 16th, five weeks 
after discontinuation of study treatment, all values except GGT (117 U/L; ULN 51) were within 
normal range. The AE remained ongoing at the time of last follow-up and was considered to be 
possibly related to the study drug. 
 
Patient 3020008 was a 44-year-old white male with a body weight of 83 kg and a height of 178 cm 
(BMI 26.2 kg/m2). His medical history included asthma and hepatitis five years ago (2007). His 
concomitant medication included citalopram 20 mg daily. The patient commenced study treatment 
with selisistat 50 mg once daily on 30th March 2012. LFT values at Screening and at Baseline were 
elevated with GGT 114 and 63 U/L (ULN 51 U/L), ALT 67 and 37 U/L (ULN 47 U/L) and AST 39 U/L 
(screen; ULN 37 U/L). After 4 weeks of treatment, GGT remained slightly elevated to 64 and elevated 
eosinophils were also seen; 7.9% (ULN 7.0%). On 01 June 2012 (Study Day 64), after 10 weeks of 
study treatment, an adverse event of acute rise in liver enzymes was noted (hepatic enzymes 
increased) with GGT 72, ALT 89 and AST 98 and further study treatment was discontinued on 6th 
June 2012 (Study Day 69). At follow-up visits, values were normalising with GGT remaining elevated 
to 107 U/L 4 weeks after discontinuation of study treatment. On August 14th, 9 weeks after 
discontinuation of study treatment, a clearly elevated ALT was noted by the local laboratory (253 
U/L; ULN 47and the patient was referred to a gastroenterologist. Repeat blood sampling at the local 
laboratory in October showed normalisation of all LFT values. At the time of last follow-up, the AE 
was ongoing, and was considered to be possibly related to the study drug. 
 
Patient 3030004 was a 51-year-old white male with a body weight of 82 kg and height of 106.4 cm 
(BMI: 23.7 kg/m2), without relevant medical history. His concomitant medication included St. John’s 
Wort 1 tablet daily, and paracetamol 2 tablets as needed. The patient commenced study treatment 
with selisistat 50 mg once daily on 29th February 2012. GGT was elevated at Screening and Baseline 
(72 and 140 U/L; ULN 51), ALT was 92 U/L (ULN 47 U/L) and AST 53 U/L (ULN 37 U/L) at baseline. 
After 4 weeks of study treatment, ALT, AST and GGT remained slightly elevated and after 8 weeks, 
on 25th April 2012 (Study Day 57) a mild AE of alanine aminotransferase increased was noted with 
GGT 106 U/L, ALT 103 U/L, AST 54 and other values normal. Study treatment was continued and 
values remained essentially unchanged. At the follow-up visit, four weeks later, GGT was elevated to 
64 U/L but all other values were normal. Bilirubin and eosinophils were normal throughout. The AE 
resolved on 20th June 2012 (Study Day 113), and was considered to be possibly related to the study 
drug. 
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Patient 3030006 was a 59-year-old white female with a body weight of 82 kg and a height of 173 cm 
(BMI 27.3 kg/cm2), and a relevant medical history including eczema and lower back pain. Her 
concomitant medication included Fexofenadine 180 mg daily, co-codamol 1 to 2 tablets as needed, 
Naproxen 250 mg as needed, Paracetamol 1 g as needed, nasal mometasone, skin ointments. The 
patient commenced study treatment with selisistat 200 mg once daily on 14th March 2012. GGT was 
slightly elevated to 37 and 35 U/L (ULN 33 U/L) at Screening and Baseline. During study treatment, 
GGT values ranged between 37 and 50 U/L After 8 weeks treatment, on 9th May 2012 (Study Day 57) 
a mild AE of elevated GGT (47 U/L) was noted. Study treatment was continued without further 
elevations and at follow-up, 4 weeks after completion of study treatment (04 July 2012); GGT was at 
the same level (49 U/L). A later follow-up (October 3rd 2012) performed at the local laboratory, also 
showed GGT slightly above the ULN. At the time of last follow-up, the AE was ongoing, and was 
considered to be possibly related to the study drug. 
 
Patient 3040004 was a 40-year-old white male with a body weight of 87 kg and a height of 180 cm 
(BMI 26.7 kg/m2) with a medical history of depression and anxiety and colonoscopy for a rectal 
bleeding 2 years earlier. The patient was on concomitant medication with sertraline hydrochloride 
350 mg once daily, zopiclone 7.5 mg daily, propranolol 150 mg daily, quetiapine 350 mg daily, 
tadalafil 10 mg as needed, lamotrigine 250 mg daily and clonazepam 1 mg daily. He was enrolled and 
started on study treatment with selisistat 200 mg once daily on March 1st 2012. At Baseline and 
after 4 weeks of treatment, all values were normal. The patient experienced loose bowel movement 
2 to 5 times a day that started approximately 4 weeks after initiation of study treatment and study 
treatment was interrupted on April 20th 2012 (Study Day 51). On 24th April 2012 (Study Day 55), at 
the Week 8 visit, a moderate AE of alanine aminotransferase increased was noted (62 U/L; ULN 47) 
and study treatment was withdrawn; all other values were normal. Two weeks later and at follow-
up, all values were normal. The AE of alanine aminotransferase increase was considered to be 
resolved on 10th May 2012 (Study Day 71), and was considered to be possibly related to the study 
drug. According to the investigator, the patient had previously also experienced diarrhoea in 
episodes and the relation between the symptoms and the discrete ALT elevation is therefore not 
fully clear. 
 
Patient 3050003 was a 59-year-old white female with a body weight of 57 kg and height of 154 cm 
(BMI 24.8 kg/m2). She had no relevant medical history and no reported concomitant medication. The 
patient commenced study treatment with selisistat 200 mg once daily on 12th January 2012. At 
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Baseline and after 4 weeks of treatment, all values were normal. After 8 weeks of treatment, slightly 
elevated LFTs were noted with AST 40 U/L (ULN 37) and GGT 90 U/L (ULN 33). The patient was 
diagnosed with the mild AE of liver function test abnormality on 07th March 2012 (Study Day 56). 
Study treatment was continued and the patient was asymptomatic throughout the course of the 
study. The patient completed the full duration of the study (12 weeks) and LFTs were slightly but not 
further elevated during continued study treatment with AST 42 U/L (ULN 37) and GGT 38 U/L (ULN 
33) after 12 weeks. The AE resolved on 2nd May 2012 (Study Day 112) and was considered to be 
possibly related to the study drug. 
 
Patient 3050007 was a 45-year-old white female with a body weight of 70 kg and height of 154 cm 
(BMI 29.4 kg/m2). Her medical history included endometriosis, headache and depression and her 
concomitant medications included paroxetine 40 mg daily, ibuprofen 800 mg daily. During the study, 
the patient also received trimethoprim 400 mg daily (from 29th April 2012 to 1st May 2012) and 
paracetamol in a total dose of 8 g daily (from 27th April 2012 to 7th May 2012). The patient 
commenced study treatment with selisistat 50 mg once daily on 13th March 2012. At Baseline, at 
screening and after 4 weeks of treatment, GGT was slightly elevated (42, 45 and 49 U/L; ULN 33), 
other values were normal. After 8 weeks of treatment, a moderate AE of liver function test abnormal 
was noted with ALP 275 U/L (ULN 135), AST 74 U/L (ULN 37), ALT 110 U/L (ULN 47) and GGT 184 U/L 
(ULN 33). Study treatment was withdrawn on 14 May 2012 (Study Day 63). During follow-up, LFT 
values quickly normalised and were normal 2 weeks after cessation of study treatment, with the 
exception of a remaining, slightly elevated GGT (63 U/L; ULN 33). At the latest follow-up visit, on 11th 
June 2012, values were essentially unchanged with GGT 43 U/L (ULN 33), i.e. back to the same level 
as before the study. The patient was asymptomatic throughout the study. The AE resolved on 11th 
June 2012 (Study Day 91), and was considered to be unlikely related to the study drug. 
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